

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number  
WO 2005/056756 A2

(51) International Patent Classification<sup>7</sup>:

C12N

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2004/040506

(22) International Filing Date: 3 December 2004 (03.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10/727,358 3 December 2003 (03.12.2003) US

(71) Applicant (for all designated States except US): MEMORIAL SLOAN-KETTERING CANCER CENTER [US/US]; 1275 York Avenue, New York, NY 10021 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:


(75) Inventors/Applicants (for US only): KOLESNCIK, Richard, N. [US/US]; 343 E. 74th Street, Apt. 18A, New York, NY 10021 (US). XING, Hongmei, R. [CA/US]; 539 West 112th Street, Apt. 6C, New York, NY 10025 (US).

— without international search report and to be republished upon receipt of that report

(74) Agent: JACKSON, David, A.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: KINASE SUPPRESSOR OF RAS INACTIVATION FOR THERAPY OF RAS MEDIATED TUMORIGENESIS



(57) Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking of Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.

WO 2005/056756 A2

## KINASE SUPPRESSOR OF RAS INACTIVATION FOR THERAPY OF RAS MEDIATED TUMORIGENESIS

### GOVERNMENTAL SUPPORT

[0001] The research leading to the present invention was supported, at least in part, by a grant from the National Institutes of Health, Grant No.CA42385 and Grant No.CA52462. Accordingly, the Government may have certain rights in the invention.

### FIELD OF THE INVENTION

[0002] The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid complementary to KSR RNA to specifically inhibit KSR and block of Ras mediated tumorigenesis.

### BACKGROUND OF THE INVENTION

[0003] Ras plays an essential role in oncogenic transformation and genesis. Oncogenic H-, K-, and N-Ras arise from point mutations limited to a small number of sites (amino acids 12, 13, 59 and 61). Unlike normal Ras, oncogenic *ras* proteins lack intrinsic

GTPase activity and hence remain constitutively activated (Trahey, M., and McCormick, F. (1987) *Science* 238: 542-5; Tabin, C. J. et al. (1982) *Nature*. 300: 143-9; Taparowsky, E. et al. (1982) *Nature*. 300: 762-5). The participation of oncogenic *ras* in human cancers is estimated to be 30% (Almoguera, C. et al (1988) *Cell*. 53:549-54).

[0004] Mutations are frequently limited to only one of the *ras* genes, and the frequency is tissue- and tumor type-specific. K-*ras* is the most commonly mutated oncogene in human cancers, especially the codon-12 mutation. While oncogenic activation of H-, K-, and N-*Ras* arising from single nucleotide substitutions has been observed in 30% of human cancers (Bos, J.L. (1989) *Cancer Res* 49, 4682-9), over 90% of human pancreatic cancer manifest the codon 12 K-*ras* mutation (Almoguera, C. et al. (1988) *Cell* 53, 549-54; Smit, V.T. et al. (1988) *Nucleic Acids Res* 16, 7773-82; Bos, J.L. (1989) *Cancer Res* 49, 4682-9). Pancreatic ductal adenocarcinoma, the most common cancer of the pancreas, is notorious for its rapid onset and resistance to treatment. The high frequency of K-*ras* mutations in human pancreatic tumors suggests that constitutive Ras activation plays a critical role during pancreatic oncogenesis. Adenocarcinoma of the exocrine pancreas represents the fourth-leading cause of cancer-related mortality in Western countries. Treatment has had limited success and the five-year survival remains less than 5% with a mean survival of 4 months for patients with surgically unresectable tumors (Jemal, A et al (2002) *CA Cancer J Clin* 52, 23-47; Burris, H.A., 3rd et al. (1997) *J Clin Oncol* 15, 2403-13). This point mutation can be identified early in the course of the disease when normal cuboidal pancreatic ductal epithelium progresses to a flat hyperplastic lesion, and is considered causative in the pathogenesis of pancreatic cancer (Hruban, R.H. et al (2000) *Clin Cancer Res* 6, 2969-72; Tada, M. et al. (1996) *Gastroenterology* 110, 227-31). The regulation of oncogenic K-*ras* signaling in human pancreatic cancer, however, remains largely unknown.

**[0005]** *K-ras* mutations are present in 50% of the cancers of colon and lung (Bos, J. L. et al. (1987) *Nature*. 327: 293-7; Rodenhuis, S. et al. (1988) *Cancer Res.* 48: 5738-41). In cancers of the urinary tract and bladder, mutations are primarily in the *H-ras* gene (Fujita, J. et al. (1984) *Nature*. 309: 464-6; Visvanathan, K. V. et al. (1988) *Oncogene Res.* 3: 77-86). *N-ras* gene mutations are present in 30% of leukemia and liver cancer.

Approximately 25% of skin lesions in humans involve mutations of the Ha-Ras (25% for squamous cell carcinoma and 28% for melanomas) (Bos, J. L. (1989) *Cancer Res.* 49:4683-9; Migley, R. S. and Kerr, D. J. (2002) *Crit Rev Oncol Hematol.* 44:109-20). 50-60% of thyroid carcinomas are unique in having mutations in all three genes (Adjei, A. A. (2001) *J Natl Cancer Inst.* 93: 1062-74).

**[0006]** Constitutive activation of Ras can be achieved through oncogenic mutations or via hyperactivated growth factor receptors such as the EGFRs. Elevated expression and/or amplification of the members of the EGFR family, especially the EGFR and HER2, have been implicated in various forms of human malignancies (as reviewed in Prenzel, N. et al. (2001) *Endocr Relat Cancer*. 8: 11-31). In some of these cancers (including pancreas, colon, bladder, lung), EGFR/HER2 overexpression is compounded by the presence of oncogenic Ras mutations. Abnormal activation of these receptors in tumors can be attributed to overexpression, gene amplification, constitutive activation mutations or autocrine growth factor loops (Voldborg, B. R. et al. (1997) *Ann Oncol.* 8: 1197-206). For growth factor receptors, especially the EGFRs, amplification or /and overexpression of these receptors frequently occur in the cancers of the breast, ovary, stomach, esophagus, pancreatic, lung, colon neuroblastoma.

**[0007]** While various therapeutic strategies have been developed to inactivate key components of the Ras-Raf-MAPK cascade, specific inhibition of gain-of-function or constitutive Ras (*gfRas*) action has not been achieved clinically (Adjei, A.A. (2001) *J*

*Natl Cancer Inst* 93, 1062-74; Cox, A.D. & Der, C.J. (2002) *Curr Opin Pharmacol* 2,388-93).

**[0008]** Therefore, in view of the aforementioned deficiencies attendant with prior art methods to inactivate or inhibit the Ras pathway, and particularly Ras-mediated cancers, it should be apparent that there still exists a need in the art for methods and compositions for specific inhibition of the Ras pathway and particularly for inhibition of *gfr* Ras.

**[0009]** The citation of references herein shall not be construed as an admission that such is prior art to the present invention.

#### SUMMARY OF THE INVENTION

**[0010]** The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). The compositions and methods of the present invention inhibit the expression and/or activity of KSR. In one aspect, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR. It is herein demonstrated that on specific inhibition of KSR the Ras pathway is disrupted and, specifically, Ras-mediated tumors and tumorigenesis is inhibited or blocked, existing tumors regress, metasasis is inhibited and proliferation of tumor or cancer cells is inhibited.

**[0011]** The present invention further relates to methods and means for radiosensitization, particularly of hyperproliferative, cancer or tumor cells, by specific inhibition of KSR expression and/or activity. In one such aspect, the hyperproliferative, cancer or tumor cells are resistant to ionizing radiation (IR) induced apoptosis or cell death. Inhibition of KSR, including by administration or expression of antisense oligonucleotide complementary to KSR, results in sensitization of cells to ionizing radiation, whereby the

division or growth of cells is blocked or the cells are more effectively killed by IR than in the absence of the antisense oligonucleotide. The administration or expression of antisense oligonucleotide complementary to KSR facilitates and enhances cancer therapy, including radiation therapy.

**[0012]** The present invention further relates to methods and means for modulating angiogenesis, particularly by modulation of VEGF expression upon activation or inhibition of expression and/or activity of KSR. VEGF expression is modulated by specific inhibition or activation of KSR expression and/or activity. Activation or enhanced expression of KSR increases the amount or expression of VEGF in or by cells. Thus, activation or enhanced expression of KSR in a cell or tissue provides a method of stimulating angiogenesis. Inhibition, blockage or reduction of KSR decreases the amount or expression of VEGF, thereby having an anti-angiogenic effect. In one such aspect, VEGF expression of cancer or tumor cells is blocked by inhibition of KSR, including by administration or expression of antisense oligonucleotide complementary to KSR, resulting in inhibition of angiogenesis in the cancer or tumor. In one aspect, inhibition of KSR, including by administration or expression of antisense oligonucleotide complementary to KSR, provides a method of inhibiting angiogenesis in a tumor, tissue or cells expressing KSR, particularly a tissue or tumor expressing *gfRas* or wherein the Ras pathway is hyperactivated or Ras is overexpressed or amplified.

**[0013]** The present invention provides oligonucleotides and nucleic acids which specifically inhibit or block the expression and activity of KSR. In particular, antisense oligonucleotides and the expression of nucleic acid complementary to KSR RNA specifically inhibits expression of KSR and blocks *gfRas* mediated tumorigenesis. The present invention provides an oligonucleotide which is substantially complementary to a region of KSR RNA, wherein said oligonucleotide inhibits the expression of KSR. The invention further provides an oligonucleotide which is substantially complementary to a

nucleic acid encoding mammalian KSR. In particular embodiments, oligonucleotides are provided which are substantially complementary to nucleic acid encoding mammalian KSR, particularly human and mouse KSR.

**[0014]** In an aspect of the invention an oligonucleotide is provided which is substantially complementary to a translation initiation site, 5' untranslated region, coding region or 3' untranslated region of mRNA encoding mammalian KSR. In one such aspect, the invention thus provides an oligonucleotide which is substantially complementary to a translation initiation site, 5' untranslated region, coding region or 3' untranslated region of mRNA encoding human KSR as provided in FIGURE 14 and SEQ ID NO: 24. In a particular embodiment, the invention provides an antisense oligonucleotide substantially complementary to the N-terminal coding region of mammalian KSR mRNA, particularly to the region of nucleotides 1 through 761 of the coding region of mammalian KSR mRNA. In one embodiment, the invention includes an antisense oligonucleotide comprising a sequence substantially complementary to the CA1 region of KSR. The invention provides oligonucleotides comprising a sequence substantially complementary to nucleotides encoding amino acids 33 to 72 of the sequence of human KSR and amino acids 42 to 82 of the sequence of mouse KSR, or a portion thereof.

**[0015]** In a further embodiment, the invention includes an antisense oligonucleotide comprising a sequence substantially complementary to nucleotides 97 to 216 of the coding sequence of human KSR (SEQ ID NO: 25) or nucleotides 124 to 243 of the coding sequence of mouse KSR (SEQ ID NO: 1), or a portion thereof, such nucleotides encoding amino acids 33 to 72 of human KSR (SEQ ID NO: 26) and amino acids 42 to 82 of mouse KSR (SEQ ID NO: 2) or a portion thereof. In particular, oligonucleotides of the invention include oligonucleotides comprising a sequence substantially complementary to nucleotides selected from the group of: nucleotides 124 to 141 of human KSR, corresponding to nucleotides 151 to 168 of mouse KSR (SEQ ID NO: 3);

nucleotides 154 to 171 of human KSR (SEQ ID NO: 27), corresponding nearly identically (with a single base pair difference at the 5' most nucleotide) to nucleotides 181 to 198 of mouse KSR (SEQ ID NO:4); and nucleotides 187 to 204 of human KSR, corresponding to nucleotides 214 to 231 of mouse KSR (SEQ ID NO:5). The invention includes antisense oligonucleotides comprising a sequence selected from the group of SEQ ID NOS: 6-8 and SEQ ID NOS: 29-38.

**[0016]** The oligonucleotides of the present invention may be labeled with a detectable label. In particular aspects, the label may be selected from enzymes, ligands, chemicals which fluoresce and radioactive elements. In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

**[0017]** In a particular aspect, the nucleic acids and oligonucleotides of the present invention may be modified, either by manipulation of the chemical backbone of the nucleic acids or by covalent or non-covalent attachment of other moieties. In each or any case, such manipulation or attachment may serve to modify the stability, cellular, tissue or organ uptake, or otherwise enhance efficacy of the nucleic acids and oligonucleotides. In further aspects of the invention, the oligonucleotides may be covalently linked to other molecules, including but not limited to polypeptides, carbohydrates, lipid or lipid-like moieties, ligands, chemical agents or compounds, which may serve to enhance the uptake, stability or to target the oligonucleotides.

[0018] In further embodiments, the oligonucleotides of the present invention are modified in their chemical backbone. In a particular embodiment, the oligonucleotides comprise at least one phosphorothioate (P-S) linkage.

[0019] Recombinant DNA molecules comprising a nucleic acid sequence which encodes on transcription an antisense RNA complementary to mammalian KSR RNA or a portion thereof are provided by the invention. Further, the recombinant DNA molecules comprise a nucleic acid sequence wherein said nucleic acid sequence is operatively linked to a transcription control sequence. Cell lines transfected with these recombinant DNA molecules are also included in the invention.

[0020] In a further aspect, an expression vector is provided which is capable of expressing a nucleic acid which is substantially complementary to the coding sequence of KSR RNA, or a portion thereof, wherein said nucleic acid inhibits the expression of KSR. In a particular aspect, this includes an expression vector capable of expressing an oligonucleotide which is substantially complementary to the CA1 region of the coding sequence of KSR RNA, particularly of mouse or human KSR (SEQ ID NO: 1 or SEQ ID NO: 25), or a portion thereof, wherein said oligonucleotide inhibits the expression of KSR.

[0021] Compositions of the nucleic acids and oligonucleotides are an additional aspect of the invention. The invention includes a composition comprising an oligonucleotide which is substantially complementary to a region of KSR RNA and a pharmaceutically acceptable carrier or diluent. The invention thus provides a pharmaceutical composition comprising a therapeutically effective amount of an oligonucleotide which is substantially complementary to a region of KSR RNA and a pharmaceutically acceptable carrier or diluent.

[0022] In a further aspect, compositions are provided comprising one or more chemotherapeutic or radiotherapeutic agent and an oligonucleotide which is targeted to a mRNA encoding mammalian KSR and which inhibits KSR expression.

[0023] In an additional embodiment, the invention provides a composition comprising an expression vector and a pharmaceutically acceptable carrier or diluent, wherein said expression vector is capable of expressing nucleic acid which is substantially complementary to the coding sequence of KSR RNA, or a portion thereof, wherein said nucleic acid inhibits the expression of KSR.

[0024] Methods for inhibiting expression of KSR are provided. In one aspect, a method of inhibiting the expression of mammalian KSR comprising contacting cells which express KSR with an effective amount of a nucleic acid which is complementary to a portion of the mRNA encoding KSR is included. In particular, a method of inhibiting the expression of mammalian KSR is provided, comprising contacting cells which express KSR with an effective amount of the oligonucleotide of the present invention whereby expression of mammalian KSR is inhibited. In an additional aspect, a method of inhibiting expression of KSR is provided, wherein tissues or a tumor, particularly a tissue or tumor expressing *g*fRas or wherein the Ras pathway is hyperactivated or Ras is overexpressed or amplified, is contacted with an effective amount of the oligonucleotide or nucleic acid of the present invention, thus inhibiting the expression of KSR.

[0025] In a further embodiment, the invention provides compositions and methods for the inhibition or blockage of the activity of KSR, including the kinase or phosphorylation activity of KSR. In an additional aspect, a method of inhibiting expression of KSR is provided, wherein a tumor, tissue or cells expressing KSR, particularly a tissue or tumor expressing *g*fRas or wherein the Ras pathway is hyperactivated or Ras is overexpressed

or amplified, is contacted with an effective amount of the nucleic acid or composition of the present invention, thus inhibiting the activity of KSR.

**[0026]** The invention further includes a method of treating or preventing a hyperproliferative condition associated with the expression of *gf-Ras* or heightened expression of Ras in a mammal comprising administering to said mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein. In one aspect of this method, said compound or agent is an antisense oligonucleotide which specifically hybridizes to a portion of the mRNA encoding KSR.

**[0027]** A method of treating or preventing a hyperproliferative condition associated with the expression of *gf-Ras* or heightened expression or hyperactivation of Ras in a mammal is provided, comprising expressing in said mammal or administering to said mammal a therapeutically effective amount of a nucleic acid which is complementary to a portion of the mRNA encoding KSR.

**[0028]** In a further aspect, a method of treating or inhibiting the progression of cancer in a mammal is included, comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein. Cancers which are susceptible to the invention's method include cancer selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer. Thus, a method is provided for treating or inhibiting the progression of cancer in a mammal comprising administering to a mammal a therapeutically effective amount of one or more oligonucleotide of the present invention.

[0029] The invention provides a method for sensitizing hyperproliferative, cancer or tumor cells in a mammal to ionizing radiation or other radiation or chemotherapy comprising administering to a mammal a therapeutically effective amount of one or more inhibitor of KSR expression and/or activity. The invention provides a method for sensitizing hyperproliferative, cancer or tumor cells in a mammal to ionizing radiation or other radiation or chemotherapy comprising administering to a mammal a therapeutically effective amount of one or more oligonucleotide of the present invention.

[0030] The invention provides a method for modulating angiogenesis in a mammal by modulation of VEGF expression upon activation or inhibition of expression and/or activity of KSR. Inhibition, blockage or reduction of KSR decreases the amount or expression of VEGF, thereby having an anti-angiogenic effect. In a particular such method, VEGF expression of cancer or tumor cells is blocked by inhibition of KSR, including by administration or expression of antisense oligonucleotide complementary to KSR, resulting in inhibition of angiogenesis in the cancer or tumor. The invention provides a method of inhibiting angiogenesis in a tumor, tissue or cell expressing KSR, particularly a tissue or tumor expressing *gf* Ras or wherein the Ras pathway is hyperactivated or Ras is overexpressed or amplified, comprising administering to said mammal an inhibitor of KSR, including a therapeutically effective amount of one or more antisense oligonucleotide complementary to KSR. In a further method for modulating angiogenesis, the activation or enhanced expression of KSR increases the amount or expression of VEGF in or by cells. A method of stimulating angiogenesis is provided comprising activating or enhancing expression of KSR in a cell or tissue.

[0031] In addition, a method is provided for identifying compounds or agents which inhibit the expression of KSR comprising the steps of:

- (a) incubating a cell expressing KSR in the presence and absence of a candidate compound or agent; and
- (b) detecting or measuring the expression of KSR in the presence and absence of a candidate compound or agent,

whereby a decrease in the expression of KSR in the presence of said candidate compound or agent versus in the absence of said candidate compound or agent indicates that said compound or agent inhibits the expression of KSR.

**[0032]** The invention includes additional compositions which can inhibit the expression of a protein, in particular KSR, at the transcriptional level by blocking translation of KSR mRNA or by facilitating destruction or destabilization of the RNA such that translation cannot efficiently take place. In this aspect, the invention provides a ribozyme that cleaves KSR mRNA.

**[0033]** The present invention naturally contemplates several means for preparation of the nucleic acids and oligonucleotides of the present invention, including as illustrated herein known recombinant techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The knowledge of the cDNA and amino acid sequences of KSR as disclosed herein facilitates the preparation of the nucleic acids of the invention by such recombinant techniques, and accordingly, the invention extends to expression vectors prepared from the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.

**[0034]** Other objects and advantages will become apparent to those skilled in the art from a review of the following description which proceeds with reference to the following illustrative drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0035]** **FIGURE 1** depicts targeted disruption of the *ksr* gene in mice. **A**, Strategy for targeting the *ksr* allele. Simplified restriction maps of the 5' region of the wild-type *ksr* allele, the targeting vector, and the mutated allele are shown. Homologous recombination with endogenous *ksr* replaces an internal 1.1-kb *Sma*I-*Spe*I genomic fragment with a Neo cassette. **B**, Southern blot analysis of an ES clone showing the correct insertion of the targeting construct. Genomic DNA isolated from ES cells was digested with *Bgl*II and *Xho*I and hybridized to the 5' probe located just outside the 5' arm of the *ksr* targeting region as shown in **A**. The wild-type allele yields a 5.7-kb fragment whereas the mutant allele yields a 3.1-kb fragment. **C**, Genotyping of *ksr*<sup>-/-</sup> mice by PCR. The size of the PCR product is 493 bp for the wt allele and 312 bp for the mutated allele. **D**, Expression of *ksr* in wild type mouse embryos. The sizes of the two transcripts are 6.4 kb and 7.4 kb. **E**, Northern blot analysis of tissue *ksr* mRNAs. Poly-A<sup>+</sup> RNA, isolated from different tissues of adult *ksr*<sup>+/+</sup>, *ksr*<sup>+/−</sup>, and *ksr*<sup>−/−</sup> mice, was hybridized with a probe corresponding to domains CA2-CA4 in *ksr* cDNA. mRNA from NIH3T3 cells was used as control. **F**, KSR protein expression. Lysates prepared from wild-type and *ksr*<sup>−/−</sup> tissues were analyzed by western blot with a specific anti-KSR monoclonal antibody. Note that brain expresses the slightly shorter B-KSR1 isoform while lung and spleen express the longer KSR1 isoform. Lysates were also prepared from two independent sets of *ksr*<sup>+/+</sup> and *ksr*<sup>−/−</sup> MEFs. Equal loading was confirmed by reprobing blots with an anti-α-tubulin antibody.

**[0036]** **FIGURE 2** depicts skin phenotype in newborn *ksr*<sup>−/−</sup> mice. Full thickness skin cuts of 10-day old *ksr*<sup>+/+</sup>, *ksr*<sup>−/−</sup> and *egfr*<sup>−/−</sup> mice were sectioned 4-6  $\mu$ m thick, placed on glass slides, and stained with hematoxylin and eosin. s –serpentine, bl –blister, do-disoriented.

**[0037]** **FIGURE 3** depicts defects in EGF- and TPA- induced MAPK signaling and proliferation in *ksr*<sup>−/−</sup> MEFs. **A**, Western blot analysis of MAPK activity upon EGF and TPA treatments. Low-passage MEFs derived from *ksr*<sup>+/+</sup> and *ksr*<sup>−/−</sup> were made quiescent

by 48 h incubation in serum-free medium and stimulated with low doses of EGF for 3 min (upper panel) or with TPA for 10 min (lower panel). Cells were lysed in NP40 buffer and activation of the MAPK cascade was examined by western blot with anti-phospho specific antibodies for the activated forms of MAPK(ERK1/2). Shown are representative blots from one of four independent experiments. **B**, Activation of endogenous Raf-1 upon EGF (upper panel) and TPA (lower panel) treatments were determined by Raf-1 activity assay as described herein in Methods. MEK1 phosphorylation was examined by western blot with anti-phospho specific antibodies for the activated forms of MEK1. Shown are representative blots from one or four independent experiments. **C**, Proliferation of MEFs.  $0.15 \times 10^6$  *ksr*<sup>+/+</sup> or *ksr*<sup>-/-</sup> low-passage MEFs were seeded on 60 mm plates and grown as described in Methods. Cells were trypsinized every other day and counted by hemacytometer. Data (mean±SD) are compiled from three independent experiments.

[0038] **FIGURE 4.** Disruption of *ksr* gene abrogated oncogenic Ras-mediated tumorigenesis in *ksr*<sup>-/-</sup> mice. **A**, RT-PCR detection of *v-Ha-ras* expression from total RNA isolated from the epidermis of Tg.AC/*ksr*<sup>+/+</sup> and Tg.AC/*ksr*<sup>-/-</sup> mice following TPA treatment. Intron spanning primers specific for the 3'UTR region of the *v-Ha-ras* transgene were used. The larger 279 bp amplicon, detected in the absence of reverse transcriptase [RT(-)], is derived from DNA and unspliced RNA. The smaller 214 bp amplicon is derived from spliced mRNA and is indicative of transgene expression. **B**, Mice, grouped according to genotype (10/group), were treated with 5 µg of TPA twice a week for 15 weeks. Papillomas were counted weekly for 20 weeks.

[0039] **FIGURE 5.** Inducible A431-Tet-Off-pTRE-KSR cells. **A** and **B**, Western blot analysis of wild type Flag-KSR-S and Flag-DN-KSR expression (**A**), and inhibition of endogenous KSR1 expression by KSR-AS (**B**). Flag-KSR-S and DN-KSR were immunoprecipitated (IP) with the monoclonal anti-Flag (M2) antibody and detected by WB. The identity of Flag-KSR was confirmed by re-probing with a monoclonal anti-KSR

antibody (BD Biosciences). Endogenous KSR1 was immunoprecipitated as described in Methods and detected as above. **C**, Dose-dependent inhibition of Flag-KSR-S expression by doxycycline. KSR-S cells were treated with indicated doses of Dox for 24 h and Flag-KSR-S expression after Dox treatment was determined by WB as above. **D** and **E**, Inactivation of KSR1 by KSR-AS or DN-KSR leads to alterations in morphology (**D**), and the development of a multinuclei phenotype (**E**). A431-pTRE cells were examined under the phase-contrast microscope and photographed at 20x magnification for cell morphology (**D**) and 40x magnification for multinucleation (**E**).

**[0040] FIGURE 6.** Inactivation of KSR1 abolishes EGF-stimulated biological responses in A431 cells. **A**, Cell proliferation assay without (*i*) and with (*ii*) EGF stimulation. Proliferation assays were performed as described in Methods. **B**, Cell cycle distribution of A431-pTRE cells was determined by FACS analysis as described in Methods. The proportion of cells in the different phases of the cell cycle was calculated from the experimental fluorescence histograms. **C**, Matrigel invasion assay in response to EGF stimulation. To optimize the stimulatory effect of overexpression of KSR-S on A431 cell invasion, the assay was terminated after 12 h (*i*). To maximize the inhibitory effect of KSR-AS and DN-KSR on A431 cell invasion, the assay was terminated after 18 h (*ii*). **D**, Soft agar colony formation assays in response to EGF stimulation were performed as in Methods. For each cell line or treatment, 4 plates were counted. These results represent one of four similar studies.

**[0041] FIGURE 7.** Inactivation of KSR1 prevents A431 tumorigenesis. **A**, Growth curve of A431 tumors.  $10^6$  A431-pTRE cells were injected s.c. into nude mice as described in Methods. To determine the specificity of KSR-S on A431 tumorigenesis, Dox (100 mg/ml) was added to the drinking water of a group of KSR-S tumor-bearing mice (KSR-S + Dox) 3 days prior to tumor implantation and continued throughout the experiment to turn off KSR-S expression. Mice receiving KSR-AS and DN-KSR cells were monitored

up to 120 days. These results represent one of three similar experiments. There were 5 mice in each experimental group. **B**, H&E staining of A431 tumors. Formalin-fixed, paraffin-embedded and 5 mm-cut A431-pTRE tumor sections were stained with H&E as described in Methods. Black arrows in **(i)** and **(ii)** indicate squamous differentiation. Black arrows in **(iii)** and **(iv)** indicate multinucleated tumor cells, and **(v)** is the enlargement of the framed field in **(iii)** of a multinucleated cell.

**[0042] FIGURE 8.** Inactivation of KSR1 by AS-ODN attenuates A431 tumorigenesis. **A**, Immunofluorescence staining of endogenous KSR1 expression after treatment with 1 mM Control- or AS-ODNs was performed as in Methods. Nuclei were counter stained with DAPI. To compare the intensity of fluorescence labeling, all images of KSR expression were taken with the same exposure time. **B** and **C**, Dose-dependent inhibition of A431 cell proliferation (**B**) and invasion (**C**) by AS-ODN treatment. For the proliferation assay, 30% confluent A431 cells were treated with the indicated doses of Control- or AS-ODNs as in Fig. 3. Cell proliferation after ODN treatment was calculated as percent of non-treated controls. Invasion assays were set up after 48 h of ODN treatment as above. **D**, Attenuation of A431 tumorigenesis by continuous infusion of AS-ODN at 5 mg/kg/day. A431 seed tumor fragments freshly prepared as described in Methods, were transplanted s.c. into the right lateral flank of nude mice. Continuous infusion of ODNs was initiated 2 days prior to tumor transplantation. There were 5 mice in each treatment group. These results represent one of three similar experiments.

**[0043] FIGURE 9.** Inactivation of KSR1 by AS-ODN inhibits oncogenic K-ras signaling *in vitro* in PANC-1. **A**, Dose-dependent inhibition of PANC-1 cell proliferation by AS-ODN treatment. PANC-1 cells were treated with the indicated doses of Control- or AS-ODNs and cell proliferation assays were performed as in FIGURE 7. **B**, AS-ODN treatment (5  $\mu$ M) attenuated the proliferation of a panel of human pancreatic cancer cell lines. The seeding density for each cell lines was determined in preliminary studies so

that all cell lines were 30-40% confluent when transfected with ODNs. **C**, c-Raf-1 is epistatic to KSR1. PANC-1 cells were first treated with Sense- or AS-ODNs for 48 h and then transfected with the BXB-Raf as in Methods. 48 h after transfection, invasion and colony formation assays were set up as in FIGURE 7. The inhibitory effect of AS-ODN on PANC-1 cell invasion (**C**) and transformation (**D**) was reversed by dominant positive BXB-Raf. **E**, AS-ODN treatment inhibited endogenous KSR1 expression in PANC-1 cells. Endogenous KSR1 was immunoprecipitated from non-treated (NT), Sense-ODN-treated or AS-ODN-treated PANC-1 cells, and KSR1 expression was determined by WB as described in Methods. Purified Flag-KSR served as a positive control for the WB. **F**, MAPK and PI-3 kinase activation in AS-ODN-treated and BXB-Raf-1-transfected PANC-1 cells in response to EGF were determined by WB analysis using phospho-MAPK and phospho-Akt specific antibodies as described in Methods. Under these conditions, b-actin and total Akt were unchanged (not shown). These results represent one of three similar experiments.

**[0044] FIGURE 10.** AS-ODN treatment abolished PANC-1 and A549 tumorigenesis *in vivo*. **A**, Continuous infusion of AS-ODN abolished PANC-1 tumor growth. PANC-1 xenografts derived either from  $10^6$  PANC-1 cells (**i**), or from freshly harvested seed PANC-1 tumors (**ii**) were transplanted into nude mice as described in Methods. **A (i)**, established PANC tumors (approximately  $100 \text{ mm}^3$ ) were treated with 10 mg/kg/day of Control- or AS-ODNs for 14 days. Mice bearing regressed AS-ODN-treated tumors were monitored up to 4 weeks. **A(ii)**, freshly prepared PANC-1 seed tumor fragments were transplanted into nude mice as above. Infusion with ODNs was initiated two days prior to tumor implantation and continued for an additional 14 days. These results represent one of three similar experiments. There were 5 mice for each treatment group. **B**, AS-ODN treatment inhibited endogenous tumoral KSR1 expression. Tumoral KSR1 was immunoprecipitated from Saline-, Sense- or AS-ODN-treated PANC-1 tumors and its expression determined by WB as above. **C**, Inhibition of *ksr1* had no effect of Ras

activation in PANC-1 tumors. Ras activation status, measured by the amount of GTP-Ras in Saline-, Control-ODN-, Sense-ODN- or AS-ODN-treated PANC-1 tumors was determined using the Ras activation assay kit. **D**, KSR AS-ODN treatment prevented A549 tumor growth (**i**) and inhibited lung metastases via systemic dissemination (**ii**). A549 seed tumor fragments, freshly prepared as in Methods, were transplanted to nude mice. Treatment with control- or AS-ODNs were initiated when tumors reached 150 mm<sup>3</sup> and continued for additional 18 days (**i**). When animals were sacrificed at the end of the experiment, lungs were resected from control- or AS-ODN-treated mice and stained with Indian ink to visualize surface lung metastases derived via systemic dissemination (**ii**). These results represent one of three similar experiments. There were 5 mice for each treatment group.

**[0045]** **FIGURE 11** depicts a comparative alignment of the mouse KSR polypeptide sequence (SEQ ID NO: 9) and human KSR polypeptide sequence (SEQ ID NO: 10).

**[0046]** **FIGURE 12.** **A**, depicts the nucleic acid coding (cDNA) sequence of mouse *ksr* (SEQ ID NO: 11). **B**, depicts the partial nucleic acid coding (cDNA) sequence of human *ksr* (SEQ ID NO:12).

**[0047]** **FIGURE 13** depicts the specific and dose-dependent inhibition of PANC-1 cell proliferation by AS-ODN treatment. **A**, Dose-dependent inhibition of PANC-1 cell proliferation by AS-ODN treatment; proliferation of K562 cells is not inhibited by AS-ODN treatment. **B**, Western blot analysis of endogenous KSR1 gene expression in K562 and PANC-1 cells. Treatment of K562 cells with 5 $\mu$ M KSR AS-ODN-1 elicited comparable reduction of endogenous KSR1 gene expression (over 80%) to that observed in PANC-1 cells.

[0048] **FIGURE 14** depicts the human KSR1 full length mRNA sequence (SEQ ID NO:24).

[0049] **FIGURE 15** depicts the human KSR nucleic acid and protein sequence annotated with the locations of the CA1 to CA5 domains and the target sequences for AS-ODNs. The full length human KSR1 protein is predicted to have 866 amino acids.

[0050] **FIGURE 16** depicts the mouse KSR nucleic acid and protein sequence annotated with the locations of the CA1 to CA5 domains and the target sequences for the AS-ODNs.

[0051] **FIGURE 17** depicts the human KSR-1 full length mRNA sequence with the nucleic acid target sequences for human AS-ODN1 through AS-ODN12 depicted.

[0052] **FIGURE 18** depicts proliferation assay of PANC-1 cells treated with control ODN, AS-ODN2(181-198) (mouse) (AS-ODN2-old) and AS-ODN2(154-171) (human) (AS-ODN2-new).

[0053] **FIGURE 19** presents percentage of ionizing-radiation induced apoptosis as scored with Annexin V staining in A431 cells expressing vector, wild-type Flag-KSR (KSR-S), Flag-AS-KSR (KSR-AS) or dominant-negative Flag-Ki-KSR (Ki-KSR).

[0054] **FIGURE 20** presents percentage of ionizing-radiation induced apoptosis as scored with Annexin V staining in A431 cells treated with AS-ODN2(214-231), control ODN or expressing vector.

[0055] **FIGURE 21A and 21B** depicts expression of KSR-AS radiosensitizes A431 cells to ionizing radiation.

**[0056]** **FIGURE 22A and 22B** depicts inactivation of KSR (by KSR-AS expression) abrogates both baseline and EGF-stimulated VEGF production in A431 cells.

#### DETAILED DESCRIPTION

**[0057]** In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al, "Molecular Cloning: A Laboratory Manual" (1989); "Current Protocols in Molecular Biology" Volumes I-III [Ausubel, R. M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes I-III [J. E. Celis, ed. (1994)]; "Current Protocols in Immunology" Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

**[0058]** Therefore, if appearing herein, the following terms shall have the definitions set out below.

**[0059]** The terms "oligonucleotides", "antisense", "antisense oligonucleotides", "KSR ODN", "KSR antisense" and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to nucleic acid material including single or multiplenucleic acids, and extends to those oligonucleotides complementary to the nucleic acid sequences described herein, including as presented in FIGURE 12 A, 12 B and 14 and in SEQ ID NOS: 11, 12, and 24, including conserved and activity domains thereof as depicted in FIGURES 11, 15 and

16, and having the profile of activities set forth herein and in the Claims, particularly in being capable of inhibiting the expression of KSR. In particular, the oligonucleotides of the present invention may be substantially complementary to nucleic acid sequence specific to KSR, as provided in SEQ ID NO: 1 or SEQ ID NO:25, or to a portion thereof, as provided for example in SEQ ID NO: 3, 4, 5 and 27. Exemplary oligonucleotides include any of SEQ ID NOS 6-8 and SEQ ID NOS: 28-39. Accordingly, nucleic acids or analogs thereof displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the nucleic acids or of KSR.

[0060] NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, 243:3552-59 (1969), abbreviations for amino acid residues are shown in the following Table of Correspondence:

TABLE OF CORRESPONDENCE

<u>SYMBOL</u>	<u>AMINO ACID</u>	
<u>1-Letter</u>	<u>3-Letter</u>	
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine
A	Ala	alanine

S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
T	Thr	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
Q	Gln	glutamine
E	Glu	glutamic acid
W	Trp	tryptophan
R	Arg	arginine
D	Asp	aspartic acid
N	Asn	asparagine
C	Cys	cysteine

**[0061]** It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. The above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.

**[0062]** A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; i.e., capable of replication under its own control.

**[0063]** A "vector" is a replicon, such as plasmid, phage, virus, retrovirus or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

**[0064]** A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

**[0065]** An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.

**[0066]** A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

**[0067]** Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

**[0068]** A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

**[0069]** An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

**[0070]** A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

**[0071]** The term "oligonucleotide," as used herein in referring to a nucleic acid of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. In particular, and in accordance with the present invention, the oligonucleotide should particularly associate with the RNA encoding KSR and should be of the appropriate sequence and size or length so as to specifically and stably associate with the target RNA such that expression (i.e., translation) of the RNA is blocked or such that stability of the RNA is negatively affected. In one particular aspect of the invention, the antisense oligonucleotides of the present invention are from about 8 to about 50 nucleotides in length, particularly oligonucleotides from 10 to 30 nucleotides in length, particularly oligonucleotides from 15 to 25 nucleotides.

**[0072]** The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

[0073] The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

[0074] As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

[0075] A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

**[0076]** Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

**[0077]** It should be appreciated that also within the scope of the present invention are DNA or nucleic acid sequences which code for KSR having the same amino acid sequence as the KSR sequences disclosed herein, including SEQ ID NO: 11 and SEQ ID NO: 12, but which are degenerate these sequences. By "degenerate to" is meant that a different three-letter codon is used to specify a particular amino acid. It is well known in the art that the following codons can be used interchangeably to code for each specific amino acid:

<b>[0078]</b> Phenylalanine (Phe or F)	UUU or UUC
Leucine (Leu or L)	UUA or UUG or CUU or CUC or CUA or CUG
Isoleucine (Ile or I)	AUU or AUC or AUA
Methionine (Met or M)	AUG
Valine (Val or V)	GUU or GUC or GUA or GUG
Serine (Ser or S)	UCU or UCC or UCA or UCG or AGU or AGC
Proline (Pro or P)	CCU or CCC or CCA or CCG
Threonine (Thr or T)	ACU or ACC or ACA or ACG
Alanine (Ala or A)	GCU or GCG or GCA or GCG
Tyrosine (Tyr or Y)	UAU or UAC
Histidine (His or H)	CAU or CAC

Glutamine (Gln or Q)	CAA or CAG
Asparagine (Asn or N)	AAU or AAC
Lysine (Lys or K)	AAA or AAG
Aspartic Acid (Asp or D)	GAU or GAC
Glutamic Acid (Glu or E)	GAA or GAG
Cysteine (Cys or C)	UGC or UGC
Arginine (Arg or R)	CGU or CGC or CGA or CGG or AGA or AGG
Glycine (Gly or G)	GGU or GGC or GGA or GGG
Tryptophan (Trp or W)	UGG
Termination codon	UAA (ochre) or UAG (amber) or UGA (opal)

[0079] It should be understood that the codons specified above are for RNA sequences. The corresponding codons for DNA have a T substituted for U.

[0080] Mutations can be made in *ksr* such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative change is more likely to alter the structure, activity or function of the resulting protein. The present invention should be considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein.

[0081] The following is one example of various groupings of amino acids:

Amino acids with nonpolar R groups

Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine

[0082] Amino acids with uncharged polar R groups

Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine

[0083] Amino acids with charged polar R groups (negatively charged at pH 6.0)

Aspartic acid, Glutamic acid

[0084] Basic amino acids (positively charged at pH 6.0)

Lysine, Arginine, Histidine (at pH 6.0)

[0085] Another grouping may be those amino acids with phenyl groups:

Phenylalanine, Tryptophan, Tyrosine

[0086] Another grouping may be according to molecular weight (i.e., size of R groups):

Glycine	75
Alanine	89
Serine	105
Proline	115
Valine	117
Threonine	119
Cysteine	121
Leucine	131
Isoleucine	131
Asparagine	132

Aspartic acid	133
Glutamine	146
Lysine	146
Glutamic acid	147
Methionine	149
Histidine (at pH 6.0)	155
Phenylalanine	165
Arginine	174
Tyrosine	181
Tryptophan	204

**[0087]** Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free NH<sub>2</sub> can be maintained.

**[0088]** Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site for disulfide bridges with another Cys. A His may be introduced as a particularly "catalytic" site (i.e., His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro may be introduced because of its particularly planar structure, which induces  $\beta$ -turns in the protein's structure.

**[0089]** Two amino acid sequences are "substantially homologous" when at least about 70% of the amino acid residues (preferably at least about 80%, and most preferably at least about 90 or 95%) are identical, or represent conservative substitutions.

**[0090]** A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

**[0091]** The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.

**[0092]** The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, more preferably by at least 70 percent, most preferably by at least 90 percent, a clinically significant change in the mitotic activity of a target cellular mass, or other feature of pathology such as for example, reduced tumor mass, reduced tumor cell proliferation, reduction in metastatic capacity, or enhanced apoptosis, as may attend its presence and activity.

**[0093]** As used herein, "pg" means picogram, "ng" means nanogram, "ug" or " $\mu$ g" mean microgram, "mg" means milligram, "ul" or " $\mu$ l" mean microliter, "ml" means milliliter, "l" means liter.

**[0094]** A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

**[0095]** The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and wash. However, one skilled in the art will appreciate that such "standard hybridization conditions" are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like. Also important in the determination of "standard hybridization conditions" is whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20°C below the predicted or determined  $T_m$  with washes of higher stringency, if desired.

**[0096]** The present invention relates to methods and compositions for the specific inhibition of expression and/or activity of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR. It is herein demonstrated that on specific inhibition of KSR the Ras pathway is disrupted and, specifically, that Ras-mediated tumors, tumorigenesis and metastasis regress, are inhibited, or are blocked. In particular antisense oligonucleotides and the

coding sequence of human KSR (SEQ ID NO:25) corresponding to nucleotides 124 to 243 of mouse KSR (SEQ ID NO: 1), or a portion thereof. The invention provides an oligonucleotide comprising a sequence substantially complementary to nucleotides encoding amino acids 33 to 72 of human KSR (SEQ ID NO:26) and 42 to 82 of mouse KSR (SEQ ID NO: 2) or a portion thereof. In particular, oligonucleotides of the invention include oligonucleotides comprising a sequence substantially complementary to nucleotides selected from the group of: nucleotides 124 to 141 of human KSR, corresponding to nucleotides 151 to 168 of mouse KSR (SEQ ID NO: 3); nucleotides 154 to 171 of human KSR (SEQ ID NO: 27), corresponding closely to nucleotides 181 to 189 of mouse KSR (SEQ ID NO: 4), with a single base change at the 5'-most nucleotide; and nucleotides 187 to 204 of human KSR, corresponding to nucleotides 214 to 231 of mouse KSR (SEQ ID NO: 5). The invention includes antisense oligonucleotides comprising a sequence selected from the group of SEQ ID NOS: 6-8 and SEQ ID NOS: 28-39.

**[0100]** In a particular aspect, the nucleic acids and oligonucleotides of the present invention may be modified, either by manipulation of the chemical backbone of the nucleic acids or by covalent or non-covalent attachment of other moieties. In each or any case, such manipulation or attachment may serve to modify the stability, cellular, tissue or organ uptake, or otherwise enhance efficacy of the nucleic acids and covalently linked to other molecules, including but not limited to polypeptides, carbohydrates, lipid or lipid-like moieties, ligands, chemical agents or compounds, which may serve to enhance the uptake, stability or to target the oligonucleotides.

**[0101]** In further embodiments, the oligonucleotides of the present invention are modified in their chemical backbone. In a particular embodiment, the oligonucleotides comprise at least one phosphorothioate linkage.

expression of nucleic acid complementary to KSR RNA specifically inhibits expression of KSR and blocks *g*f Ras mediated tumorigenesis.

**[0097]** The present invention provides an oligonucleotide which is substantially complementary to a region of KSR RNA, wherein said oligonucleotide inhibits the expression of KSR. The invention further provides an oligonucleotide which is substantially complementary to a nucleic acid encoding mammalian KSR. In a particular embodiment, an oligonucleotide is provided which is substantially complementary to a nucleic acid encoding human KSR.

**[0098]** In an aspect of the invention an oligonucleotide is provided which is substantially complementary to a translation initiation site, 5' untranslated region, coding region or 3' untranslated region of mRNA encoding mammalian KSR. In one such aspect, the invention thus provides an oligonucleotide which is substantially complementary to a translation initiation site, 5' untranslated region, coding region or 3' untranslated region of mRNA encoding human KSR as provided in FIGURE 14 and SEQ ID NO: 24. In a particular embodiment, the invention provides an antisense oligonucleotide substantially complementary to the N-terminal coding region of mammalian KSR mRNA, particularly to the region of nucleotides 1 through 761 of the coding region of mammalian KSR mRNA. In one embodiment, the invention includes an antisense oligonucleotide comprising a sequence substantially complementary to the CA1 region of KSR (SEQ ID NO:1 and SEQ ID NO:25). The invention provides oligonucleotides comprising a sequence substantially complementary to nucleotides encoding amino acids 33 to 72 of human KSR (SEQ ID NO:26) or 42 to 82 of mouse KSR (amino acids SEQ ID NO: 2), or a portion thereof, of the sequence of KSR.

**[0099]** In a further embodiment, the invention includes an antisense oligonucleotide comprising a sequence substantially complementary to nucleotides 97 to 216 of the

**[0102]** The oligonucleotides of the present invention may be combined with oligonucleotides directed to other targets, by mixture or by non-covalent or covalent attachment. For instance, the KSR antisense oligonucleotides of the present invention may be combined with antisense directed to raf as described in U.S. Patent 6,391,636 (incorporated herein by reference) or to other oncogenic or proliferative proteins.

**[0103]** Recombinant DNA molecules comprising a nucleic acid sequence which encodes on transcription an antisense RNA complementary to mammalian KSR RNA or a portion thereof are provided by the invention. Further, the recombinant DNA molecules comprise a nucleic acid sequence wherein said nucleic acid sequence is operatively linked to a transcription control sequence. Cell lines transfected with these recombinant DNA molecules are also included in the invention.

**[0104]** In a further aspect, an expression vector is provided which is capable of expressing a nucleic acid which is substantially complementary to the coding sequence of KSR RNA, or a portion thereof, wherein said nucleic acid inhibits the expression of KSR. In a particular aspect, this includes an expression vector capable of expressing an oligonucleotide which is substantially complementary to the CA1 region of the coding sequence of KSR RNA, or a portion thereof, wherein said oligonucleotide inhibits the expression of KSR.

**[0105]** In an additional embodiment, the invention provides a composition comprising an expression vector and a pharmaceutically acceptable carrier or diluent, wherein said expression vector is capable of expressing nucleic acid which is substantially complementary to the coding sequence of KSR RNA, or a portion thereof, wherein said nucleic acid inhibits the expression of KSR.

**[0106]** Methods for inhibiting expression of KSR are provided. In one aspect, a method of inhibiting the expression of mammalian KSR comprising contacting cells which express KSR with an effective amount of a nucleic acid which is complementary to a portion of the mRNA encoding KSR is included. In particular, a method of inhibiting the expression of mammalian KSR is provided, comprising contacting cells which express KSR with an effective amount of the oligonucleotide of the present invention whereby expression of mammalian KSR is inhibited. In a further aspect, a method of modulating KSR activity is provided comprising contacting cells which express KSR with an effective amount of an agent or compound which modulates KSR activity. In one such aspect, a method of modulating KSR activity is provided comprising contacting cells which express KSR with an effective amount of an agent or compound which blocks, inhibits or otherwise reduces the activity of KSR.

**[0107]** In addition, a method is provided for identifying compounds or agents which inhibit the expression of KSR comprising the steps of:

- (a) incubating a cell expressing KSR in the presence and absence of a candidate compound or agent; and
- (b) detecting or measuring the expression of KSR in the presence and absence of a candidate compound or agent,

whereby a decrease in the expression of KSR in the presence of said candidate compound or agent versus in the absence of said candidate compound or agent indicates that said compound or agent inhibits the expression of KSR.

**[0108]** Methods for inhibiting activity, including and preferably kinase or phosphorylation activity, of KSR are provided. In one aspect, a method of inhibiting the activity of mammalian KSR comprising contacting cells which express KSR with an effective amount of a compound or agent that inhibits or blocks KSR is included. In particular, a method of inhibiting the activity of mammalian KSR is provided, comprising

contacting cells which express KSR with an effective amount of a compound, agent or composition of the present invention whereby activity of mammalian KSR is inhibited.

**[0109]** In addition, a method is provided for identifying compounds or agents which inhibit the activity, including kinase or phosphorylation activity, of KSR comprising the steps of:

- (a) incubating a cell expressing KSR in the presence and absence of a candidate compound or agent; and
- (b) detecting or measuring the activity of KSR in the presence and absence of a candidate compound or agent,

whereby a decrease in the activity of KSR in the presence of said candidate compound or agent versus in the absence of said candidate compound or agent indicates that said compound or agent inhibits the activity of KSR. In one aspect of the invention the activity and/or expression of KSR may be assessed or monitored by determining the phosphorylation status of the KSR kinase target or of a peptide comprising a kinase target sequence domain. For instance, the phosphorylation status of Raf or a Raf-derived peptide may be utilized in such an assessment. The activity or expression of KSR may also be assessed *in vitro* or *in vivo* in tumor cells or tumor animal models, whereby Ras mediated tumorigenesis, cell proliferation or metastasis is monitored, including as described in the Examples herein.

**[0110]** The present invention naturally contemplates several means for preparation of the nucleic acids and oligonucleotides of the present invention, including as illustrated herein known recombinant techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The knowledge of the cDNA and amino acid sequences of KSR as disclosed herein facilitates the preparation of the nucleic acids of the invention by such recombinant techniques, and accordingly, the invention extends to

expression vectors prepared from the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.

[0111] Another feature of this invention is the expression of the nucleic acids disclosed herein. As is well known in the art, nucleic acid or DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Such operative linking of a nucleic acid sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.

[0112] A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col El, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAS, e.g., the numerous derivatives of phage  $\lambda$ , e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the  $2\mu$  plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like. In addition, viral and retroviral vectors, including but not limited to adenovirus and adeno-associated virus, may be useful in such expression.

[0113] Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these vectors

to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the *LTR* system, the major operator and promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast - mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

**[0114]** A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi such as yeasts, and animal cells, such as CHO, R1.1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and tumor cells, transformed cells, human cells and plant cells in tissue culture.

**[0115]** It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

**[0116]** In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its

controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products. Considering these and other factors a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

**[0117]** The present invention further includes transgenic animals and animal models wherein KSR is knocked out or otherwise nullified (as in the *ksr*<sup>-/-</sup> animals described herein) or wherein KSR is overexpressed as further described herein. Such animal models include mammals for instance mice, rats, pigs, rabbits, dogs, monkeys, etc. and any other recognized vertebrate or invertebrate system for study, including ducks, fish, *drosophila*, *C. elegans*, etc. In the case of nullified KSR, these animals are useful for the study of oncogenesis or the blockage of tumorigenesis in a KSR null background, including to identify other factors in tumorigenesis or metastasis. In the case of KSR overexpressors, wherein tumorigenesis, cell proliferation and metastasis is enhanced, these systems may be useful for the rapid study of tumor models and for evaluating potential anti-cancer compounds or agents, including those targeting KSR as well as other pathways.

**[0118]** As mentioned above, nucleic acids and oligonucleotides of the present invention can be prepared synthetically rather than cloned. In general, one will select preferred codons for the intended host if the sequence will be used for expression. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods

and assembled into a complete coding sequence. See, e.g., Edge, *Nature*, 292:756 (1981); Nambair et al., *Science*, 223:1299 (1984); Jay et al., *J. Biol. Chem.*, 259:6311 (1984).

**[0119]** Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. (See Weintraub, 1990; Marcus-Sekura, 1988.) In the cell, they hybridize to that mRNA, forming a double stranded molecule and interfering with the expression of mRNA into protein. Antisense methods have been used to inhibit the expression of many genes *in vitro* (Marcus-Sekura, 1988; Hambor et al., 1988).

**[0120]** The antisense oligonucleotides of the invention are selected as substantially complementary to a region of KSR mRNA. The oligonucleotides of the present invention may be complementary to regions including but not limited to: a) the 5'-cap site of an mRNA molecule (Ojala et al. (1997) *Antisense Nucl. Drug Dev.* 7:31-38); b) the transcription start site (Monia et al. (1992) *J. Biol. Chem.* 267:19954-19962); c) the translation initiation codon (Dean et al. (1994) *Proc. Natl. Acad. Sci. U.S.A.* 91:11762-11766); d) the translation stop codon (Wang et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:3318-3322); e) mRNA splice sites (Agrawal et al. (1988) *Proc. Natl. Acad. Sci. U.S.A.* 86:7790-7794; Colige et al. (1993) *Biochem.* 32:7-11); f) the 5'-untranslated region of mRNA molecules (Duff et al. (1995) *J. Biol. Chem.* 270:7161-7166; Yamagami et al. (1996) *Blood* 87:2878-2884); g) the 3'-untranslated region of mRNA molecules (Bennett et al. (1994) *J. Immunol.* 152:3530-3540; Dean et al. (1994) *J. Biol. Chem.* 269:16146-16424); and h) the coding region (Laptev et al. (1994) *Biochem.* 33:11033-11039; Yamagami et al. (1996) *Blood* 87:2878-2884).

**[0121]** The skilled artisan can readily utilize any of several strategies to facilitate and simplify the selection process for nucleic acids and oligonucleotides effective in

inhibition of KSR expression. Predictions of the binding energy or calculation of thermodynamic indices between an oligonucleotide and a complementary sequence in an mRNA molecule may be utilized (Chiang et al. (1991) *J. Biol. Chem.* 266:18162-18171; Stull et al. (1992) *Nucl. Acids Res.* 20:3501-3508). Antisense oligonucleotides may be selected on the basis of secondary structure (Wickstrom et al (1991) in *Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS*, Wickstrom, ed., Wiley-Liss, Inc., New York, pp. 7-24; Lima et al. (1992) *Biochem.* 31:12055-12061). Schmidt and Thompson (U.S. Patent 6416,951) describe a method for identifying a functional antisense agent comprising hybridizing an RNA with an oligonucleotide and measuring in real time the kinetics of hybridization by hybridizing in the presence of an intercalation dye or incorporating a label and measuring the spectroscopic properties of the dye or the label's signal in the presence of unlabelled oligonucleotide. In addition, any of a variety of computer programs may be utilized which predict suitable antisense oligonucleotide sequences or antisense targets utilizing various criteria recognized by the skilled artisan, including for example the absence of self-complementarity, the absence hairpin loops, the absence of stable homodimer and duplex formation (stability being assessed by predicted energy in kcal/mol). Examples of such computer programs are readily available and known to the skilled artisan and include the OLIGO 4 or OLIGO 6 program (Molecular Biology Insights, Inc., Cascade, CO) and the Oligo Tech program (Oligo Therapeutics Inc., Wilsonville, OR).

[0122] In addition, antisense oligonucleotides suitable in the present invention may be identified by screening an oligonucleotide library, or a library of nucleic acid molecules, under hybridization conditions and selecting for those which hybridize to the target RNA or nucleic acid (see for example U.S. Patent 6,500,615). Mishra and Toulme have also developed a selection procedure based on selective amplification of oligonucleotides that bind target (Mishra et al (1994) *Life Sciences* 317:977-982). Oligonucleotides may also be selected by their ability to mediate cleavage of target RNA by RNase H, by selection

and characterization of the cleavage fragments (Ho et al (1996) *Nucl Acids Res* 24:1901-1907; Ho et al (1998) *Nature Biotechnology* 16:59-630). Generation and targeting of oligonucleotides to GGGA motifs of RNA molecules has also been described (U.S. Patent 6,277,981).

**[0123]** Inhibition of *ksr* gene expression can be measured in ways which are routine in the art, for example by Northern blot assay of mRNA expression or Western blot assay of protein expression as well known to the skilled artisan. Effects on cell proliferation or tumor cell growth can also be measured, *in vitro* or *in vivo*, in cell, tumor or animal model systems, by methods well known to the skilled artisan, including as taught in the examples of the instant application. Similarly, inhibition of KSR activity, particularly phosphorylation or kinase activity may be measured.

**[0124]** "Substantially complementary" is used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide or nucleic acid. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility or expression, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under physiological conditions in the case of *in vivo* assays or therapeutic treatment or, in the case of *in vitro* assays, under conditions in which the assays are conducted.

**[0125]** In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. Oligonucleotide includes oligomers comprising non-naturally occurring monomers, or portions thereof, which function

similarly and such modified or substituted oligonucleotides may be preferred over native forms because of, for example, enhanced cellular uptake and increased stability against nucleases. The oligonucleotides of the present invention may contain two or more chemically distinct regions, each made up of at least one nucleotide, for instance, at least one region of modified nucleotides that confers one or more beneficial properties (for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the RNA target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids (for example, RNase H - a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex).

**[0126]** In a preferred embodiment, the region of the oligonucleotide which is modified to increase KSR mRNA binding affinity comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher Tm (i.e., higher target binding affinity) than 2'-deoxyoligonucleotides against a given target. In another preferred embodiment, the oligonucleotide is modified to enhance nuclease resistance. Cells contain a variety of exo- and endo-nucleases which can degrade nucleic acids. A number of nucleotide and nucleoside modifications have been shown to confer relatively greater resistance to nuclease digestion. Oligonucleotides which contain at least one phosphorothioate modification are presently more preferred (Geary, R.S. et al (1997) Anticancer Drug Des 12:383-93; Henry, S. P. et al (1997) Anticancer Drug Des 12:395-408; Banerjee, D. (2001) Curr Opin Investig Drugs 2:574-80). In some cases, oligonucleotide modifications which enhance target binding affinity are also, independently, able to enhance nuclease resistance.

**[0127]** Specific examples of some preferred oligonucleotides envisioned for this invention include those containing modified backbones, for example, phosphorothioates,

phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones. The amide backbones disclosed by De Mesmaeker et al. (1995) *Acc. Chem. Res.* 28:366-374) are also preferred. Also preferred are oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506). In other preferred embodiments, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleobases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al., *Science*, 1991, 254, 1497). Oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH, SH, SCH<sub>3</sub>, F, OCN, heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide.

**[0128]** Oligonucleotides may also include, additionally or alternatively base modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-me pyrimidines, particularly 5-methylcytosine (5-me-C) (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as

synthetic nucleobases, including but not limited to, 2-aminoadenine, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine (Kornberg, A., DNA Replication, W.H. Freeman & Co., San Francisco, 1980, pp75-77; Gebeyehu, G., et al., 1987, Nucl. Acids Res. 15:4513). A "universal" base known in the art, e.g., inosine, may be included.

**[0129]** Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86: 6553), cholic acid (Manoharan et al. (1994) Bioorg. Med. Chem. Let. 4:1053), a thioether, for example, hexyl-S-tritylthiol (Manoharan et al. (1992) Ann. N.Y. Acad. Sci. 660: 306; Manoharan et al. (1993) Bioorg. Med. Chem. Let. 3: 2765), a thiocholesterol (Oberhauser et al. (1992) Nucl. Acids Res.20:533), an aliphatic chain, for example, dodecandiol or undecyl residues (Saison-Behmoaras et al. (1991) EMBO J. 10:111; Kabanov et al. (1990) FEBS Lett. 259:327; Svinarchuk et al. (1993) Biochimie 75:49), a phospholipid, a polyamine or a polyethylene glycol chain (Manoharan et al. (1995) Nucleosides & Nucleotides 14:969). Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides are known in the art, for example, U.S. Pat. Nos. 5,138,045, 5,218,105 and 5,459,255.

**[0130]** Farrel and Kloster (U.S. Patent 6,310,047) describe the enhancement of delivery and of *in vivo* nuclease resistance of antisense oligonucleotides using high affinity DNA binding polynuclear platinum compounds.

**[0131]** It is not necessary for all positions in a given oligonucleotide to be uniformly

modified, and more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at a single nucleoside within an oligonucleotide.

**[0132]** The oligonucleotides in accordance with this invention preferably are from about 8 to about 50 nucleotides in length. Particularly preferred oligonucleotides are from 10 to 30 nucleotides in length, particularly preferred are from 15 to 25 nucleotides. In the context of this invention it is understood that this encompasses non-naturally occurring oligomers as hereinbefore described, having 8 to 50 monomers.

**[0133]** The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the skilled artisan. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives.

**[0134]** The therapeutic possibilities that are raised by the methods and compositions, particularly oligonucleotides, of the present invention derive from the demonstration in the Examples herein that inactivation of KSR, including by genetic knockout, by inhibition of its expression utilizing antisense oligonucleotides, and by expression of reverse complement RNA or antisense DNA constructs, results in specific blockage of Ras-mediated tumorigenesis and cellular hyperproliferation, including via *gf*-Ras, and treatment or inhibition of progression of cancer. The present invention contemplates pharmaceutical intervention in the cascade of reactions in which overexpressed or amplified, hyperactivated or oncogenic Ras, including *gf*-Ras, is implicated, to regress, block, treat or inhibit the progression of Ras-mediated tumors, oncogenesis, metastasis and angiogenesis. Thus, in instances where it is desired to reduce or inhibit Ras,

including *gf*-Ras, the nucleic acids and oligonucleotides of the present invention could be introduced to block or inhibit the Ras pathway.

**[0135]** The invention further includes a method of treating or preventing a hyperproliferative condition associated with the expression of *gf*-Ras or heightened expression or hyperactivation of Ras or the Ras pathway in a mammal comprising administering to said mammal a therapeutically effective amount of a compound or agent which inhibits the expression or activity of mammalian KSR protein. In one aspect of this method, said compound or agent is an antisense oligonucleotide which specifically hybridizes to a portion of the mRNA encoding KSR. A method of treating or preventing a hyperproliferative condition associated with the expression of *gf*-Ras or heightened expression or hyperactivation of Ras in a mammal is provided, comprising expressing in said mammal or administering to said mammal a therapeutically effective amount of a nucleic acid which is complementary to a portion of the mRNA encoding KSR.

**[0136]** The invention further provides a method for sensitizing hyperproliferative, cancer or tumor cells in a mammal to ionizing radiation or other radiation or chemotherapy comprising administering to a mammal a therapeutically effective amount of one or more inhibitor of KSR expression and/or activity. The invention provides a method for sensitizing hyperproliferative, cancer or tumor cells in a mammal to ionizing radiation or other radiation or chemotherapy comprising administering to a mammal a therapeutically effective amount of one or more oligonucleotide of the present invention.

**[0137]** The present invention further provides a method for modulating angiogenesis, particularly by modulation of VEGF expression upon activation or inhibition of expression and/or activity of KSR. VEGF expression is modulated by specific inhibition or activation of KSR expression and/or activity. Activation or enhanced expression of KSR increases the amount or expression of VEGF in or by cells. Thus, activation or

enhanced expression of KSR in a cell or tissue provides a method of stimulating angiogenesis. Inhibition, blockage or reduction of KSR decreases the amount or expression of VEGF, thereby having an anti-angiogenic effect. In one such aspect, VEGF expression of cancer or tumor cells is blocked by inhibition of KSR, including by administration or expression of antisense oligonucleotide complementary to KSR, resulting in inhibition of angiogenesis in the cancer or tumor. Inhibition of KSR, including by administration or expression of antisense oligonucleotide complementary to KSR, provides a method of inhibiting angiogenesis in a tumor, tissue or cells expressing KSR, particularly a tissue or tumor expressing *g1Ras* or wherein the Ras pathway is hyperactivated or Ras is overexpressed or amplified.

[0138] In a further aspect, a method of treating or inhibiting the progression of cancer in a mammal is included, comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression or activity of mammalian KSR protein. Cancers which are susceptible to the invention's method include cancer selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer. In one aspect, a method of treating or inhibiting the progression of pancreatic cancer in a mammal is provided, comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression or activity of mammalian KSR protein.

[0139] Thus, a method is provided for treating or inhibiting the progression of cancer in a mammal comprising administering to a mammal a therapeutically effective amount of one or more oligonucleotide of the present invention. A method is provided for treating or inhibiting the progression of pancreatic cancer in a mammal comprising administering

to a mammal a therapeutically effective amount of one or more oligonucleotide of the present invention.

**[0140]** The present invention further contemplates therapeutic compositions useful in practicing the therapeutic methods of this invention. A subject therapeutic composition includes, in admixture, a pharmaceutically acceptable carrier (excipient) or diluent and one or more nucleic acid or oligonucleotide of the invention as described herein as an active ingredient. In a preferred embodiment, the composition comprises an oligonucleotide capable of inhibiting the expression of KSR.

**[0141]** Compositions of the nucleic acids and oligonucleotides are an additional aspect of the invention. The invention includes a composition comprising an oligonucleotide which is substantially complementary to a region of KSR RNA and a pharmaceutically acceptable carrier or diluent. The invention thus provides a pharmaceutical composition comprising a therapeutically effective amount of an oligonucleotide which is substantially complementary to a region of KSR RNA and a pharmaceutically acceptable carrier or diluent.

**[0142]** In a further aspect, compositions are provided comprising one or more chemotherapeutic or radiotherapeutic agent and an oligonucleotide which is targeted to a mRNA encoding mammalian KSR and which inhibits KSR expression.

**[0143]** The preparation of therapeutic compositions which contain nucleic acids, oligonucleotides, or analogs as active ingredients is well understood in the art. Such compositions can be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The compositions may be prepared in solid pill form, including slow release

formulations. The composition may be in a patch form for transdermal application, particularly in slow release format. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.

**[0144]** A nucleic acid or oligonucleotide can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

**[0145]** The therapeutic nucleic acid-, oligonucleotide-, analog- or active fragment-containing compositions may be administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

**[0146]** The therapeutic compositions may further include an effective amount of the nucleic acid or oligonucleotide, and one or more of the following active ingredients or agents: a chemotherapeutic agent, a radiotherapeutic agent, an immunomodulatory agent, an anti-mitotic agent.

**[0147]** The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip or infusion, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intrathecal or intraventricular administration. For oral administration, it has been found that oligonucleotides with at least one 2'-substituted ribonucleotide are particularly useful because of their absorption and distribution characteristics. U.S. Pat. No. 5,591,721 (Agrawal et al.) and may be suitable for oral administration. Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Compositions for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. In addition to such pharmaceutical carriers, cationic lipids may be included in the formulation to facilitate oligonucleotide uptake. One such composition shown to facilitate uptake is Lipofectin (BRL Bethesda Md.).

**[0148]** Dosing is dependent on severity and responsiveness of the condition to be treated, with course of treatment lasting from several days to several months or until a cure is effected or a diminution of disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be calculated based on IC50s or EC50s in *in vitro* and *in vivo* animal studies. For example, given the molecular weight of compound (derived from oligonucleotide sequence and chemical structure) and an effective dose such as an IC50, for example (derived experimentally), a dose in mg/kg is routinely calculated.

**[0149]** The oligonucleotides of the invention are also useful for detection and diagnosis of KSR expression. For example, radiolabeled oligonucleotides can be prepared by radioactive (e.g.  $^{32}\text{P}$ ) labeling at the 5' end or 3' end (including with polynucleotide kinase), contacted with tissue or cell samples suspected of KSR expression or of gf-Ras and unbound oligonucleotide removed. Radioactivity remaining in the sample indicates bound oligonucleotide (which in turn indicates the presence of KSR or of gf-Ras) and can be quantitated using a scintillation counter or other routine means. Radiolabeled oligonucleotide can also be used to perform autoradiography of tissues to determine the localization, distribution and quantitation of KSR or gf-Ras expression for research, diagnostic or therapeutic purposes. In addition, the radiolabel may have a therapeutic effect in promoting cell death or blocking cellular proliferation. Analogous assays for fluorescent detection of raf expression can be developed using oligonucleotides of the invention which are conjugated with fluorescein or other fluorescent tag instead of radiolabeling.

**[0150]** The oligonucleotides of the present invention may be labeled with a detectable label. In particular aspects, the label may be selected from enzymes, chemicals which

fluoresce and radioactive elements. In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Enzyme labels are also useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known, including but not limited to peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

**[0151]** The invention includes additional compositions which can inhibit the expression of a protein, in particular KSR, at the transcriptional level by blocking translation of KSR mRNA or by facilitating destruction or destabilization of the RNA such that translation cannot efficiently take place. In this aspect, the invention provides a ribozyme that cleaves KSR mRNA.

**[0152]** Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs

have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, 1988.). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

[0153] Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type. (Hasselhoff and Gerlach, 1988) *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

[0154] The use of RNA interference strategies to inhibit the expression of KSR is further embodied in the invention. Thus, methods of RNA interference and small interfering RNA compositions are included in the methods and compositions of the present invention. RNA interference refers to the silencing of genes specifically by double stranded RNA (dsRNA) (Fine, A. et al (1998) Nature 391:806-811). In one embodiment, short or small interfering RNA (siRNA) is utilized (Elbashir, S.M. et al (2001) Nature 411:494-498). In addition, long double stranded RNA hairpins may be employed (Tavernarakis, N. et al (2000) Nature Genet 24:180-183; Chuang, C.F. and Meyerowitz, E.M. (2000) PNAS USA 97:4985-90; Smith, NA et al (2000) Nature 407:319-20). Virus-mediated RNA interference against K-Ras has been described (B rummelkamp, T.R. et al (2002) Cancer Cell 2:243-247).

[0155] The invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are

presented in order to more fully illustrate the preferred embodiments of the invention and should in no way be construed, however, as limiting the broad scope of the invention.

### EXAMPLES

[0156] These studies demonstrate that mammalian KSR integrates signaling through the EGFR/Ras/MAPK signaling module. That EGFR, Ras and KSR are on the same signaling pathway in mammalian cells is supported by the unusual hair follicle phenotype manifested in EGFR knockout mice and recapitulated in the KSR knockout, by the attenuation of EGF-induced MAPK signaling in MEFs, and by the abrogation of EGFR-/Ras-mediated tumorigenesis in multiple experimental models. Further, genetic and pharmacologic approaches identified KSR as required for various aspects of tumorigenesis *in vitro* and *in vivo*. *In vitro*, loss of KSR function reduced proliferation of MEFs, A431 and MCF-7 cells, abrogated Ras-mediated MEF transformation, and attenuated A431 and MCF-7 cell invasion. *In vivo*, inactivation of KSR antagonized *v-Ha-Ras*-mediated tumor formation and growth of an established EGFR-driven tumor that requires wild type Ras for neoplastic progression. As in *C. elegans*<sup>2,3</sup>, KSR appears dispensable, for the most part, for normal development, but required when increased signaling through the EGFR/Ras pathway is necessary, as occurs acutely in response to EGF stimulation or chronically in Ras-mediated tumors. This suggests that pharmacologic inactivation might yield a therapeutic gain. Indeed, the results presented herein, including *in vivo* models of Ras-mediated tumorigenesis, show significant inhibition of cell proliferation and cell invasion on inactivation of *ksr*. These studies demonstrate the use of *ksr* antisense oligonucleotides (KSR-AS ODNs) as a therapeutic approach in cancer and tumorigenesis, particularly K-Ras mediated tumorigenesis.

### EXAMPLE 1

## ABSTRACT

[0157] In *Drosophila melanogaster* and *Caenorhabditis elegans*, Kinase Suppressor of Ras (KSR) positively modulates Ras/mitogen-activated protein kinase (MAPK) signaling either upstream of or parallel to Raf<sup>1-3</sup>. The precise signaling mechanism of mammalian KSR, and its role in Ras-mediated transformation, however, remains uncertain. Utilizing cells markedly overexpressing recombinant KSR, some groups reported KSR inhibits MAPK activation and Ras-induced transformation<sup>4-6</sup> while others observed enhancing effects<sup>7-10</sup>. Evidence suggests these discrepancies reflect gene dosage effects<sup>11</sup>. To gain insight into KSR function *in vivo*, we generated mice homozygous null for KSR. *ksr*<sup>-/-</sup> mice are viable and without major developmental defects. Newborn mice, however, display a unique hair follicle phenotype previously observed in EGFR-deficient mice, providing genetic support for the notion that EGFR, Ras and KSR are on the same signaling pathway in mammals. Embryonic fibroblasts from *ksr*<sup>-/-</sup> animals were defective in EGF activation of the MAPK pathway, and displayed diminished proliferative potential and impaired Ras-dependent transformability. Tumor formation in Tg.AC mice, resulting from skin-specific *v-Ha-ras* expression, was abrogated in the *ksr*<sup>-/-</sup> background. Thus, evidence presented herein suggests KSR transduces EGFR-/Ras-mediated neoplasia, which may be potentially targeted by anti-KSR therapeutic strategies.

## INTRODUCTION

[0158] Kinase suppressor of Ras (KSR) was identified in *Drosophila melanogaster* and *Caenorhabditis elegans* as a positive modulator of Ras/mitogen-activated protein kinase (MAPK) signaling either upstream of or parallel to Raf (1-3). Although an intensive effort has been directed at elucidating the biochemical properties of mammalian KSR, its precise signaling mechanism remains uncertain. In particular, its role in Ras-mediated transformation has not been addressed convincingly. Some groups reported KSR inhibits MAPK activation and Ras-induced transformation (4-6) while others observed enhancing

effects (8-10). These experiments utilized cell systems overexpressing recombinant KSR to levels far beyond endogenous KSR, and evidence suggests these discrepancies might reflect gene dosage (11). While we and others argue the necessity of both the kinase and scaffolding functions of KSR for its optimal activation of the Raf-MAPK cascade (26-30), others believe that KSR signals solely via its scaffolding function (9, 12, 31).

[0159] To gain insight into the *in vivo* function of KSR, we generated a mouse homozygous null for KSR. *ksr*<sup>-/-</sup> mice are viable and without major developmental defects. Newborn mice, however, display a unique hair follicle phenotype previously observed in EGFR-deficient mice. Mouse embryonic fibroblasts (MEFs) from *ksr*<sup>-/-</sup> animals displayed diminished proliferative potential and impaired oncogenic *v-Ha-Ras*-dependent transformation. Moreover, EGF and TPA activated the MAPK cascade to a similar extent in MEFs, yet only c-Raf-1 activation by mitogenic doses of EGF depended on *ksr*. The KSR knockout mouse thus allows the delineation of KSR-dependent and independent mechanisms of c-Raf-1 activation. Further, tumor formation in Tg.AC mice resulting from skin-specific *v-Ha-ras* expression, which utilizes MAPK signaling for transformation (32), was abrogated in the *ksr*<sup>-/-</sup> background. These defects in proliferation, transformation and tumor formation suggest KSR transduces some forms of Ras-mediated neoplasia.

## RESULTS AND DISCUSSION

[0160] To investigate the *in vivo* function of KSR in mammals, we targeted the mouse *ksr* locus to obtain mice deficient in KSR expression. *ksr*<sup>-/-</sup> mice were generated by homologous recombination in embryonic stem (ES) cells using the pF9 targeting vector shown in FIGURE 1a. The targeted region included the starting methionine (ATG codon at nt 83 in *ksr* cDNA) and the following 74 amino acids encompassing 85% of the KSR unique CA1 domain. Two targeted ES clones (FIGURE 1b) were microinjected into

C57BL/6 blastocysts and both resulted in chimeric mice that transmitted the mutated *ksr* allele through to the germline. Crosses of the *ksr*<sup>+/−</sup> mice generated progeny with genotypes of the expected Mendelian frequencies. A PCR-based screening strategy was developed to detect both the wild-type (wt) and mutated alleles from mouse genomic DNA (FIGURE 1c).

[0161] As previously reported (12), Northern blot analysis revealed wt KSR transcripts of 6.4 and 7.4 kb. The smaller transcript was detected by embryonic day 7, while the larger transcript was observed from day 11 on (FIGURE 1d). In the adult, numerous tissues expressed *ksr* transcripts including heart, spleen, lung, thymus, and brain (FIGURE 1e). Kidney displayed little if any *ksr* mRNA, while the larger transcript was restricted to brain. The existence of this larger mRNA was recently reported by Morrison and co-workers to represent a splice variant of murine KSR1, named B-KSR1 (12). Importantly, *ksr*<sup>−/−</sup> mice did not express detectable levels of either *ksr* mRNA in any tissue tested (FIGURE 1e). KSR1 and B-KSR1 proteins were also not detected by Western blot analysis in tissues or in mouse embryo fibroblasts (MEFs) from *ksr*<sup>−/−</sup> mice (FIGURE 1f). The lack of KSR was also confirmed by RT-PCR analysis with primers specific for the 3'-UTR of *ksr* cDNA (not shown). Our data thus suggest that replacement of the 5' region of *ksr* including the start coding site and most of the CA1 domain successfully abolished expression of both murine KSR forms.

[0162] KSR knockout mice were viable and fertile, with no major developmental defects. No gross histologic abnormalities of the major organs were apparent in young mice or in adults up to one year of age. Animal weight, behavior and brood size were also unaffected in the KSR knockout. However, histologic examination of the skin of 10-day-old *ksr*<sup>−/−</sup> mice revealed noticeably fewer hair follicles, which were disorganized in dermal location (depth) and orientation (direction), and manifested asynchronous growth (FIGURE 2a vs. 2b,c). Further, a significant proportion displayed a serpentine

morphology (FIGURE 2b). In other follicles, the inner root sheath separated from the hair shaft, resulting in formation of blisters or cysts (FIGURE 2c). Strikingly, this phenotype closely resembles that found in the skin of EGFR-deficient mice (13) (FIGURE 2d). Grossly, *egfr*<sup>-/-</sup> mice display short, wavy pelage hair and curly whiskers during the first weeks of age, with pelage and vibrissa hairs becoming progressively sparser and atrophic over time, eventually leading to alopecia (13). Although these gross phenotypes were not seen in *ksr*<sup>-/-</sup> mice, increased alopecia and sparse hair growth were observed following treatment with the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) compared to similarly treated *ksr*<sup>+/+</sup> controls (not shown). The manifestation of this unique hair follicle phenotype by both knockouts supports the contention that EGFR and KSR might be on the same pathway in mice.

[0163] To further elucidate the effect of KSR disruption on activation of the EGFR/MAPK pathway, we generated MEFs from *ksr*<sup>+/+</sup> and *ksr*<sup>-/-</sup> littermates and evaluated their response to low, mitogenic doses of EGF and TPA, two growth stimuli known to activate the MAPK cascade. After 48 hr of serum starvation, MAPK activation in response to various doses of EGF (0.01-100ng/ml) or TPA (10nM-1uM) was determined by Western blot analysis using the monoclonal and anti-phospho-p44/42 MAPK (Thr<sup>202</sup>/Tyr<sup>204</sup>) antibody. *ksr*<sup>-/-</sup> MEFs displayed a significant reduction in EGF- and TPA-induced MAPK (ERK1/2) activation at all doses examined, while total MAPK content remained largely unchanged (FIGURE 3A). For EGF stimulation, inhibition of MAPK activation was manifest at doses as low as 0.01 ng/ml (not shown), whereas at 100 ng/ml EGF, MAPK activation was partially restored (FIGURE 3A, upper panel, Lane 8).

[0164] To examine Raf-1 activation under conditions of MAPK inhibition, endogenous Raf-1 was evenly immunoprecipitated from all MEF lysates (not shown) and activity assayed using kinase-inactive MEK (K97M) as a substrate. While Raf-1 activity was

greatly inhibited (>90%) in *ksr*<sup>-/-</sup> MEFs in response to mitogenic doses of EGF (FIGURE 3B, upper panel, lanes 4 and 6), no inhibition was observed when stimulated with 100 ng/ml EGF (FIGURE 3B, upper panel, lane 8). Thus, partial inhibition of MAPK activation in response to 100 ng/ml EGF in *ksr*<sup>-/-</sup> MEFs is independent of Raf-1 activation, likely resulting from the known MAK scaffolding function of KSR. These results indicate that EGF-stimulated Raf-1 activation in MEFs is dose-dependent and may occur via KSR-dependent and independent mechanisms, consistent with our previous findings (28).

[0165] The requirement for KSR for TPA-induced c-Raf-1 activation differed from that of mitogenic doses of EGF. In contrast to complete inhibition of c-Raf-1 activation after stimulation with mitogenic doses of EGF upon deletion of *ksr*, TPA-induced Raf-1 activation was not altered in *ksr*<sup>-/-</sup> MEFs (FIGURE 3B, lower panel). Thus, the use of the KSR knockout MEFs allows for the definition of two mechanisms of c-Raf-1 activation, a KSR-dependent mechanism necessary for mitogenic EGF stimulation, and a KSR-independent mechanism used by TPA, and perhaps pharmacologic doses of EGF. Loss of KSR thus can impact M APK activation by two mechanisms, via loss of c-Raf-1 activation as well as the MEK scaffolding function of KSR.

[0166] To examine the biologic consequence of MAPK inhibition on cell proliferation *in vivo*, a proliferation assay was performed using MEFs in the exponential phase of cell growth. Consistent with reduction in signaling through the MAPK mitogenic pathway, which provides proliferative signals, a 50% reduction in growth rate in *ksr*<sup>-/-</sup> MEFs was observed (FIGURE 3C).

[0167] To determine the potential impact of KSR inactivation in Ras-mediated transformation, c-Myc and Ha-rasV12 constructs were transduced into *ksr*<sup>+/+</sup> and *ksr*<sup>-/-</sup> early-passage MEFs using high-titer retroviruses, and the ability to grow as colonies in

soft agar was assessed as described (15). While *ksr*<sup>+/+</sup> fibroblasts did not form colonies in soft-agar, they did so in the presence of Myc and Ras oncogenes (not shown). In contrast, *ksr*<sup>-/-</sup> MEFs could not be transformed by Ha-rasV12, even though they were immortalized by c-Myc. Taken together, all these results show that inactivation of KSR by genetic deletion attenuates signaling through the EGFR/Ras/MAPK pathway.

[0168] The participation of oncogenic *ras* in human cancers is estimated to be 30% (33) and approximately 25% of skin lesions in humans involve mutations of the Ha-Ras (25% for squamous cell carcinoma and 28% for melanomas) (34,35). Since *ksr*<sup>-/-</sup> mice showed a defect in normal development of the hair follicle, presumably via impairment of EGFR signaling, we examined the role of KSR in gain-of-function Ras in the skin. For these studies, we employed Tg.AC mice, which harbor oncogenic *v-Ha-ras* fused to the  $\zeta$ -globin promoter (16-18), a standardized model for the study of two-stage skin carcinogenesis. The *v-Ha-ras* transgene of Tg.AC mice is transcriptionally silent until induced in latent neoplastic cells (putative stem cells) closely associated with the outer root sheath cells of the hair follicle (19), a site consistent with our localization of KSR in mouse skin (not shown). Tg.AC mice (in FVB/N strain background) were crossed with *ksr*<sup>-/-</sup> mice (in a mixed C57BL/6:129sv background). F1 offspring heterozygous for the *ksr* gene were then interbred to obtain F2 offspring carrying the *v-Ha-ras* transgene in the *ksr*<sup>+/+</sup> and *ksr*<sup>-/-</sup> background. To determine if disruption of *ksr* might influence tumorigenesis in this model, we topically treated the dorsum of F2 mice twice weekly for 15 weeks with vehicle (acetone), or with 5  $\mu$ g of TPA. Animals were monitored for development of skin malignancies for 20 weeks.

[0169] Initial control studies using RT-PCR to detect the *v-Ha-ras* transgene mRNA showed that loss of KSR function in *ksr*<sup>-/-</sup> mice had no impact on TPA-induced expression of the oncogenic *v-Ha-ras* transgene in the skin (FIGURE 4A). However, 70% of Tg.AC transgenic mice in a *ksr*<sup>+/+</sup> background developed papillomas, while only 10%

in a *ksr*<sup>-/-</sup> background displayed papillomas (FIGURE 4B). The average number of papillomas in our study was 2-4 per mouse in each group. These studies with Tg.AC mice demonstrate that genetic inactivation of KSR prevents EGFR-/Ras-mediated skin tumorigenesis.

[0170] In summary, these studies demonstrate that mammalian KSR integrates signaling through the EGFR/Ras/MAPK signaling module. That EGFR, Ras and KSR are on the same signaling pathway in mammalian cells is supported by the unusual hair follicle phenotype manifested in EGFR knockout mice and recapitulated in the KSR knockout, by the attenuation of EGF-induced MAPK signaling in MEFs, and by the abrogation of EGFR-/Ras-mediated tumorigenesis in multiple experimental models (see also Example 2). These studies further demonstrate that Raf-1 activation may occur by KSR-dependent and independent mechanisms. We believe this observation may help to resolve some of the questions regarding upstream elements of the Ras/Raf-1-MAPK module and provides new targets and reagents for additional investigation. In *C. elegans* (2,3), KSR appears dispensable, for the most part, for normal development, but required when increased signaling through the EGFR/Ras pathway is necessary and for some forms of oncogenic Ras-transduced MAPK-mediated tumorigenesis, as occurs acutely in response to EGF stimulation or chronically in Ras-mediated tumors, indicating that KSR inactivation could yield a therapeutic gain, particularly for selective abrogation of the Ras/MAPK signaling of human tumorigenesis.

## METHODS

[0171] Gene targeting. Mouse *ksr* genomic DNA clones were isolated by screening a  $\lambda$ FixII phage library prepared from mouse strain 129/sv (Stratagene, La Jolla, CA) using the 5' coding region (nt 1-786) of mouse *ksr* cDNA (Genbank accession # U43585). The

mouse *ksr* cDNA sequence is provided in FIGURE 12A. The targeting vector pF9 was constructed by inserting a 2.5-kb *SpeI-SmaI* fill-in fragment from the 5' end of the mouse *ksr* genomic clone into the *NotI* fill-in site of pPGK-NTK vector (a gift from Dr. Frank Sirotnak). A 6.3-kb *SpeI-HindIII* fill-in fragment from the 3' downstream region of the mouse *ksr* genomic clone was inserted into the vector at the *Clal* fill-in site. The resulting plasmid was linearized with *KpnI* and electroporated into 129/Sv-derived W9.5 ES cells (Chrysalis DNX Transgenic Sciences, Princeton, New Jersey). Two hundred G418/Gancyclovir-resistant ES cell clones were analyzed by Southern blot using a 0.6 kb *Bgl*II-*SpeI* probe derived from genomic sequences located immediately outside (5') those present in pF9. This probe hybridizes to a 5.7-kb DNA fragment for the wt *ksr* allele and a 3.1-kb fragment from the disrupted allele. Heterozygous ES cells were microinjected into blastocyst-stage C57BL/6 mouse embryos at the Sloan-Kettering Institute's Transgenic Core Facility. Injected blastocysts were then transplanted into the uterus of pseudopregnant C57BL/6 mice. Chimeric males were crossed to C57BL/6 females. Germline transmission was monitored by Southern blot in agouti F1 offspring. For mouse genotyping, genomic DNA was isolated from mouse tails with the DNeasy kit (Qiagen Inc., Valencia, CA) and was either digested with *Bgl*II and *Xba*I and examined by Southern blot as for ES cells, or analyzed by PCR amplification with two sets of primers. Primers for the wt allele were derived from the cDNA sequence of mouse *ksr* CA1 domain: upstream primer, 5'-TATCTCCATCGGCAGTCT-3' (SEQ ID NO:20), downstream primer, 5'- TCGACGCTCACACT TCAA-3' (SEQ ID NO:21). The primers for the mutant allele were from the sequence of the neomycin phosphotransferase gene: upstream primer, 5'-CTGACCGCTTCCTCGT-3' (SEQ ID NO:22); downstream primer, 5'-ATAGAGCCCACCGCATCC-3'(SEQ ID NO:23). The size of the expected product is 493-bp for the wt and 312-bp for the disrupted allele. Standard PCR conditions were employed: initial denaturation of 5 min at 94°C, followed by 30 cycles with annealing at 56°C, extension at 72°C, and denaturation at 94°C, all for 30 sec.

**[0172] Northern and western blot analysis.** Poly A<sup>+</sup> RNA was prepared from adult mouse tissues using the Oligotex kit from Qiagen Inc. (Valencia, CA). The blots were hybridized with a specific <sup>32</sup>P-labeled probe corresponding to the CA2-CA4 domains of murine *ksr* cDNA (1.47-kb). For embryonic tissues, we used a Mouse Embryo MTN Blot (BD Biosciences, San Diego, CA). Protein homogenates were prepared from *ksr*<sup>+/+</sup> and *ksr*<sup>-/-</sup> tissues, or MEFs in RIPA buffer and fractionated by SDS-PAGE (100 µg protein/lane). KSR expression was detected by western blot with a mouse monoclonal anti-KSR antibody (BD Biosciences, San Diego, CA) or a goat polyclonal anti-KSR antibody generated to amino acids 855 to 871 of KSR (c-19, Santa Cruz Biotechnology, Santa Cruz, CA). MEK and MAPK activation in MEFs were detected by western blot with anti-phospho-MEK and anti-phospho-MAPK specific antibodies: polyclonal anti-MEK, polyclonal anti-p44/42 MAPK, monoclonal anti-phospho-p44/42 MAPK (Thr<sup>202</sup>/Tyr<sup>204</sup>) and polyclonal anti-phospho-MEK1/2 (Ser<sup>217</sup>/Ser<sup>221</sup>) (Cell Signaling, Beverly, CA).

**[0173] Histology.** Skin tissues were collected from 10-day old *ksr*<sup>+/+</sup>, *ksr*<sup>-/-</sup> and *egfr*<sup>-/-</sup> (kindly provided by Dr. Laura Hansen) mice and fixed for 15-18 hours in 10% neutral buffered formalin, washed 2 hours in 70% ethanol and embedded in paraffin blocks. The blocks were sectioned 4-6 µm thick, placed on glass slides and stained with hematoxylin and eosin.

**[0174] MEF studies.** MEFs, derived from *ksr*<sup>+/+</sup> and *ksr*<sup>-/-</sup> day 12-13 embryos, were prepared as described<sup>15</sup>. 0.25 x 10<sup>6</sup> early passage MEFs (PDL<6) were seeded in 6-well plates and grown in DMEM supplemented with 10% FBS for 24 h at 37°C. After 48 h in serum-free medium, cells were stimulated with 0.05-1.0 ng/ml EGF for 3 min, washed with PBS and lysed in 0.2 ml of NP-40 lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 2 mM EDTA, 10% Glycerol, 1% Nonidet P-40 plus protease and phosphatase inhibitors). Raf-1 activity was performed as previously described (27). Briefly, 300 ug of total lysate

was immunoprecipitated with a polyclonal anti-Raf-1 antibody (Upstate Biotechnology, Lake Placid, NY), washed with NP-40 buffer containing 0.5M NaCl and incubated with the kinase-dead GST-MEK-1 (K97M). Activated MEK-1 was visualized by Western blot with a polyclonal anti-phospho-MEK antibody (Cell Signaling, Beverly, CA). To analyze cell proliferation,  $0.15 \times 10^6$  *ksr*<sup>+/+</sup> or *ksr*<sup>-/-</sup> low-passage MEFs were seeded on 60 mm plates and counted at the indicated time points by hemacytometer. Data (mean+/- SD) are compiled from three independent experiments. To assess transformation capacity, MEFs from *ksr*<sup>+/+</sup> and *ksr*<sup>-/-</sup> mice were transduced sequentially with retroviral plasmids pWZL-Hygro-c-myc and pBabe-Puro-H-RasV12 (kindly provided by Scott Lowe, Cold Spring Harbor Laboratories), resuspended in 0.3% noble agar and seeded in 60 mm plates as described (15). Colonies consisting of at least 50 cells were counted after 3 weeks.

**[0175] Generation of Tg.AC/*ksr*<sup>-/-</sup> mice.** Homozygous male and female Tg.AC transgenic mice (16) were obtained at 3-4 week of age from Charles River Laboratories Inc. (Wilmington, MA). To produce the target population, *ksr*<sup>-/-</sup> mice were first bred to hemizygous Tg.AC mice containing the *v-Ha-ras* transgene. The resulting F1 females and males, heterozygous for *ksr* and hemizygous for the Tg.AC transgene, were then bred to obtain offspring in the *ksr* background. Nonresponder Tg.AC mice (17) were excluded from the study group. Presence of the Tg.AC transgene was determined by PCR amplification as follows: initial denaturation of 1 min 10 sec at 74°C, followed by 30 cycles with annealing at 55°C for 1min, extension at 72°C for 3min, and denaturation at 94°C for 1 min. The sequence of the Forward Primer was 5'-GGAACCTTACTTCTGTGGTGTGAC-3' (SEQ ID NO:13), and the sequence of the Reverse Primer was 5'-TAGCAGACACTCTATGCCTGTGTG-3' (SEQ ID NO: 14). PCR results were confirmed by Southern blot analysis as described (17).

[0176] Skin tumor experiments. Mice were treated twice weekly with 5 µg TPA (Sigma Chemical Company, St. Louis, Missouri) for 15 weeks and observed for papilloma development as described (16). Offspring from the original Tg.AC mice in the FVB/N background from Charles River Laboratory were used as controls. Papillomas were counted weekly for 20 weeks. *v-Ha-ras* transgene expression in skin after TPA treatment was assessed by nested PCR as described (24).

## REFERENCES

1. Therrien, M. et al. KSR, a novel protein kinase required for RAS signal transduction. *Cell* **83**, 879-88 (1995).
2. Kornfeld, K., Hom, D. B. & Horvitz, H. R. The *ksr-1* gene encodes a novel protein kinase involved in Ras-mediated signaling in *C. elegans*. *Cell* **83**, 903-13 (1995).
3. Sundaram, M. & Han, M. The *C. elegans* *ksr-1* gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. *Cell* **83**, 889-901 (1995).
4. Denouel-Galy, A. et al. Murine Ksr interacts with MEK and inhibits Ras-induced transformation. *Curr Biol* **8**, 46-55 (1998).
5. Yu, W., Fantl, W. J., Harrowe, G. & Williams, L. T. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK. *Curr Biol* **8**, 56-64 (1998).
6. Joneson, T. et al. Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated (ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras effectors. *J Biol Chem* **273**, 7743-8 (1998).
7. Zhang, Y. et al. Kinase suppressor of Ras is ceramide-activated protein kinase. *Cell* **89**, 63-72. (1997).
8. Xing, H., Kornfeld, K. & Muslin, A. J. The protein kinase KSR interacts with 14-3-3 protein and Raf. *Curr Biol* **7**, 294-300 (1997).

9. Michaud, N. R. et al. KSR stimulates Raf-1 activity in a kinase-independent manner. *Proc Natl Acad Sci U S A* **94**, 12792-6 (1997).
10. Basu, S., Bayoumy, S., Zhang, Y., Lozano, J. & Kolesnick, R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. *J Biol Chem* **273**, 30419-26 (1998).
11. Cacace, A. M. et al. Identification of constitutive and ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. *Mol Cell Biol* **19**, 229-40 (1999).
12. Muller, J., Cacace, A. M., Lyons, W. E., McGill, C. B. & Morrison, D. K. Identification of B-KSR1, a novel brain-specific isoform of KSR1 that functions in neuronal signaling. *Mol Cell Biol* **20**, 5529-39 (2000).
13. Hansen, L. A. et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. *Am J Pathol* **150**, 1959-75. (1997).
14. Wennstrom, S. & Downward, J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. *Mol Cell Biol* **19**, 4279-88 (1999).
15. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **88**, 593-602 (1997).
16. Leder, A., Kuo, A., Cardiff, R. D., Sinn, E. & Leder, P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. *Proc Natl Acad Sci U S A* **87**, 9178-82 (1990).
17. Kantz, D. C., Lacks, G. D. & Cannon, R. E. Chemiluminescence-based method for genotyping Tg.AC responder mice. *Biotechniques* **27**, 278-80 (1999).

18. Humble, M. C. et al. Radial transformation-associated recombination cloning from the mouse genome: isolation of Tg.AC transgene with flanking DNAs. *Genomics* **70**, 292-9. (2000).
19. Hansen, L. A. & Tennant, R. W. Follicular origin of epidermal papillomas in v-Ha-ras transgenic TG.AC mouse skin. *Proc Natl Acad Sci U S A* **91**, 7822-6. (1994).
20. Merlino, G. T. et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. *Science* **224**, 417-9. (1984).
21. Ogiso, Y., Sakai, N., Watari, H., Yokoyama, T. & Kuzumaki, N. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. *Gene Ther* **1**, 403-7. (1994).
22. Cotter, F. E. et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. *Oncogene* **9**, 3049-55. (1994).
23. Agrawal, S., Temsamani, J. & Tang, J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. *Proc Natl Acad Sci U S A* **88**, 7595-9. (1991).
24. Battalora, M. S. et al. Age-dependent skin tumorigenesis and transgene expression in the Tg.AC (v-Ha-ras) transgenic mouse. *Carcinogenesis* **22**, 651-9. (2001).
25. Xing, R. H., Mazar, A., Henkin, J. & Rabbani, S. A. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. *Cancer Res* **57**, 3585-93. (1997).
26. Wang, X and Studzinski, G.P, Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by “MEK-specific” inhibitors PD 098059 and U 0126 in differentiating HL60 cells, *Exp Cell Res.* 268:294-300, 2001.

27. Xing, H. R., Lozano, J., and Kolesnick, R. Epidermal growth factor treatment enhances the kinase activity of kinase suppressor of Ras, *J Biol Chem.* 275:17267-80, 2000.
28. Xing, H.R. and Kolesnick R. Kinase suppressor of Ras signals through Thr269 of c-Raf-1, *J Biol Chem.* 276:9733-41., 2001.
29. Yan, F., John, S. K., and Polk, D. B. Kinase suppressor of Ras determines survival of intestinal epithelial cells exposed to tumor necrosis factor, *Cancer Res.* 61:8668-75., 2001.
30. Yan, F. and Polk, D. B. Kinase suppressor of ras is necessary for tumor necrosis factor alpha activation of extracellular signal-regulated kinase/mitogen-activated protein kinase in intestinal epithelial cells, *Cancer Res.* 61:963-9., 2001.
31. Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D., and Therrien, M. KSR is a scaffold required for activation of the ERK/MAPK module, *Genes Dev.* 16:427-38., 2002.
32. Hamilton, M. and Wolfman, A. Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor, *J Biol Chem.* 273:28155-62., 1998.
33. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, *Cell.* 53:549-54., 1988.
34. Bos, J., L. ras oncogenes in human cancer: a review, *Cancer Res.* 49:4683-9., 1989.
35. Migley, R. S. and Kerr, D. J. Ras as a target in cancer therapy, *Crit Rev Oncol Hematol.* 44:109-20., 2002.

EXAMPLE 2

## ABSTRACT

[0177] Given the prevalence of oncogenic *ras* mutations in human cancers, selective inactivation of gain-of-function (*gf*) Ras signaling represents a highly attractive therapeutic approach, although it has not been achieved clinically. Here, *gf* Ras signaling was targeted indirectly via genetic or pharmacologic inactivation of Kinase Suppressor of Ras1 (KSR1), an immediate downstream effector selective for *gf* Ras. KSR1 inactivation abrogated *gf* Ras-mediated tumorigenesis induced by constitutively activated epidermal growth factor receptor or oncogenic K-Ras mutation in several human tumor cell lines and in nude mice xenografts. Inhibition of *ksr1* via continuous infusion of KSR antisense oligonucleotides (AS-ODNs) prevented growth of oncogenic K-*ras*-dependent human PANC-1 pancreatic and A549 non-small-cell lung carcinoma (NSCLC) xenografts in nude mice, effected regression of established PANC-1 tumors, and inhibited A549 lung metastases, without apparent toxicity. These studies suggest KSR AS-ODNs as a treatment for *gf* Ras-dependent human malignancies, in particular pancreatic cancer for which there is presently no effective curative therapy.

## INTRODUCTION

[0178] Adenocarcinoma of the exocrine pancreas represents the fourth-leading cause of cancer-related mortality in Western countries. Treatment has had limited success and the five-year survival remains less than 5% with a mean survival of 4 months for patients with surgically unresectable tumors (1,2) . While oncogenic activation of H-, K-, and N-Ras arising from single nucleotide substitutions has been observed in 30% of human cancers (5) , over 90% of human pancreatic cancer manifest the codon 12 K-*ras* mutation (3-5) . This point mutation can be identified early in the course of the disease when

normal cuboidal pancreatic ductal epithelium progresses to a flat hyperplastic lesion, and is considered causative in the pathogenesis of pancreatic cancer (6,7) . The regulation of oncogenic K-ras signaling in human pancreatic cancer, however, remains largely unknown. While various therapeutic strategies have been developed to inactivate key components of the Ras-Raf-MAPK cascade, specific inhibition of *gf* Ras action has not been achieved clinically (8,9).

**[0179]** Recent studies demonstrated that Kinase Suppressor of Ras (KSR1) positively modulates the Ras/MAPK signaling arm of the EGFR/Ras pathway. KSR1 acts downstream of Ras, either upstream of or parallel to Raf in *Drosophila* and *C. elegans* (10-12) . Mammalian forms of KSR1, identified on the basis of sequence homology (12), suggest that KSR signaling is evolutionarily conserved. The precise mechanisms of mammalian KSR signaling and its biological functions, however, remain largely unknown. Genetic studies from *ksr1*-deficient *C. elegans* and mice demonstrate that while *ksr1* is dispensable for normal development (10,11,13) , it may be obligate for *gf* Ras signaling through the MAPK cascade (see Example 1 above). In *C. elegans*, KSR loss-of-function (*lf*) reverts the *gf* Ras-mediated multivulva phenotype (10,11) caused by the same codon 13 mutation that confers oncogenic potential onto mammalian Ras.

**[0180]** To elucidate the role of KSR1 in Ras-mediated human malignancies, especially in pancreatic cancer, and to explore the feasibility of employing KSR1 as a therapeutic target, antisense approaches were employed to genetically and pharmacologically inactivate mammalian *ksr1*. We report here that both approaches to KSR1 inactivation abrogated *gf* Ras signaling of tumorigenesis, either via constitutively activated EGFR or oncogenic K-Ras mutation. Further, antisense-mediated inhibition of *ksr1* gene expression via continuous infusion of KSR AS-ODNs prevented the oncogenic K-ras-dependent growth of human PANC-1 pancreatic and A549 non-small-cell lung carcinoma (NSCLC) xenografts in nude mice, elicited regression of established PANC-1 tumors,

and inhibited A549 lung metastases without apparent toxicity. These studies demonstrate that KSR AS-ODNs might represent a tumor-specific therapeutic agent for the treatment of oncogenic K-ras-dependent human malignancies.

## RESULTS

### **[0181] Inhibition of *ksr1* gene expression induces morphologic changes in A431 cells.**

In *C. elegans*, KSR1 regulates *gf*Ras signaling of vulval development, a pathway initiated through LET-23, the EGFR homolog (10,11). To explore the role of mammalian KSR1 in EGFR-mediated tumorigenesis, we employed the A431 human epidermoid carcinoma tumor line in which tumor growth is driven through wild type Ras by a 100-fold excess of activated EGFR/HER1 ( $10^7$  receptors/cell) (14). We generated A431 cell lines stably expressing inducible forms of wild type KSR1 (KSR-S), antisense KSR1 (KSR-AS) and dominant negative KSR1 (DN-KSR) using the Retro-Tet-Off system. While Flag-tagged KSR-S and DN-KSR were expressed to similar levels (FIGURE 5A), stable expression of the KSR-AS resulted in a 60% reduction of endogenous KSR expression (FIGURE 5B). Further, doxycycline (Dox) treatment elicited a dose-dependent inhibition of KSR-S expression (FIGURE 5C), and Dox withdrawal following its addition effectively restored KSR-S expression (not shown). Similar results were found in the DN-KSR and KSR-AS cells (not shown). These observations indicate that the KSR-Tet-Off system is tightly regulated by Dox.

**[0182] The effect of manipulating KSR1 levels on the morphology of stably transfected A431 cells was examined first. While non-transfected (not shown), vector-transfected and KSR-S-transfected A431 cells displayed the similar cobblestone morphology of poorly differentiated squamous epithelial cells (FIGURE 5D), abrogation of *ksr1* expression by KSR-AS produced a marked change in cell morphology. The KSR-AS cell somata gradually enlarged and flattened, cytoplasmic processes retracted, and cells grew in a**

more scattered pattern (FIGURE 5D). Further, these cells became multinucleated (FIGURE 5E), indicative of the failure to complete cytokinesis with a resultant proliferation defect (see below) (15). Phase-contrast microscopy reveals that while over 80% of KSR-AS cells contained multiple nuclei, multinucleated cells were rarely seen (<8%) in control or KSR-S cells. Similar morphologic changes were observed in DN-KSR cells (FIGURE 5D and 5E) indicating that inhibition of *ksr1* gene expression in A431 cells might have profound effects on EGFR-mediated biological events in this tumor cell line.

**[0183] Inhibition of *ksr1* gene expression attenuates A431 tumorigenesis.**

To assess the consequences of KSR1 inhibition on the malignant properties of A431 cells and their response to EGF *in vitro*, cell proliferation, invasion and transformation assays were performed. When KSR-S was overexpressed by A431 cells, both baseline and EGF-stimulated proliferation (FIGURE 6A), invasion (FIGURE 6C) and transformation (FIGURE 6D) were markedly enhanced. In contrast, depletion of *ksr1* expression in KSR-AS cells resulted a significant inhibition of baseline proliferation, invasion and transformation (FIGURE 6,  $p<0.05$  in each case), and the abrogation of EGF responses (FIGURE 6). The DN-KSR effect was similar to that observed with KSR-AS (FIGURE 6).

**[0184]** Consistent with the observed alterations in cell growth, KSR significantly impacted cell cycle distribution as determined by FACS analysis (FIGURE 6B). While there was a significant elevation of S-phase cells in exponentially growing KSR-S cells, a sharp reduction in S-phase cells coupled with a concomitant increase of G2/M-phase cells was observed in KSR-AS cells compared to vector-transfected controls ( $p<0.05$  in each case). These observations were confirmed by Ki-67 staining (not shown). The specificity of KSR-S and KSR-AS in mediating stimulation and inhibition, respectively, of proliferation, invasion and transformation was confirmed by turning off the KSR-S and

KSR-AS expression by Dox treatment (not shown). These observations demonstrate that while overexpression of KSR enhanced the neoplastic properties of A431 cells, inactivation of KSR by KSR-AS or DN-KSR rendered A431 cells less malignant.

[0185] To elucidate whether KSR1 down-regulation might have a similar anti-proliferative effect *in vivo*,  $10^6$  KSR-S, KSR-AS, DN-KSR or vector-transfected A431 cells were injected subcutaneously (s.c.) into the right flank of immunodeficient (nude) mice. While tumor take was 100% in mice receiving KSR-S and vector-transfected cells, KSR-S tumors had an earlier onset (FIGURE 7A, left-shifted growth curve,  $p<0.05$ ), were 200% larger in size on day 25, and had 2.5-fold more Ki-67 positive cells than vector-transfected tumors of the comparable size (not shown). Examination of tumor specimens removed on day 25 revealed continued expression of Flag-KSR-S (not shown). The specificity of KSR-S in mediating these effects was confirmed by feeding a group of KSR-S tumor-bearing mice with Dox-containing water which shut off tumoral KSR-S expression efficiently (not shown), and almost completely prevented the growth stimulatory effect of KSR-S on A431 tumors (FIGURE 7A, KSR-S vs. KSR-S + Dox,  $p<0.01$ ). In contrast, mice injected with  $10^6$  A431 KSR-AS or DN-KSR cells failed to develop any tumors when observed up to 120 days (FIGURE 7A and not shown). When the inocula size was increased to  $10 \times 10^6$  and prepared in 50% Matrigel, only 1 out of 20 mice in each case developed a late onset (day 42 for KSR-AS and day 36 for DN-KSR) slow growing tumor. Further, squamous differentiation was evident in both the vector- and KSR-S tumors (FIGURE 7B (i) and (ii), black arrows), although KSR-S tumors had less kerohyalin granules and a higher mitotic index (not shown). In contrast, squamous differentiation was absent from KSR-AS and DN-KSR tumors (FIGURE 7B (iii) and (iv)). Moreover, consistent with our observations *in vitro*, 25% of the KSR-AS and 18% of the DN-KSR tumor cells were multinucleated *in vivo* (FIGURE 7B (iii) and (iv), black arrows, and (v)).

[0186] These observations demonstrate that inhibition of A431 tumorigenesis by KSR-AS involves attenuation of proliferation and induction of multinucleation.

To confirm that prevention of A431 tumorigenesis by KSR-AS is due to inhibition of *ksr1* expression by KSR-AS, we designed phosphorothioate AS-ODNs against the unique CA1 domain (SEQ ID NO: 1) (amino acids 42-82 (SEQ ID NO:2)) of KSR1, which is conserved between the mouse and human (12), to inactivate *ksr1* expression pharmacologically. Among the AS-ODNs tested, the AS-ODN against nucleotides 214 to 231 (SEQ ID NO:5) of KSR1 (designated AS-ODN1(214-231)), which has no sequence homology to any other mammalian gene, exhibited the most potent and specific antisense effect, and was chosen for further characterization. *In vitro* treatment of A431 cells with 1  $\mu$ M KSR AS-ODN (SEQ ID NO: 8) for 24 h resulted in a 90% reduction of endogenous KSR1 expression as determined by immunofluorescence staining (FIGURE 8A) and Western blotting (not shown), while control ODNs had no apparent effect (FIGURE 8A and not shown). Moreover, expression of other cellular proteins including the EGFR, H-Ras, c-Raf-1 and MAPK was not altered by treatment with KSR AS-ODN or control ODNs (not shown), indicating that the antisense effect was specific for KSR. Similar to inactivation of KSR by stable expression of full-length KSR-AS, KSR AS-ODN treatment attenuated A431 cell proliferation (FIGURE 8B) and invasion (FIGURE 8C) in a dose-dependent fashion ( $p<0.05$ ). At 1 mM, KSR AS-ODN inhibited A431 cell proliferation and invasion by 80% and 70%, respectively. In contrast, Control-ODN (FIGURE 8C), which lacks homology to any mammalian gene (16), or Sense-ODN or mismatch AS-ODNs (not shown), were ineffective.

[0187] To assess the antitumor activity of KSR AS-ODNs *in vivo*, AS-ODNs or control ODNs were delivered via continuous s.c. infusion to provide sustained tumor exposure. Infusion was initiated two days prior to tumor implantation in order to reach a steady state ODN plasma level.  $10^6$  A431 cells were injected s. c. into nude mice to obtain seed tumors of  $400 \text{ mm}^3$ . Approximately 50 mg of the freshly prepared seed tumor fragments

were then transplanted to AS-ODN- or Control ODN-treated mice. Treatment with KSR AS-ODN at a low dose of 5 mg/kg/day effectively reduced tumoral KSR1 levels by 85% and attenuated A431 tumor growth by 80% (FIGURE 8D,  $p<0.01$ ), without apparent toxicity, consistent with the known lack of toxicity of this therapeutic approach (17). In contrast, no antitumor effects were observed following treatment with vehicle alone (saline) or with identical doses of the Control-ODN, or Sense-ODN (FIGURE 8D and not shown). Similar results were obtained when treatment was initiated using mice with established A431 tumors of 150 mm<sup>3</sup> (not shown). Collectively, these results demonstrate that KSR1 is obligate for EGFR signaling of A431 tumorigenesis *in vivo* via hyperactivated wild type Ras. Further, the antitumor activity of KSR AS-ODNs appeared to be achieved via selective inhibition of *ksr1* gene expression with high specificity. These studies suggest that it might be feasible to use KSR AS-ODN to abrogate EGFR/Ras signaling of human tumorigenesis.

**[0188]** Inhibition of *ksr1* expression abrogates oncogenic K-*ras*-mediated human pancreatic tumorigenesis via specific attenuation of Ras/Raf-MAPK signaling. To elucidate the importance of KSR1 in mediating oncogenic Ras signaling of human tumorigenesis and to explore the therapeutic potential of KSR AS-ODNs, we employed the human pancreatic cancer PANC-1 xenograft mouse model. This tumor manifests the oncogenic codon 12-mutation of K-*ras*. Similar to A431 cells, treatment of PANC-1 cells *in vitro* with KSR AS-ODNs attenuated cell proliferation (FIGURE 9A), invasion (FIGURE 9C) and transformation (FIGURE 9D) in a dose-dependent fashion (FIGURE 9 and not shown) ( $p<0.05$  in each case). Further, treatment with 5  $\mu$ M AS-ODN led to a 90% reduction of endogenous KSR1 expression (FIGURE 9E). To confirm the effectiveness of KSR AS-ODN in inhibiting oncogenic K-*ras* function, a panel of codon-12 K-*ras* mutated human pancreatic cancer cell lines were treated with 5  $\mu$ M of KSR AS-ODN and assayed for cell proliferation. While cell growth was inhibited by 50 to 80% in

all cell lines after AS-ODN treatment ( $p < 0.01$  each), Sense-ODN had no apparent effect (FIGURE 9B).

[0189] We previously demonstrated that KSR1 activation is required for c-Raf-1 and subsequent MAPK activation *in vitro* in response to mitogenic doses of EGF stimulation (18,19). To molecularly order KSR1 and Raf-1 in oncogenic K-ras signaling, PANC-1 cells were treated with 5  $\mu$ M AS-ODN, transfected with the dominant positive BXB-Raf-1 and assayed for cell invasion and transformation. If Raf-1 is downstream of KSR, *gfr*Af-1 (BXB-Raf-1) should reverse the inhibitory effect of KSR inactivation by AS-ODNs on PANC-1 cell invasion and transformation. Indeed, while BXB-Raf-1 had no effect on endogenous KSR1 expression (FIGURE 9E), it completely reversed the inhibitory effect of AS-ODN on PANC-1 cell invasion (FIGURE 9C) and transformation (FIGURE 9D). These observations indicate that c-Raf-1 is epistatic to KSR1, consistent with our *in vitro* findings and with the current literature (19-22). Additional studies were performed to examine the mechanism by which KSR1 inactivation affected oncogenic Ras-mediated intracellular signaling. For these studies, AS-ODN-treated and BXB-Raf-1-transfected PANC-1 cells were serum-depleted for 48 h and stimulated with 1 ng/ml of EGF. MAPK and PI-3 kinase activation were assayed by Western blot analysis using phospho-MAPK and phospho-Akt specific antibodies. While AS-ODN treatment blocked EGF-induced MAPK activation (FIGURE 9F, upper panel, lane 6 vs. lane 2), it had no apparent effect on Akt activation (FIGURE 9F, lower panel, lane 6 vs. lane 2). Sense-ODN had no effect on either MAPK or Akt activation (FIGURE 9F). Moreover, the inhibitory effect of AS-ODN on MAPK activation could be completely reversed by expression of BXB-Raf-1 (FIGURE 9F, upper panel, lane 4 vs. lane 2). Total MAPK and Akt content were largely unaffected by treatment with ODNs or transfection with BXB-Raf-1 (FIGURE 9F and not shown). These results suggest that abrogation of oncogenic K-Ras signaling in pancreatic cancer cells by KSR AS-ODN is likely achieved by specific inhibition of the Ras-Raf-MAPK cascade. To test the therapeutic potential of

KSR AS-ODNs to treat human pancreatic cancer, PANC-1 xenografts either derived from  $10^6$  cultured PANC-1 cells (FIGURE 10A (*i*)), or from freshly harvested seed PANC-1 tumors (prepared as described above) (FIGURE 10A (*ii*)), were transplanted into nude mice. The steady state plasma AS-ODN levels for the 5 and 10 mg/kg/day doses of infusion were determined by OliGreen and HPLC assays to be 63 and 123 ng/ml, respectively, consistent with that reported in the literature using similar doses (23). For PANC-1 tumors arising from the injected cells, tumors were allowed to reach 100 mm<sup>3</sup> prior to the initiation of AS-ODN treatment. Infusion of AS-ODNs at 10 mg/kg/day for 14 days resulted in 40% reduction in tumor volume with a 100% response rate (FIGURE 10A (*i*), p<0.05 vs. Control-ODN). A group of AS-ODN treated tumors that had regressed were monitored for tumor re-growth after the treatment was discontinued. Only 1 of 5 tumors exhibited re-growth while the rest remained regressed and stable for up to 4 weeks (not shown). For PANC-1 xenografts propagated via serial passage *in vivo*, continuous infusion of KSR AS-ODNs, initiated 2 days prior to tumor transplantation, attenuated the growth of PANC-1 tumors in a dose-dependent fashion (FIGURE 10A (*ii*)). No apparent toxicity (weight loss, behavioral alteration, organomegaly, inflammation, bleeding) was observed at any dose and was confirmed by histologic examination of numerous tissues at autopsy (not shown). At 75 mg/kg/day, PANC-1 tumor growth was completely abolished and all mice remain tumor-free up to 4 weeks after the treatment was discontinued (FIGURE 10A (*ii*) and not shown). In contrast, treatment with vehicle alone (saline), Control-ODN, or Sense-ODN exhibited no antitumor effects at all doses examined (FIGURE 10A and not shown). These observations support the conclusion that the antitumor effects observed for KSR AS-ODNs occur through an antisense mechanism of action. Similar anti-neoplastic effects of KSR AS-ODN were observed in PANC-1 tumors transplanted orthotopically under the pancreatic capsular tissue (not shown).

[0190] To confirm the specificity of KSR in mediating K-ras signaling of pancreatic

tumorigenesis, we examined endogenous *ksr1* gene expression in saline-, Sense-ODN and AS-ODN-infused PANC-1 tumors. KSR1 expression was inhibited by 90% in all AS-ODN-treated animals examined, while it was largely unchanged by saline or Sense-ODN infusion (FIGURE 10B), confirming a sequence-specific target effect. As an additional control, the effect of AS-ODN treatment on Ras activation *in vivo* was measured by determining the amount of GTP-Ras in PANC-1 tumors using the GST-RBD-Raf-1 pull down assay as described in Methods. Consistent with the data of A431 and PANC-1 cells in culture (not shown), AS-ODN treatment had no apparent effect on Ras activation (FIGURE 10C), indicating that signaling events upstream of Ras activation were intact and inactivation of oncogenic K-*ras* signaling in PANC-1 cells by KSR depletion occurs downstream of Ras.

[0191] To confirm the effectiveness of KSR AS-ODNs in hindering other oncogenic K-*ras*-dependent human tumors, the codon 12 K-*ras* mutated A549 human non-small-cell lung carcinoma model (NSCLC) was selected. For these studies, 50 mg A549 seed tumor fragments, prepared similarly to A431 and PANC-1 seed tumors as above, were transplanted s. c. into nude mice. Treatment with KSR AS-ODN was initiated when A549 tumors reached 150 mm<sup>3</sup>. At 10 mg/kg/day, KSR AS-ODN completely inhibited the growth of the established A549 tumors while Saline, Control-ODN or Sense-ODN had no apparent effect (FIGURE 10D (i)). When animals were sacrificed at the end of the experiment, lungs were resected from Sense-ODN- or AS-ODN-treated mice and stained with Indian ink to visualize surface lung metastases derived via systemic dissemination. Control-ODN-treated lungs had an average of 8-11 metastatic foci. AS-ODN treatment elicited a dose-dependent inhibition of A549 lung metastasis (FIGURE 10D (ii), p<0.05). These observations suggest that while KSR1 is obligate for K-*ras*-dependent primary tumor growth, it may also play an essential role in the metastatic progression of these tumors. Further, KSR AS-ODN could be an effective agent in the management of K-*ras*-dependent human malignancies.

## DISCUSSION

[0192] The present studies provide evidence that KSR1 is obligate for *gf* Ras signaling at the tissue level, and that inhibition of *ksr1* expression leads to selective regression of *gf* Ras-dependent tumors. Previous clinical studies designed to treat *gf* Ras-dependent tumors by inhibition of elements of the Ras/Raf-1/MAPK signaling cascade have to date been largely unsuccessful (9). While toxicity for most agents has been acceptable, success of treatment has been limited by lack of specificity in inhibiting different Ras isoforms, which recent data suggest may have distinct biologic functions (24-26) and lack of selectivity towards *gf* versus physiologic Ras signaling (8,9). Similar problems exist for experimental drugs designed to inhibit elements of the Raf-1/MEK1/MAPK cascade (9). The present studies on the effects of KSR AS-ODNs provide an approach to specifically attenuate *gf* Ras signaling in the treatment of Ras-dependent human tumors.

[0193] While the targeting of DNA sequences with AS-ODN technology represents an attractive therapeutic approach to the treatment of cancer (27), a principle problem with this approach has been the designation of specificity of the AS-ODN effect for the gene of interest. We provide a number of different lines of evidence to support the notion that the inhibition of tumorigenesis observed with KSR AS-ODNs is due to selective inactivation of *gf* *K-ras* signaling via inhibition of *ksr1*. Our data show that genetic inhibition of *ksr1* expression by the KSR-AS Tet-Off construct yielded comparable antisense-mediated effects *in vitro* and *in vivo* as KSR AS-ODNs. Further, various ODNs, designed to control for sequence-dependent and sequence-independent non-antisense artifacts, had no effects on *ksr1* gene expression, or on tumor growth in cell culture or *in vivo*. In addition to ODN sequence specificity, the effects of KSR AS-ODN on *ksr1* expression were specific for the intended target as expression of other genes of the EGFR-Ras-MAPK pathway was unaffected. Finally, conditional overexpression of

KSR-S by A431 cells delivered a phenotype opposite to KSR inactivation by KSR-AS, and both KSR-S and KSR-AS effects were reversible in the Tet-Off system by turning off expression by Dox treatment. These results collectively attest that the antitumor effects of KSR AS-ODN are achieved by an antisense mechanism.

**[0194]** The lack of normal tissue toxicity in animals treated with KSR AS-ODNs is consistent with recent reports that *ksr1* is dispensable for normal development in *C. elegans* and mice (10,11,13, and see Example 1 above). As recent investigations have uncovered a second *ksr* allele, *ksr2* in *C. elegans* (28) and in mice (29), the lack of tissue toxicity after depletion of *ksr1* by KSR AS-ODN might be due to compensation by *ksr2* for normal cellular functions. Alternately, the lack of toxicity may reflect topological distribution of KSR. Recent evidence suggests that elements of the Ras/Raf-1/MAPK pathway are compartmentalized in more than one type of membrane microdomains (26,30), and that compartmentalization is associated with regulation of activity. In this regard, Ras and c-Raf-1 associate with sphingolipid enriched microdomains (also known as rafts) in the plasma membrane and with the bulk membrane fraction. Raft association, at least for c-Raf-1, appears to involve binding to the sphingolipid ceramide (31). Further, depending on activation status, Ras forms may traffic between compartments (32), with *g*Ras preferentially targeting the bulk membrane.

**[0195]** Whether KSR, which some groups argue is ceramide-activated (20,33), plays a specific role in the *g*Ras activation process, and hence its inactivation would marginally affect normal cellular function, will be the topic of future investigation. Lastly, the apparent lack of toxicity of our KSR ODN is not surprising as the phosphorothioate class of AS-ODNs, the most commonly used AS-ODNs, are generally well tolerated. Administration via continuous infusion in preclinical models and in human clinical trials have established that sequence-independent toxicities (activation of the complement system, prolongation of activated partial thromboplastin time and alterations of

hematological parameters) are usually not encountered at doses at which pharmacologic antisense effects are achieved (34-36).

**[0196]** These studies also suggest that the therapeutic benefit of KSR AS-ODNs may not be limited to oncogenic K-ras-dependent human cancers, but might include a broader spectrum of tumor types, as our studies with KSR AS-ODNs were found effective against the tumor line A431, which is driven by hyperactivated wild type Ras. The therapeutic action of KSR AS-ODNs on established tumors *in vivo* likely involves both inhibition of tumor cell proliferation and induction of tumoral cell death. The anti-proliferative effect of KSR1 inactivation was evident by a decrease in cells in S phase and the induction of multinuclei phenotype *in vitro* and *in vivo*. Additionally, AS-ODN-treated A431 and PANC-1 tumors contained large necrotic areas (60-80% of the surface of the cut section). The mechanism of the latter effect, however, remains unknown. Previous studies demonstrated that significant microvascular endothelial apoptosis might also contribute to the anti-tumor effect as a result of *ras* inactivation (37). However, in our models, only sporadic endothelial cell apoptosis was detected by CD34 and TUNEL staining in PANC-1 tumors treated with KSR AS-ODNs (not shown). The role of KSR in angiogenesis must await further investigation in more relevant models of tumor angiogenesis.

**[0197]** Another important finding emerging from the present study is that KSR appears required for oncogenic Ras-mediated tumor metastatic progression. Inhibition of A549 lung metastases with KSR AS-ODN treatment is in agreement with our preliminary data that MMP-2 and 9 activities were increased in A431-KSR-S cells and inhibited in A431-KSR-AS cells (data not shown). Investigations are underway to elucidate the role of KSR in tumor progression.

**[0198]** The effective use of KSR AS-ODNs also provides the potential for improved understanding of the regulation of critical downstream events involved in *g*fRas

signaling, which at the present time, are only partially known. Raf-MAPK and PI-3 kinase modules are two established downstream pathways mediating *gf*Ras signaling of tumorigenesis (38-41). Here we provided evidence that KSR1 functions as a critical mediator of *gf*Ras likely via specific regulation of the Raf-1-MAPK signaling arm. Support for this notion is derived from recent studies demonstrating that MMTV-MT-dependent mammary tumor genesis, signaled primarily via src and PI-3 kinase via wild type Ras, was not affected in *ksr* -/- mice (13). In contrast, tumor genesis of oncogenic v-Ha-Ras-mediated epidermal skin tumors, signaled through the c-Raf-1/MAPK cascade, was abrogated in *ksr1* -/- mice (Lozano and Kolesnick, unpublished). Further, the present studies with KSR antisense support the molecular ordering of c-Raf-1 as epistatic to mammalian KSR1, which is consistent with genetic results from *Drosophila* and *C. elegans* (10,11). We believe these observations may help to resolve some of the disputes regarding upstream elements of the Ras/Raf-1/MAPK module.

**[0199]** In summary, the current study provides original observations supporting KSR1 as a new molecular target for the treatment of human malignancies dependent on *gf*Ras signaling.

## METHODS

**[0200]** Cell culture and generation of Retro-Tet-Off A431 cell lines. Human epidermal carcinoma cell line A431, lung carcinoma cell line A549 and pancreatic cell lines PANC-1, Capan-2, PL-45, HPAF-II, AsPc-1 and MiapaPa-2 were obtained from ATCC (Manassas, VA). The full-length wild type mouse *ksr1* cDNA, which is over 90% identical to human *ksr1* (12), was cloned in both sense (KSR-S) and antisense (KSR-AS) orientations into the pRetro-TRE under a doxycycline-inducible promoter in pRetro-Tet-Off (Clontech, Palo Alto, CA). DN-KSR (D683A/D700A/R589M) was sub-cloned similarly. A431 cells were infected with medium collected from PT67 packaging cells

transfected with KSR-S, KSR-AS, DN-KSR or the empty vector, and maintained under double selection (0.1 mg/ml neomycin and 0.1 mg/ml Hygromycin).

**[0201]** Western blot, immunofluorescence and immunohistochemistry. Total cell lysates and tumor lysates were prepared in NP-40 buffer as described (18,42). Immunoprecipitation (IP) or Western blotting (WB) was performed according to the manufacturer's protocols with the following antibodies: monoclonal anti-Flag M2 antibody from Sigma (St Louis, MO), polyclonal anti-p44/42 MAPK, monoclonal anti-phospho-p44/42 MAPK (Thr202/Tyr204), polyclonal anti-phospho-MEK1/2 (Ser217/Ser221) and polyclonal anti-phospho-Akt (Ser 473) antibodies from Cell Signaling (Beverly, CA), and polyclonal anti-c-Raf-1 antibody from Upstate Biotechnology Inc. (Lake Placid, NY). Endogenous KSR1 expression was determined by immunoprecipitation and WB analysis from 1 mg of total lysates or by immunofluorescence microscopy, using the monoclonal anti-KSR antibody (BD Biosciences, San Diego, CA) (1:100 dilution) and HRP- or Texas-Red-conjugated goat anti-mouse secondary antibodies, respectively (Molecular Probes, Eugene, Oregon). Histology and immunohistochemistry were performed on formalin-fixed, paraffin-embedded tumor or tissue specimens. 5 mm-cut sections were deparaffinized, rehydrated in graded alcohols, and H & E stained or immunostained using the avidin-biotin immunoperoxidase (Vector Laboratories, Burlingame, CA) method (43). The following primary antibodies were used: rat anti-mouse CD34 (1:50) antibody from PharMingen (San Diego, CA) and polyclonal anti-human Ki67 antibody (1:100) (Vector Laboratories). Diaminobenzidine was used as the chromogen and hematoxylin as the nuclear counterstain as described (43). Apoptosis were assessed by terminal deoxy transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) (Roch, Mannheim, Germany) as described (43).

**[0202] Proliferation, Matrigel invasion and soft agar transformation assays.**  $2 \times 10^4$  A431 cells or  $1-3 \times 10^4$  human pancreatic cells were plated in 6-well plates. The total number of cells/well was counted at the indicated time points to construct cell growth curves. For EGF treatment, 1.0 ng/ml of EGF was added to the culture and replaced every other day. The invasion assay was performed as described (42). Cells on the underside of the filters were counted in 10 randomly chosen fields (40X magnification) and reported as an average number of cells invaded per field. For EGF treatment, cells were replaced with serum-free medium for 2 h prior to the experiment. The Soft Agar assay was set up in 35mm culture plates coated with 1.5 ml culture medium containing 0.5% agar and 5% FBS.  $5 \times 10^3$  cells were suspended in 1.5 ml medium containing 0.1% agar and 5% FBS, and added to the agar pre-coated plates. Colonies consisting of more than 50 cells were scored after 14-21 days of incubation using a dissecting microscope. For EGF treatment, FBS was omitted from the culture medium.

**[0203] Cell cycle analysis.** Cell cycle distribution was determined by FACS analysis. For these studies, cell pellets collected from exponentially growing monolayers were washed twice with PBS containing 0.5% FBS and fixed with 100% ethanol for 15 min. Fixed cells were treated with RNase A (0.1 mg/ml) for 30 min at 37°C and stained with propidium iodide (0.05 mg/ml). The proportion of cells in the different phases of the cell cycle was calculated from the experimental fluorescence histograms.

**[0204] In vitro treatment with KSR AS-ODN.** KSR1 AS-ODN (5'-CTTTGCCTCTAGGGTCCG-3') (SEQ ID NO: 8)(AS-ODN1(214-231)) and KSR sense-ODN (5'-CGGACCCTAGAGGCAAAG-3') (SEQ ID NO: 15) were generated as phosphorothioate derivatives against nucleotides 214 to 231 (SEQ ID NO: 1) of the unique CA1 domain (amino acids (AAs) 42-82) of KSR1 by Genelink Inc. (Hawthorne, NY). Control ODN (5'-CACGTCACGCGCGACTATT-3') (SEQ ID NO: 16) was prepared similarly. For *in vitro* studies, ODNs were dissolved in sterile water and

delivered to cells by Oligofectamine (Invitrogen, Carlsbad, CA) when cells were 30-40% confluent according to manufacturer's instructions. Cell proliferation was assayed at the indicated time points. 48 h after treatment, invasion and transformation assays were set up as above. For some studies, Control- and AS-ODN-treated PANC-1 cells were transfected with the dominant positive RSV-Raf-BXB (kindly provided by Dr. Joseph Bruder, NCI).

**[0205] Tumor induction and *in vivo* treatment with KSR AS-ODN.** For tumor induction,  $10^6$  cultured tumor cells suspended in 0.1 ml of PBS, or 50 mg of tumor fragments freshly harvested from serial passaged seed tumors, were transplanted subcutaneously into the right lateral flank of 6-8 wk old male athymic NCRnu (Germantown, NY). Tumor growth was measured every other day by calipers and tumor volume calculated as described (42). To determine the specificity of KSR-S on A431 tumorigenesis, a group of KSR-S tumor-bearing mice were fed with Dox-containing water (100 mg/ml). To determine the antitumor activity of KSR-AS ODN *in vivo*, infusion with Sense-, Control- or AS-ODNs via Alzet osmotic minipumps was initiated either 2 days prior to tumor transplantation or when tumor reached  $100-150\text{ mm}^3$ . A 5.0 - 75 mg/kg body weight/day dose range of ODN was chosen based on similar AS studies *in vivo* (34,44)

**[0206] Ras activation assay.** Ras activation status (GTP-Ras) in control ODNs or AS-ODN-treated PANC-1 cells or tumors was measured using the Ras activation assay kit (Upstate Biotechnology Inc., Lake Placid, NY) according to manufacturer's instructions as described (45).

**[0207] Statistical analysis.** All data were evaluated by the Student's *t* test (two-tailed) with  $p < 0.05$  considered significant.

## REFERENCES

1. Jemal, A., Thomas, A., Murray, T. & Thun, M. Cancer Statistics, 2002. *CA Cancer J Clin* 52, 23-47. (2002).
2. Burris, H.A., 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 15, 2403-13. (1997).
3. Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 53, 549-54. (1988).
4. Smit, V.T. et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. *Nucleic Acids Res* 16, 7773-82. (1988).
5. Bos, J.L. ras oncogenes in human cancer: a review. *Cancer Res* 49, 4682-9. (1989).
6. Hruban, R.H., Goggins, M., Parsons, J. & Kern, S.E. Progression model for pancreatic cancer. *Clin Cancer Res* 6, 2969-72. (2000).
7. Tada, M. et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. *Gastroenterology* 110, 227-31. (1996).
8. Adjei, A.A. Blocking oncogenic Ras' signaling for cancer therapy. *J Natl Cancer Inst* 93, 1062-74. (2001).
9. Cox, A.D. & Der, C.J. Farnesyltransferase inhibitors: promises and realities. *Curr Opin Pharmacol* 2, 388-93 (2002).
10. Kornfeld, K., Hom, D.B. & Horvitz, H.R. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in *C. elegans*. *Cell* 83, 903-13 (1995).
11. Sundaram, M. & Han, M. The *C. elegans* ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. *Cell* 83, 889-901 (1995).
12. Therrien, M. et al. KSR, a novel protein kinase required for RAS signal transduction. *Cell* 83, 879-88 (1995).
13. Nguyen, A. et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen- activated protein kinase activation in vivo. *Mol Cell Biol* 22, 3035-45 (2002).

14. Merlino, G.T. et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. *Science* 224, 417-9 (1984).
15. Chang, W.P. & Little, J.B. Delayed reproductive death in X-irradiated Chinese hamster ovary cells. *Int J Radiat Biol* 60, 483-96 (1991).
16. Cotter, F.E. et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. *Oncogene* 9, 3049-55. (1994).
17. Agrawal, S., Temsamani, J. & Tang, J.Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. *Proc Natl Acad Sci U S A* 88, 7595-9. (1991).
18. Xing, H.R., Lozano, J. & Kolesnick, R. Epidermal growth factor treatment enhances the kinase activity of kinase suppressor of Ras. *J Biol Chem* 275, 17276-80 (2000).
19. Xing, H.R. & Kolesnick, R. Kinase suppressor of Ras signals through Thr269 of c-Raf-1. *J Biol Chem* 276, 9733-41. (2001).
20. Yan, F., John, S.K. & Polk, D.B. Kinase suppressor of Ras determines survival of intestinal epithelial cells exposed to tumor necrosis factor. *Cancer Res* 61, 8668-75 (2001).
21. Anselmo, A.N., Bumeister, R., Thomas, J.M. & White, M.A. Critical contribution of linker proteins to Raf kinase activation. *J Biol Chem* 7, 7 (2001).
22. Wang, X. & Studzinski, G.P. Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by MEK-specific inhibitors PD 098059 and U0126 in differentiating HL60 cells. *Exp Cell Res* 268, 294-300. (2001).
23. Gray, G.D. & Wickstrom, E. Rapid measurement of modified oligonucleotide levels in plasma samples with a fluorophore specific for single-stranded DNA. *Antisense Nucleic Acid Drug Dev* 7, 133-40. (1997).
24. Roy, S., Wyse, B. & Hancock, J.F. H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis. *Mol Cell Biol* 22, 5128-40. (2002).

25. Koera, K. et al. K-ras is essential for the development of the mouse embryo. *Oncogene* 15, 1151-9. (1997).
26. Wolfman, A. Ras isoform-specific signaling: location, location, location. *Sci STKE* 2001, E2. (2001).
27. Kushner, D.M. & Silverman, R.H. Antisense cancer therapy: the state of the science. *Curr Oncol Rep* 2, 23-30. (2000).
28. Ohmachi, M. et al. *C. elegans* ksr-1 and ksr-2 have both unique and redundant functions and are required for MPK-1 ERK phosphorylation. *Curr Biol* 12, 427-33 (2002).
29. Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D. & Therrien, M. KSR is a scaffold required for activation of the ERK/MAPK module. *Genes Dev* 16, 427-38. (2002).
30. Prior, I.A. et al. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. *Nat Cell Biol* 3, 368-75. (2001).
31. Hekman, M. et al. Associations of B- and C-Raf with cholesterol, phosphatidylserine, and lipid second messengers: preferential binding of Raf to artificial lipid rafts. *J Biol Chem* 277, 24090-102. (2002).
32. Trahey, M. & McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. *Science* 238, 542-5. (1987).
33. Zhang, Y. et al. Kinase suppressor of Ras is ceramide-activated protein kinase. *Cell* 89, 63-72 (1997).
34. Geary, R.S., Leeds, J.M., Henry, S.P., Monteith, D.K. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. *Anticancer Drug Des* 12, 383-93. (1997).
35. Henry, S.P., Monteith, D. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. *Anticancer Drug Des* 12, 395-408. (1997).

36. Banerjee, D. Genasense (Genta Inc). *Curr Opin Investig Drugs* 2, 574-80. (2001).
37. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. *Nature* 400, 468-72. (1999).
38. Stokoe, D., Macdonald, S.G., Cadwallader, K., Symons, M. & Hancock, J.F. Activation of Raf as a result of recruitment to the plasma membrane. *Science* 264, 1463-7. (1994).
39. Howe, L.R. et al. Activation of the MAP kinase pathway by the protein kinase raf. *Cell* 71, 335-42 (1992).
40. Rodriguez-Viciano, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. *Nature* 370, 527-32 (1994).
41. Rodriguez-Viciano, P. et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. *Cell* 89, 457-67. (1997).
42. Xing, R.H., Mazar, A., Henkin, J. & Rabbani, S.A. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. *Cancer Res* 57, 3585-93 (1997).
43. Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. *Science* 293, 293-7. (2001).
44. Agrawal, S. & Zhao, Q. Antisense therapeutics. *Curr Opin Chem Biol* 2, 519-28 (1998).
45. Taylor, S.J. & Shalloway, D. Cell cycle-dependent activation of Ras. *Curr Biol* 6, 1621-7 (1996).

### EXAMPLE 3

[0208] Additional antisense oligonucleotides were synthesized and tested by proliferation assay in A431 cells as indicated in TABLE 1. Antisense nucleotides and their sequences

were selected on the basis of criteria (based on hybridization conditions) to have no stable homodimer formation, no hairpin loop formation, no self-complementary sequences, and to have no stable duplex formation (<-6 kcal/mol. Sequences were selected using the Oligo 4 program (Molecular Biology Insights, Inc., Cascade, CO) and subsequently verified with the Oligo Tech program (Oligo Therapeutics Inc., Wilsonville, OR). Antisense oligonucleotides were generated against nucleotides 151 to 168 (AS-ODN3(151-168) (AS oligo sequence 5'-CAGCCCGCGCAGACTGCC-3') (SEQ ID NO: 6) and nucleotides 181 to 198 (AS-ODN2(181-198)) (AS oligo sequence 5'-GAGGTCGTTAGACACTGA-3') (SEQ ID NO: 7) of the KSR CA1 domain (both were P-S oligonucleotides). These oligonucleotides were tested along with the AS-ODN oligonucleotide against nucleotides 214 to 231 (AS-ODN1(214-231)) (AS oligo sequence SEQ ID NO: 8) described in Example 2. These antisense oligonucleotides represent reverse complements of nucleic acids encoding the amino acid sequences GSLRGL (SEQ ID NO: 17), AVSNDL (SEQ ID NO: 18) and RTLEAK (SEQ ID NO: 19) of the CA1 domain of KSR, respectively. A431 cells were transfected with the indicated amount of KSR AS-ODNs and cell proliferation was assessed 72 hr after the treatment. The effect of AS-ODN on A431 cell proliferation was presented as percent of inhibition of vehicle-treated (Oligofectamine alone) controls. This is a representation of one of four similar studies.

TABLE 1. Screening of KSR AS-ODNs by proliferation assay in A431 cells

<b>Concentration of ODN (nM)</b>	<b>AS151-168 (% inhibition)</b>	<b>AS181-198 (% inhibition)</b>	<b>AS214-231 (% inhibition)</b>	<b>Control ODN (% inhibition)</b>
10	0	0	8	2
50	0	5	20	3

<b>100</b>	3	15	25	2
<b>200</b>	16	23	42	0
<b>400</b>	24	42	67	4
<b>800</b>	38	58	87	3

#### EXAMPLE 4

**[0209]** To establish the specificity of KSR1 in mediating *gf* Ras signaling, the well-characterized human chronic myeloid leukemia cell line K562 was employed. K562 is Bcr-abl-driven and is therefore independent of *gf* Ras signaling. The specific and dose-dependent inhibition of PANC-1 cell proliferation by AS-ODN treatment is depicted in FIGURE 13. PANC-1 and K562 cells were treated with the indicated doses of Control- or AS-ODNs and cell proliferation assays were performed (FIGURE 13A). AS-ODN-1 and AS-ODN-2 correspond to nucleotides 214-231 and 181-198 of *ksr1* cDNA, respectively. While PANC-1 cell proliferation was inhibited as expected, K562 cell proliferation was unaffected by ODN treatment. Treatment of K562 cells with 5  $\mu$ M KSR AS-ODN-1 elicited comparable reduction of endogenous KSR1 gene expression (over 80%) to that observed in PANC-1 cells, as determined by Western blot analysis (FIGURE 13B). Nonetheless, inhibition of proliferation was observed only in PANC-1 cells (FIGURE 13A). Equal loading of the gels was confirmed using total P44/42 MAPK. Note that purified Flag-KSR, which served as a positive control for the Western blot, migrates slightly slower than endogenous KSR due to the Flag-tag (FIGURE 13B). These results provide evidence that *gf* Ras signaling is specifically coupled to KSR1.

EXAMPLE 5

[0210] The full length mRNA sequence of human KSR1 has been determined. The sequence is depicted in FIGURE 14 (SEQ ID NO: 24). Antisense oligonucleotides, including those described above, were designed against the CA1 domain of human KSR nucleic acid. The human KSR antisense oligonucleotides are depicted on the annotated human KSR sequence in FIGURE 15. Oligonucleotide AS-ODN1(187-204) (5'CTTGCCCTCTAGGGTCCG 3') (SEQ ID NO: 28) against nucleotides 187 to 204 of the human sequence corresponds in sequence to AS-ODN1(214-231) (SEQ ID NO: 8) described above. Thus, AS-ODN1 is complementary to the nucleotides at positions 187-204 and 214-231 of the human and mouse cDNA, respectively. Oligonucleotide AS-ODN3(124-141) (5'CAGCCCGCGCAGACTGCC 3') (SEQ ID NO: 29) against nucleotides 124 to 141 of the human sequence corresponds in sequence to AS-ODN1(151-168) (SEQ ID NO: 6) described above. Thus, AS-ODN3 is complementary to the nucleotides at positions 124-141 and 151-168 of the human and mouse cDNA sequences, respectively. Oligonucleotide AS-ODN2(154-171) is designed against nucleotides 154 to 171 of the human sequence. AS-ODN2 is complementary to nucleotides at positions 154-171 and 181-198 of the human and mouse cDNA, respectively. The human sequence differs by a single base pair in the most 5' bp of the antisense sequence from the mouse sequence in the corresponding position, with the human AS-ODN2(154-171) sequence being 5'GAGGTCGTTAGACACTGC 3' (SEQ ID NO: 30) and the mouse sequence being 5'GAGGTCGTTAGACACTGA 3' (SEQ ID NO: 7) (the nucleotide difference is set out in bold). FIGURE 16 depicts the annotated mouse KSR cDNA sequence with antisense oligonucleotides indicated. We have compared the original AS-ODN2(181-198) to the revised human AS-ODN2(154-171)

and found they inhibited proliferation of PANC-1 cells, which are oncogenic K-ras-dependent human pancreatic cells, nearly identically (FIGURE 18).

#### EXAMPLE 6

[0211] We have designed additional potential AS-ODNs against other nucleotides of human KSR1. These ODNs (AS-ODN4 to AS-ODN12) are marked and annotated on human KSR1 nucleotide sequences in FIGURE 17. TABLE 2 is a list of these newly designed ODNs with corresponding human nucleotide target sequence.

TABLE 2

<u>AS-ODN ID #</u>	<u>Target Sequence (nt) (5'-3')</u>	<u>Sequence (5' to 3')</u>
AS-ODN4	ATGGGAGAGAAGGGAGGGC (1-18)	GCCCTCCTTCTCTCCCAT (SEQIDNO: 31)
AS-ODN5	CTGGTCCGTTACATTGT (205-222)	ACAAATGTAACGGACCAG (SEQ ID NO: 32)
AS-ODN6	GTGGCTCCGGTGAGAGG (247-264)	CCTCTCACCGGGAGCCAC (SEQ ID NO: 33)
AS-ODN7	GACTGGCTGTACACTTTC (298-315)	GAAAGTGTACAGCCAGTC (SEQ ID NO: 34)
AS-ODN8	GAGGCCGGAGGTGGTGCA (321-338)	TGCACCACTCCGGCCTC (SEQ ID NO: 35)
AS-ODN9	AGATCCCCGAGACCTCA (351-368)	TGAGGTCTCGGGGGATCT (SEQ ID NO: 36)
AS-ODN10	ATGAATGAGGCCAAGGTG (379-396)	CACCTTGGCCTCATTCAT (SEQ ID NO: 37)
AS-ODN11	AGTTGGAGTTCATTGGAT (511-528)	ATCCAATGAACTCCAAC (SEQ ID NO: 38)
AS-ODN12	GCGGCGGGAAAGTGGCTC (531-548)	GAGCCACTTCCGCCGC (SEQ ID NO: 39)

EXAMPLE 7KSR ANTISENSE OLIGONUCLEOTIDES AS RADIOSENSITIZERS

## BACKGROUND

[0212] Although ionizing radiation (IR) remains a primary treatment for human cancers, the failure to respond to radiation therapy limits the efficacy of this modality. Accumulating evidence supports the contention that a signal transduction pathway, analogous to that for cell growth and differentiation leads to resistance to IR. More specifically, constitutive activation of the EGFR/Ras pathway via *gf* Ras or hyperactivation of EGFRs lead to radioresistance in human tumor cells (1-27). The precise mechanisms underlying this action of EGFR and Ras are not well understood. Hence, identification of downstream elements of EGFR and Ras effector signaling in response to IR is critical to the development of mechanism-based therapeutic strategies for IR treatment. Of the EGFR and Ras effector signaling pathways, the Ras-Raf-MAPK (10, 28-32) and Ras-PI3-Kinase (3,33,34) pathways have been implicated to mediate EGFR/Ras regulation of radiosensitivity to IR. The relative contribution of these two signaling pathways may be tumor-type specific.

[0213] Potential mechanisms underlying EGFR/Ras-mediated radioresistance include: increased capacity for DNA damage repair, accelerated repopulation of surviving tumor cells, resistance to IR-induced apoptosis and lack of IR-induced cell cycle check point delays. IR-induced EGFR/Ras activation results in a pronounced dose-dependent proliferative response via the MAPK signaling cascade, contributing at least in part, to the mechanism of accelerated proliferation, a cause contributing to the failure of radiotherapy (49,50). As an obligate mediator of the *gf* EGFR/Ras-Raf-1-MAPK signaling of tumor cell proliferation (51), inactivation of KSR may increase the efficacy of IR therapy by abrogating the accelerated repopulation of surviving tumor cells.

[0214] In addition to potentially mediating radiation resistance through EGFR and Ras, KSR may also transmit signals for the lipid second messenger ceramide. Emerging data suggest that IR acts directly on the plasma membrane of several cell types, activating acid sphingomyelinase, which generates ceramide by enzymatic hydrolysis of sphingomyelin. Ceramide then acts as a second messenger in initiating or inhibiting an apoptotic response that is cell-type and cell-context specific (13, 15, 35-38). In addition to the tyrosine kinase based mechanism that the EGFR utilizes for KSR activation, ceramide may also directly activate KSR. In this regard, KSR was originally identified by Kolesnick and co-workers as ceramide activate protein kinase (CAPK) (39). While ceramide can signal apoptosis in some cell types through the c-Jun kinase and transcriptional regulation of gene products, such as Fas ligand or TNF $\alpha$  that mediate the death response (13, 14, 45), in other cells that contain the pro-apoptotic Bcl-2 family member BAD, ceramide induces apoptosis directly through a mechanism involving sequential Ras-dependent activation of KSR, c-Raf-1, and MEK1 (44, 46-48). In this case, the availability of a single target, such as BAD (44), converts the MAPK cascade, which is usually proliferative and/or anti-apoptotic, into a pro-apoptotic signaling pathway. Therefore, KSR may modulate radiosensitivity by regulation of ceramide-dependent and independent apoptotic responses in a cell-type specific manner. In support of the notion that KSR may prevent some forms of apoptosis from ensuing, Polk and co-workers showed that inactivation of KSR in YAMC colon cells antagonizes the anti-apoptotic signals emanating from TNF receptor, converting TNF into an inducer of apoptosis in these cells (41,42).

[0215] In the present example, we confine our studies to inactivation of the EGFR/Ras pathway as a proof-in-principle that this strategy can lead to radiosensitization. To explore this venue, we synthesized KSR specific AS-ODNs to pharmacologically inhibit KSR function (as described herein above) and employed A431 cells, which are driven through wild type Ras by an 100-fold overexpression of activated EGFR. When tested *in*

*vitro*, AS-ODNs were specifically taken up into the nucleus, resulting in decreased endogenous KSR gene expression and inhibition of A431 proliferation, invasion, transformation and tumorigenesis (see Example 2). Moreover, here we demonstrate that inactivation of KSR via genetic (expression of KSR-AS) or pharmacological (AS-ODNs) approaches yields sensitization of A431 cells to IR-induced apoptosis *in vitro*.

## RESULTS

### [0216] AS-KSR and DN Ki-KSR sensitize A431 cells to IR-induced apoptosis:

To test the hypothesis that inactivation of KSR might enhance the sensitivity to IR-induced cell killing, A431 cells stably-transfected with different KSR constructs were analyzed for their sensitivity to IR-induced apoptosis. A431 cells, due to the overexpression of activated EGFR, are known to be radioresistant (43). Serum-starved A431 cells were irradiated with a single dose of 20Gy and apoptosis was determined 24 hr post-IR by flow cytometry using Annexin V-FITC (Sigma). FIGURE 19 shows that A431 cells overexpressing wild-type Flag-KSR (KSR-S) displayed minimal IR-induced apoptosis. Expression of Flag-AS-KSR (KSR-AS) or dominant-negative Flag-Ki-KSR (Ki-KSR) radiosensitized A431 cells, resulting in a substantial increase in IR-induced apoptosis (n=3). Nearly 40% of A431- KSR-AS and Ki-KSR cells underwent apoptosis 24 hr after IR. These results, although preliminary, strongly suggest that KSR may play a key role in cellular sensitivity to IR. Comparable results were obtained when apoptosis was scored with Bisbenzimide staining.

### KSR AS-ODNs sensitize A431 cells to IR-induced apoptosis:

**[0217]** As described above, abrogation of KSR function by a genetic approach (AS-KSR and DN-Ki-KSR) sensitized A431 cells to IR-induced apoptosis. To test the effectiveness of pharmacologic inhibition of KSR1 gene expression by AS-ODN on

radiosensitivity, A431 cells were treated with 200 nM of AS-214231 for 36 hr prior to IR. Apoptosis was quantitated by flow cytometry using Annexin V-FITC. As shown in FIGURE 20, AS-214231 sensitized A431 cells, leading to a 2-fold increase in IR-induced apoptosis after 72 hours. The magnitude of this effect is comparable to that observed with overexpression of AS-KSR. In contrast, control ODN had no significant effect on radiation sensitivity to IR-induced apoptosis. It should be noted that at the concentration of Oligofectamine used, no significant elevation of basal level of apoptosis was detected (not shown). These results indicate that the radiosensitizing effect of AS-214231 is KSR sequence specific and that it might be feasible to use KSR AS-ODNs as radiosensitizers.

**[0218] Inactivation of KSR1 by KSR-AS inhibits A431 cells to IR-induced clonogenic survival:** To assess whether KSR1 is involved in the lethal effects of ionizing radiation on A431 cells, the clonogenic survival of KSR-S- and KSR-AS-transfected A431 cells was determined after increasing doses of radiation exposure. A431-pTRE, KSR-S and KSR-AS cells were plated at seeding density of  $3.4 \times 10^4$ ,  $1.4 \times 10^4$ , or  $7.0 \times 10^3$  cells/cm<sup>2</sup>, respectively in 60 mm dishes for 4 days to reach 85% confluence. Prior to radiation, the culture medium was replaced with serum-free growth medium containing 0.2% human albumin for 20-24 hr. Cultures were then subjected to 1-15Gy of radiation at a dose rate of 2.24Gy/minute, using a  $60^{Co}$  source. The culture medium was then replaced again with fresh growth medium containing 10% Tet-approved FBS for additional 24 h. Thereafter, cells were harvested by trypsinization and a clonogenic survival assay was performed using a standard procedure. The cells were seeded at different dilutions to generate 25-80 colonies per 60 mm culture dish for each radiation dose, incubated at 37°C in 5% CO<sub>2</sub> for 12 days and colonies containing over 50 cells were stained with crystal violet to determine the surviving fractions. FIGURE 21 demonstrates that overexpression of KSR-S mildly enhanced radioresistance as compared to A431-pTRE controls, associated with an increase in the shoulder width ( $D_q$ ) of the dose-survival curve, without a significant change in the slope ( $D_0$ ). In contrast,

inactivation of KSR1 by KSR-AS significantly radiosensitized A431 cells, manifested by complete elimination of the dose-survival curve shoulder and a decrease of the  $D_0$ . The dose modification factor (MDF) at 10% survival level ( $D_{10}$ ) upon KSR inactivation was 2.44. These results indicate that KSR1 is obligate for radiation-induced cell kill and that KSR1 represent a new molecular target for radiosensitization.

## REFERENCES

1. Bernhard, E. J., Stanbridge, E. J., Gupta, S., Gupta, A. K., Soto, D., Bakanauskas, V. J., Cerniglia, G. J., Muschel, R. J., and McKenna, W. G. (2000). Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. *Cancer Res.* 60: 6597-600.
2. Grant, M. L., Bruton, R. K., Byrd, P. J., Gallimore, P. H., Steele, J. C., Taylor, A. M., and Grand, R. J. (1990). Sensitivity to ionising radiation of transformed human cells containing mutant ras genes. *Oncogene*. 5: 1159-64.
3. Gupta, A. K., Bakanauskas, V. J., Cerniglia, G. J., Cheng, Y., Bernhard, E. J., Muschel, R. J., and McKenna, W. G. (2001). The Ras radiation resistance pathway. *Cancer Res.* 61: 4278-82.
4. Dent, P., Reardon, D. B., Park, J. S., Bowers, G., Logsdon, C., Valerie, K., and Schmidt-Ullrich, R. (1999). Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. *Mol Biol Cell*. 10: 2493-506.
5. Huang, S. M., and Harari, P. M. (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. *Clin Cancer Res.* 6: 2166-74.
6. Lammering, G., Valerie, K., Lin, P. S., Mikkelsen, R. B., Contessa, J. N., Feden, J. P., Farnsworth, J., Dent, P., and Schmidt-Ullrich, R. K. (2001). Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. *Clin Cancer Res.* 7: 682-90.

7. Ling, C. C., and Endlich, B. (1989). Radioresistance induced by oncogenic transformation. *Radiat Res.* 120: 267-79.
8. McKenna, W. G., Weiss, M. C., Endlich, B., Ling, C. C., Bakanauskas, V. J., Kelsten, M. L., and Muschel, R. J. (1990). Synergistic effect of the v-myc oncogene with H-ras on radioresistance. *Cancer Res.* 50: 97-102.
9. Schmidt-Ullrich, R. K., Dent, P., Grant, S., Mikkelsen, R. B., and Valerie, K. (2000). Signal transduction and cellular radiation responses. *Radiat Res.* 153: 245-57.
10. Kasid, U., Suy, S., Dent, P., Ray, S., Whiteside, T. L., and Sturgill, T. W. (1996). Activation of Raf by ionizing radiation. *Nature.* 382: 813-6.
11. Wollman, R., Yahalom, J., Maxy, R., Pinto, J., and Fuks, Z. (1994). Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. *Int J Radiat Oncol Biol Phys.* 30: 91-8.
12. Carter, S., Auer, K. L., Reardon, D. B., Birrer, M., Fisher, P. B., Valerie, K., Schmidt-Ullrich, R., Mikkelsen, R., and Dent, P. (1998). Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. *Oncogene.* 16: 2787-96.
13. Santana, P., Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E. H., Fuks, Z., and Kolesnick, R. (1996). Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. *Cell.* 86: 189-99.
14. Xia, F., Wang, X., Wang, Y. H., Tsang, N. M., Yandell, D. W., Kelsey, K. T., and Liber, H. L. (1995). Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. *Cancer Res.* 55: 12-5.
15. Chmura, S. J., Mauceri, H. J., Advani, S., Heimann, R., Beckett, M. A., Nodzenski, E., Quintans, J., Kufe, D. W., and Weichselbaum, R. R. (1997). Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. *Cancer Res.* 57: 4340-7.
16. Pirollo, K. F., Tong, Y. A., Villegas, Z., Chen, Y., and Chang, E. H. (1993). Oncogene- transformed NIH 3T3 cells display radiation resistance levels

indicative of a signal transduction pathway leading to the radiation-resistant phenotype. *Radiat Res.* 135: 234-43.

17. Fuks, Z., Persaud, R. S., Alfieri, A., McLoughlin, M., Ehleiter, D., Schwartz, J. L., Seddon, A. P., Cordon-Cardo, C., and Haimovitz-Friedman, A. (1994). Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. *Cancer Res.* 54: 2582-90.
18. Pirollo, K. F., Hao, Z., Rait, A., Ho, C. W., and Chang, E. H. (1997). Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. *Biochem Biophys Res Commun.* 230: 196-201.
19. Miller, A. C., Kariko, K., Myers, C. E., Clark, E. P., and Samid, D. (1993). Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. *Int J Cancer.* 53: 302-7.
20. McKenna, W. G., Weiss, M. C., Bakanauskas, V. J., Sandler, H., Kelsten, M. L., Biaglow, J., Tuttle, S. W., Endlich, B., Ling, C. C., and Muschel, R. J. (1990). The role of the H-ras oncogene in radiation resistance and metastasis. *Int J Radiat Oncol Biol Phys.* 18: 849-59.
21. Bernhard, E. J., McKenna, W. G., Hamilton, A. D., Sebti, S. M., Qian, Y., Wu, J. M., and Muschel, R. J. (1998). Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. *Cancer Res.* 58: 1754-61.
22. Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J., and McKenna, W. G. (1996). The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. *Cancer Res.* 56: 1727-30.
23. Kavanagh, B. D., Dent, P., Schmidt-Ullrich, R. K., Chen, P., and Mikkelsen, R. B. (1998). Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation. *Radiat Res.* 149: 579-87.
24. Schmidt-Ullrich, R. K., Mikkelsen, R. B., Dent, P., Todd, D. G., Valerie, K., Kavanagh, B. D., Contessa, J. N., Rorrer, W. K., and Chen, P. B. (1997). Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. *Oncogene.* 15: 1191-7.

25. Balaban, N., Moni, J., Shannon, M., Dang, L., Murphy, E., and Goldkorn, T. (1996). The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. *Biochim Biophys Acta.* 1314: 147-56.
26. Todd, D. G., Mikkelsen, R. B., Rorrer, W. K., Valerie, K., and Schmidt-Ullrich, R. K. (1999). Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells. *J Recept Signal Transduct Res.* 19: 885-908.
27. Reardon, D. B., Contessa, J. N., Mikkelsen, R. B., Valerie, K., Amir, C., Dent, P., and Schmidt-Ullrich, R. K. (1999). Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. *Oncogene.* 18: 4756-66.
28. Kasid, U., Pfeifer, A., Brennan, T., Beckett, M., Weichselbaum, R. R., Dritschilo, A., and Mark, G. E. (1989). Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. *Science.* 243: 1354-6.
29. Hagan, M., Wang, L., Hanley, J. R., Park, J. S., and Dent, P. (2000). Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. *Radiat Res.* 153: 371-83.
30. Kasid, U. (2001). Raf-1 protein kinase, signal transduction, and targeted intervention of radiation response. *Exp Biol Med (Maywood).* 226: 624-5.
31. Gokhale, P. C., McRae, D., Monia, B. P., Bagg, A., Rahman, A., Dritschilo, A., and Kasid, U. (1999). Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. *Antisense Nucleic Acid Drug Dev.* 9: 191-201.
32. Park, J. S., Carter, S., Reardon, D. B., Schmidt-Ullrich, R., Dent, P., and Fisher, P. B. (1999). Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells. *Mol Biol Cell.* 10: 4231-46.
33. Gupta, A. K., Bernhard, E. J., Bakanauskas, V. J., Wu, J., Muschel, R. J., and McKenna, W. G. (2000). RAS-Mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. *Radiat Res.* 154: 64-72.
34. Jones, H. A., Hahn, S. M., Bernhard, E., and McKenna, W. G. (2001). Ras inhibitors and radiation therapy. *Semin Radiat Oncol.* 11: 328-37.

35. Chmura, S. J., Nodzenski, E., Kharbanda, S., Pandey, P., Quintans, J., Kufe, D. W., and Weichselbaum, R. R. (2000). Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. *Mol Pharmacol.* 57: 792-6.
36. Chmura, S. J., Nodzenski, E., Beckett, M. A., Kufe, D. W., Quintans, J., and Weichselbaum, R. R. (1997). Loss of ceramide production confers resistance to radiation-induced apoptosis. *Cancer Res.* 57: 1270-5.
37. Verheij, M., Ruiter, G. A., Zerp, S. F., van Blitterswijk, W. J., Fuks, Z., Haimovitz-Friedman, A., and Bartelink, H. (1998). The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. *Radiother Oncol.* 47: 225-32.
38. Rosette, C., and Karin, M. (1996). Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. *Science.* 274: 1194-7.
39. Zhang, Y., Yao, B., Delikat, S., Bayoumy, S., Lin, X. H., Basu, S., McGinley, M., Chan-Hui, P. Y., Lichenstein, H., and Kolesnick, R. (1997). Kinase suppressor of Ras is ceramide-activated protein kinase. *Cell.* 89: 63-72.
40. Yao, B., Zhang, Y., Delikat, S., Mathias, S., Basu, S., and Kolesnick, R. (1995). Phosphorylation of Raf by ceramide-activated protein kinase. *Nature.* 378: 307-10.
41. Yan, F., and Polk, D. B. (2001). Kinase suppressor of ras is necessary for tumor necrosis factor alpha activation of extracellular signal-regulated kinase/mitogen-activated protein kinase in intestinal epithelial cells. *Cancer Res.* 61: 963-9.
42. Yan, F., John, S. K., and Polk, D. B. (2001). Kinase suppressor of Ras determines survival of intestinal epithelial cells exposed to tumor necrosis factor. *Cancer Res.* 61: 8668-75.
43. Kwok, T. T., and Sutherland, R. M. (1992). Cell cycle dependence of epidermal growth factor induced radiosensitization. *Int J Radiat Oncol Biol Phys.* 22: 525-7.
44. Basu S, Bayoumy S, Zhang Y, Lozano J, and Kolesnick R. (1998). BAD enables ceramide to signal apoptosis via Ras and Raf-1. *J. Biol. Chem.* 273: 30419-26.

45. Herr I., Wilhelm, D., Böhler T, Angel P. and Debatin K. (1997). Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. *EMBO J.* 16:6200-08.
46. Susin, S. A., Zamzami, N., Castedo, M., Daugas, E., Wang, H. G., Geley, S., Fassy, F., Reed, J. C., and Kroemer, G. (1997) *J. Exp. Med.* 186, 25-37.
47. Smyth, M. J., Perry, D. K., Zhang, J., Poirier, G. G., Hannun, Y. A., and Obeid, L. M. (1996) *Biochem. J.* 316, 25-28.
48. Farschon, D. M., Couture, C., Mustelin, T., and Newmeyer, D. D. (1997) *J. Cell Biol.* 137, 1117-1125.
49. Tubiana, M. (1988). Repopulation in human tumors. A biological background for fractionation in radiotherapy. *Acta Oncol.* 27: 83-8.
50. Begg, A. C. (1994). Prediction of repopulation rates and radiosensitivity in human tumours. *Int J Radiat Biol.* 65: 103-8.
51. Xing, H. R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z., and Kolesnick, R. (2003). Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. *Nat. Med.* 9: 1267-8.

#### EXAMPLE 8

##### Regulation of angiogenesis by KSR1

**[0219]** Background: Angiogenesis, the formation of new vessels from pre-existing vasculature, plays a crucial role during normal development, tissue regeneration in wound healing and post-ischemic tissue repair. In addition, angiogenesis is central to tumor growth, progression and dissemination<sup>a,b,c,d</sup>. New vessel growth and maturation are highly complex and coordinated processes, requiring the sequential activation of a series of receptors by numerous ligands<sup>e,f</sup>. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis. VEGF signaling, mediated by two receptor tyrosine kinases VEGFR-1 and VEGFR-2, represents a critical rate-limiting step not only in physiologic

angiogenesis such as embryogenesis, skeletal growth and reproductive functions, but also in pathological angiogenesis, such as that associated with tumor growth<sup>g</sup>.

[0220] Through alternative mRNA splicing, human VEGF gene gives rise to four major VEGF isoform (VEGF<sub>121</sub>, VEGF<sub>165</sub>, VEGF<sub>189</sub>, and VEGF<sub>201</sub>) having respectively 121, 163, 189 and 201 amino acids after signal sequence cleavage<sup>h,i</sup>. While VEGF<sub>121</sub> is a free diffusible protein, VEGF<sub>189</sub>, and VEGF<sub>206</sub> have high affinity for heparin and are mostly bound to heparin-containing proteoglycans in the extracellular matrix (ECM)<sup>j,k</sup>. VEGF165, the predominant isoform, is secreted yet with a significant portion remain bound to cell surface or ECM<sup>k</sup>. The biological functions of VEGF are mediated by two receptor tyrosine kinases VEGFR-1 (also known as Flt-1) and VEGFR-2 (also known as Flk-1 or KDR). VEGFR-2 is the chief mediator of VEGF signaling of endothelial cell mitogenesis and survival, angiogenesis and microvascular permeability. In contrast, VEGFR-1 does not transmit mitogenic signal effectively. It inhibits VEGFR-2 activity by sequestering VEGF and prevents it from binding VEGFR-2. In addition, VEGFR-1 modulates the release of tissue-specific growth factors from vascular bed<sup>f</sup>.

[0221] The gene expression of VEGF is tightly regulated. VEGF mRNA expression is up regulated through hypoxia-induced factor (HIF) in response to hypoxic or oxygen tension<sup>l</sup>. In addition, hyperactivation of receptor tyrosine kinases such as EGFR or oncogenic activation of Ras leads to transcriptional upregulation of VEGF expression<sup>g,m</sup>. Further, DePinho and colleagues recently demonstrate that oncogenic H-Ras signaling is obligate for melanoma tumor maintenance via regulation of VEGF production and endothelial cell survival<sup>n</sup>. Moreover, importance of Ras-Raf-1 in angiogenesis is strengthened by the observations of Cheresh and co-workers that Raf-1 confers vascular survival in response to intrinsic and extrinsic apoptotic stimuli<sup>o</sup>.

[0222] The importance of VEGF in angiogenesis has established it as a therapeutic target for cancer treatment and led to the clinical development of a variety of VEGF inhibitors.

In 1993, it was shown that a monoclonal antibody that targeted VEGF results in a dramatic suppression of tumor growth *in vivo*<sup>p</sup>, which led to the development of bevacizumab (Avastin; Genentech), a humanized variant of this anti-VEGF antibody, as an anticancer agent. The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumor angiogenesis and that blocking angiogenesis is an effective strategy to treat human cancer<sup>q</sup>.

### **Results: KSR1 is required for VEGF production in A431 cells**

[0223] Since KSR1 is an essential mediator of gain-of-function Ras signaling of tumorigenesis<sup>r,s</sup>, we evaluated the involvement of KSR1 in EGF-stimulated VEGF production in A431-pTRE-Tet-Off-KSR cell lines that we have previously characterized<sup>s</sup>. For these studies, A431-pTRE-KSR cells were seeded at 6 x 10<sup>5</sup> cells (for pTRE and KSR-S cells) or 3 x 10<sup>5</sup> cells (for KSR-AS and DN-KSR cells), respectively in 6-well culture plates and let grow for 48 hr to 80% confluent. Cells were then washed twice with PBS and incubated in 1ml serum-free medium in the presence or absence of EGF (1-100 ng/ml) for additional 24 or 48 hr. At the indicated time points, conditioned medium containing secreted forms of VEGF was collected, cell debris cleared by centrifugation and stored at -80°C until further characterization. ELISA immunoassay (R&D Systems) was performed to measure soluble forms of VEGF in conditioned medium utilizing an antibody recognizing all isoforms of VEGF according to manufacturer's instructions. FIGURE 22 shows that approximately 400 pg/ml/10<sup>5</sup> cells VEGF were secreted by A431-pTRE cells over 24h, consistent with the reported value in the literature<sup>t</sup>. Overexpression of Flag-KSR1 in A431-KSR-S cells lead to a 3-fold increase of basal VEGF production compared to that of A431-pTRE cells. In contrast, inactivation of KSR1 by either KSR-AS or a dominant negative KSR1 mutant (DN-KSR1) completely abolished baseline VEGF secretion at all time points examined. Furthermore, while VEGF in non-transfected A431 cells or in A431-pTRE and KSR-S cells could be further increased by stimulation with 100 ng/ml EGF treatment, A431-KSR1-AS and A431-DN-KSR1 cells

failed to respond to EGF stimulation. Similar results were observed when stimulated with lower doses of EGF. These results suggest that KSR1 is obligate for baseline and EGF-induced VEGF ligands production *in vitro* and KSR1 may represent a novel target for anti-angiogenic therapy to treat conditions associated with pathological angiogenesis such as cancer. Future studies will evaluate the effectiveness of KSR1 AS-ODN in inhibiting VEGF expression in A431 cells *in vitro* and in A431 tumor xenografts *in vivo*.

<sup>a</sup>Folkman, J. Nat. Med. 1, 27-31, 1995.  
<sup>b</sup>Carmellet, P. Nat. Med 9, 653-660, 2003.  
<sup>c</sup>Bergers, G et al. Science 284, 808-812, 1999.  
<sup>d</sup>Kerb, R and Folkman, J. Nat. Rev. Cancer 2, 727-739, 2002.  
<sup>e</sup>Yancopoulos, GD et al., Nature 407, 242-248, 2000.  
<sup>f</sup>Ferrara, N and Alitalo, K. Nat. Med. 9, 669-676, 2003.  
<sup>g</sup>Ferrara, N and Davis-Smith, D. Endocr. Rev. 18, 4-25, 1997.  
<sup>h</sup>Houck, KA et al. Mol. Endocrinol. 5, 1806-1814, 1991.  
<sup>i</sup>Tischer, A et al. J. Biol. Chem. 266, 11947-11954, 1991.  
<sup>j</sup>Houck, KA et al. J. Biol. Chem. 267, 26031-26037, 1992.  
<sup>k</sup>Park, JE et al. Mol. Biol. Cell 4, 1317-1326, 1993.  
<sup>l</sup>Semenza, Z. Biochem. Pharmacol. 64, 993-998, 2002.  
<sup>m</sup>Okada, F et al. pro. Natl. Acad. Sci. USA 95, 3609-3614, 1998.  
<sup>n</sup>Chin, L et al. Nature 400, 468-472, 1999.  
<sup>o</sup>Alavi, A et al. Science 301, 94-96, 2003.  
<sup>p</sup>Kim, KJ et al. Nature 362, 841-844, 1993.  
<sup>q</sup>Ferrara N et al. nat. Rev. Drug Discov. 3, 391-400, 2004.  
<sup>r</sup>Lozano, J and Xing, HR et al. Can. Res. 63, 4232-4238, 2003.  
<sup>s</sup>Xing, HR et al., Nat. Med. 19, 1267-1268, 2003.  
<sup>t</sup>Viloria-Petit, A. et al. Can. Res. 61, 5090-5101, 2001.

[0224] This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all aspects illustrate and not restrictive, the

scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

**[0225]** Various references are cited throughout this Specification, each of which is incorporated herein by reference in its entirety.

WHAT IS CLAIMED IS:

1. An oligonucleotide which is substantially complementary to a region of KSR RNA, wherein said oligonucleotide inhibits the expression of KSR.
2. The oligonucleotide of Claim 1 which is substantially complementary to a nucleic acid encoding mammalian KSR.
3. The oligonucleotide of Claim 1 which is substantially complementary to a nucleic acid encoding human KSR.
4. An oligonucleotide which is substantially complementary to a translation initiation site, 5' untranslated region, coding region or 3' untranslated region of mRNA encoding mammalian KSR.
5. An antisense oligonucleotide comprising a sequence substantially complementary to the CA1 region of KSR.
6. An antisense oligonucleotide comprising a sequence substantially complementary to nucleotides 124 to 243 (SEQ ID NO: 1) of the coding sequence of mouse KSR or nucleotides 97 to 216 of human KSR (SEQ ID NO: 25), or a portion thereof.
7. The oligonucleotide of Claim 6 comprising a sequence substantially complementary to nucleotides selected from the group of:
  - (a) 124 to 141 of the sequence of human KSR, corresponding to 151 to 168 of the sequence of mouse KSR (SEQ ID NO:3),
  - (b) 154 to 171 of the sequence of human KSR (SEQ ID NO:27)
  - (c) 181 to 198 of the sequence of mouse KSR (SEQ ID NO: 4); and

(d) 187 to 204 of the sequence of human KSR, corresponding to 214 to 231 of the sequence of mouse KSR (SEQ ID NO: 5).

8. An antisense oligonucleotide comprising a sequence selected from the group of SEQ ID NOS: 6-8 and SEQ ID NOS: 28-39.

9. The oligonucleotide of Claim 1 labeled with a detectable label.

10. The oligonucleotide of Claim 1 wherein the label is selected from enzymes, ligands, chemicals which fluoresce and radioactive elements.

11. The oligonucleotide of Claim 1 wherein said oligonucleotide comprises at least one phosphorothioate linkage.

12. A recombinant DNA molecule comprising a nucleic acid sequence which encodes on transcription an antisense RNA complementary to mammalian KSR RNA or a portion thereof.

13. The recombinant DNA molecule of Claim 12 wherein said nucleic acid sequence is operatively linked to a transcription control sequence.

14. A cell line transfected with the recombinant DNA molecule of Claim 13.

15. An expression vector capable of expressing a nucleic acid which is substantially complementary to the coding sequence of KSR RNA, or a portion/fragment thereof, wherein said oligonucleotide/nucleic acid inhibits the expression of KSR.

16. An expression vector capable of expressing an oligonucleotide which is substantially complementary to the CA1 region of the coding sequence of KSR RNA, or a portion/fragment thereof, wherein said oligonucleotide inhibits the expression of KSR.
17. A pharmaceutical composition comprising a therapeutically effective amount of an antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.
18. A composition comprising the oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.
19. A composition comprising one or more chemotherapeutic or radiotherapeutic agent and an oligonucleotide which is targeted to a mRNA encoding mammalian KSR and which inhibits KSR expression.
20. A composition comprising an expression vector and a pharmaceutically acceptable carrier or diluent, wherein said expression vector is capable of expressing nucleic acid which is substantially complementary to the coding sequence of KSR RNA, or a portion/fragment thereof, wherein said nucleic acid inhibits the expression of KSR.
21. A method of inhibiting the expression of mammalian KSR comprising contacting cells which express KSR with an effective amount of a nucleic acid which is complementary to a portion of the mRNA encoding KSR.
22. A method of inhibiting the expression of mammalian KSR comprising contacting cells which express KSR with an effective amount of the oligonucleotide of Claim 1 whereby expression of mammalian KSR is inhibited.

23. A method of treating or preventing a hyperproliferative condition associated with the expression of gf-Ras or heightened expression of Ras in a mammal comprising administering to said mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein.
24. The method of Claim 23 wherein said compound or agent is an antisense oligonucleotide which specifically hybridizes to a portion of the mRNA encoding KSR.
25. A method of treating or preventing a hyperproliferative condition associated with the expression of gf-Ras or heightened expression of Ras in a mammal comprising expressing in said mammal or administering to said mammal a therapeutically effective amount of a nucleic acid which is complementary to a portion of the mRNA encoding KSR.
26. A method of treating or inhibiting the progression of cancer in a mammal comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein.
27. The method of claim 26, wherein said cancer is selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer.
28. A method of treating or inhibiting the progression of cancer in a mammal comprising administering to a mammal a therapeutically effective amount of the oligonucleotide of Claim 1.

29. A method of conferring radiosensitivity to ionizing radiation in tumor cells in a mammal comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein.
30. A method of conferring radiosensitivity to ionizing radiation in tumor cells in a mammal comprising administering to a mammal a therapeutically effective amount of the oligonucleotide of Claim 1.
31. A method of inhibiting angiogenesis of tumor cells in a mammal comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein.
32. The method of Claim 29, 30 or 31 wherein the tumor cells are cancer cells selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer.
33. A method of inhibiting angiogenesis in a mammal comprising administering to a mammal a therapeutically effective amount of the oligonucleotide of Claim 1.
34. A method for inhibiting or reducing VEGF expression or activity in a mammal comprising administering to a mammal a therapeutically effective amount of a compound or agent which inhibits the expression of mammalian KSR protein.
35. A method for inhibiting or reducing VEGF expression or activity in a mammal comprising administering to a mammal a therapeutically effective amount of the oligonucleotide of Claim 1.

36. A method of stimulating angiogenesis in a mammal comprising administering to a mammal a therapeutically effective amount of a compound or agent which activates the expression of mammalian KSR protein or a vector expressing mammalian KSR.


37. A method of identifying compounds or agents which inhibit the expression of KSR comprising the steps of:

- (c) incubating a cell expressing KSR in the presence and absence of a candidate compound or agent; and
- (d) detecting or measuring the expression of KSR in the presence and absence of a candidate compound or agent,

whereby a decrease in the expression of KSR in the presence of said candidate compound or agent versus in the absence of said candidate compound or agent indicates that said compound or agent inhibits the expression of KSR.

38. A ribozyme that cleaves KSR mRNA.

FIG. 1A



2/47



**FIG. 1B****FIG. 1C**

FIG. 1D




FIG. 1E





FIG. 1F






**FIG. 2A****a - KSR +/+****FIG. 2B****b - KSR -/-****FIG. 2C****c - KSR -/-****FIG. 2D****d - EGFR -/-**

FIG. 3A



6/47

FIG. 3B




FIG. 3C




FIG. 4A







FIG. 4B



## FIG. 5A



## FIG. 5B



## FIG. 5C




FIG. 5D




FIG. 5E





FIG. 6A



12/47

FIG. 6B

	% G1	% S	% G2
Vector	40.1	45.1	14.8
KSR-S	25.2	60.8	14.0
KSRAS	16.4	23.2	60.4
DN-KSR	24.2	24.8	51.0

FIG. 6C




FIG. 6D




FIG. 7A





FIG. 7B








FIG. 8C  
FIG. 8B

FIG. 8D



20/47

FIG. 9A





FIG. 9B



21/47

FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F




FIG. 10A




FIG. 10B

ODNs Animals	Saline		KSR-AS				Sense	
	#1	#2	#1	#2	#3	#4	#1	#2
1	2	3	4	5	6	7	8	




FIG. 10C

ODNs Animals	Saline		Control	Sense	KSR-AS			
	#1	#2	3	#3	#1	#2	#3	#4
1	2	3	4	5	6	7		



25/47

FIG. 10D



(ii) Number of lung metastases foci  
(whole lung surface)

Dose of infusion (mg/ kg /Day)	Sense-ODNs	AS-ODN	% inhibition
10	7.4 ± 1.4	2.5 ± 0.6	65
25	10.2 ± 1.8	1.4 ± 0.5	86

26/47

## \*\*\*\* FIG.11-1

Human MGEK-EGGGGGDAAAEGGAGAAASRALQQCGQLO 34  
 Mouse MDRAALRAAA K -- V

## CA1

Human KLIDISIGSLRGLRTKCAVSNDLTQQEIRTLEAKLVRYICKQRQC 79  
 Mouse S K Q S

Human KLSVAPGERTPELNSYPRFSDWLYTFNVRPEVVQEIPRDLTLDAL 124  
 Mouse I SD A I QE

Human LEMNEAKVKETLRRCGASGDECGRQLQYALTCLRKVTLGLGEHKED 169  
 Mouse D A M W TE S Q M

Human SSWSSLDARRESGGPSTDLSAASLPWPPGSSQLGRAGNSAQGP 214  
 Mouse G I DS -L PM M S----- A T

Human RSISVSALPASDSPTPSFSEGLSDTCIPLHASGRLTPRALHSFIT 259  
 Mouse V GL S I

## CA2

Human PPTTPQLRRHTKLKPPRTPPPSRKVFQLLPSFPTLRSKSHESQ 304  
 Mouse A

Human LGNRIDDVSSMRFDLSHGSPQMVRDIDLGVTHRFSTKSWLSQVC 349  
 Mouse TP K E P L

## CA3

Human HVCQKSMIFGVKCKHCRLLKCHNKCTKEAPACRISFLPLTRLRRTE 394  
 Mouse N I A

Human SVPSDINNPVDRAAEPHFGTLPKALTKEHPPAMNHLDSSSNPSS 439  
 Mouse -

## CA4

Human TTSSTPSSPAPFPTSSNPSSATTPPNPSPGQRDSRFNFPAAAYFIH 484  
 Mouse L S -----

Human HRQQFIFPDISAFAHAAAPLPEAADGTRLDDQPKADVLEAHEAEAE 529  
 Mouse ----- CSC SST S I GV

Human EPEAGKSEAEDDED-EVDDLPSSRRPWRGPISRKASQTSVYLQEW 573  
 Mouse ED

FIG. 11-2

## FIG. 12A-1

1 GAATTCCCTC GGGGCTTTCC TGCCGAGGCG CCCGTGTCCC CGGGCTCCTC GCCTCGGCC  
 61 CCAGCGCCCG CGATGCCGAG GCATGGATAG AGCGGGCGTTG CGCGCGGCAG CGATGGCGA  
 121 GAAAAAGGAG GGCGGCGGCG GGGGCGCCGC GGCGGACGGG GGCGCAGGGG CCGCCGTCAG  
 181 CCGGGCGCTG CAGCAGTGC GGCAGCTGCA GAAGCTCATC GATACTCCA TCGGCAGTCT  
 241 GCGCGGGCTG CGCACCAAGT GCTCAGTGTCA TAACGACCTC ACACAGCAGG AGATCCGGAC  
 301 CCTAGAGGCA AAGCTGGTGA AATACATTTG CAAGCAGCAG CAGAGCAAGC TTAGTGTGAC  
 361 CCCAAGCGAC AGGACCGCCG AGCTCAACAG CTACCCACGC TTCAGTGACT GGCTGTACAT  
 421 CTTCAACGTG AGGCCTGAGG TGGTGCAGGA GATCCCCAA GAGCTCACAC TGGATGCTCT  
 481 GCTGGAGATG GACGAGGCCA AAGCCAAGGA GATGCTGCGG CGCTGGGGGG CCAGCACGGA  
 541 GGAGTGCAGC CGCCTACAGC AAGCCCTTAC CTGCCTTCGG AAGGTGACTG GCCTGGGAGG  
 601 GGAGCACAAA ATGGACTCAG GTTGGAGTTC AACAGATGCT CGAGACAGTA GCTTGGGGCC  
 661 TCCCATGGAC ATGCTTTCT CGCTGGCAG AGCGGGTGCC AGCACTCAGG GACCCCGTTC  
 721 CATCTCCGTG TCCGCCCTGC CTGCCTCAGA CTCTCCGGTC CCCGGCCTCA GTGAGGGCCT  
 781 CTCGGACTCC TGTATCCCCT TGCACACCAG CGGCCGGCTG ACCCCCCGGG CCCTGCACAG  
 841 CTTCATCACG CCCCCCTACCA CACCCCAGCT ACGACGGCAC GCCAAGCTGA AGCCACCAAG  
 901 GACACCCCCA CCGCCAAGCC GCAAGGTCTT CCAGCTGCTC CCCAGCTTCC CCACACTCAC  
 961 ACGGAGCAAG TCCCACGAGT CCCAGCTGGG AAACCGAATC GACGACGTCA CCCCAGTGA  
 1021 GTTGAACTC CCTCATGGAT CCCCCACAGCT GGTACGAAGG GATATCGGGC TCTCGGTGAC  
 1081 GCACAGGTTTC TCCACAAAGT CATGGTTGTC ACAGGTGTGC AACGTGTGCC AGAAGAGCAT  
 1141 GATTTTGTC GTGAAGTGC AACTGTCAG GTTAAAATGC CATAACAAGT GCACAAAGGA  
 1201 AGCTCCCGCC TGCAGGATCA CTTCCCTCCC ACTGGCCAGG CTTCGGAGGA CAGAGTCTGT  
 1261 CCCGTCAGAT ATCAACAACC CAGTGGACAG AGCAGCAGAG CCCCATTTC GAAACCTTCC  
 1321 CAAGGCCCTG ACAAAAGAAGG AGCACCTCC AGCCATGAAC CTGGACTCCA GCAGCAACCC  
 1381 ATCCTCCACC ACGTCTCCA CACCCCTCATC GCCGGCACCT TTCTGACCT CATCTAATCC  
 1441 CTCCAGTGCC ACCACGCCCTC CCAACCCGTC ACCTGGCCAG CGGGACAGCA GGTCAGCTT  
 1501 CCCAGACATT TCAGCCTGTT CTCAGGCAGC CCCGCTGTCC AGCACAGCCG ACAGTACACG  
 1561 GCTCGACGAC CAGCCCCAAA CAGATGTGCT AGGTGTTCAC GAAGCAGAGG CTGAGGAGCC  
 1621 TGAGGCTGGC AAGTCAGAGG CAGAGGATGA CGAGGAGGAT GAGGTGGACG ACCTCCCCAG  
 1681 CTCCCAGCCGG CCCTGGAGGG GCCCCATCTC TCGAAAGGCC AGCCAGACCA GCGTTTACCT  
 1741 GCAAGAGTGG GACATCCCCT TTGAACAGGT GGAACGGGC GAGCCCATTG GACAGGGTCG  
 1801 CTGGGGCCGG GTGCACCGAG GCGTTGGCA TGGCGAGGTG GCCATTGCGC TGCTGGAGAT  
 1861 GGACGGCCAC AATCAGGACC ACCTGAAGCT GTCAAGAAA GAGGTGATGA ACTACCGGCA  
 1921 GACGCGGCAT GAGAACGTGG TGCTCTTCAT GGGGGCCTGC ATGAACCCAC CTCACCTGGC  
 1981 CATTATCACC AGCTCTGCA AGGGGCGGAC ATTGCATTCA TTCGTGAGGG ACCCCAAGAC  
 2041 GTCTCTGGAC ATCAATAAGA CTAGGCAGAT CGCCCAAGGAG ATCATCAAGG GCATGGGTTA  
 2101 TCTTCATGCA AAAGGCATCG TGCACAAGGA CCTCAAGTCC AAGAATGTCT TCTATGACAA  
 2161 CGGCAAAGTG GTCATCACAG ACTTCGGCT GTTGGGATC TCGGGTGTGG TCCGAGAGGA  
 2221 ACGGCGCGAG AACCAACTGA AACTGTCACA TGACTGGCTG TGCTACCTGG CCCCCGAGAT  
 2281 CGTACGAGAA ATGATCCCGG GGCGGGACGA GGACCGAGCTG CCCTCTCCA AAGCAGCCGA  
 2341 TGTCATGCA TTCGGGACTG TGTGGTATGA ACTACAGGCA AGAGACTGGC CCTTTAAGCA  
 2401 CCAGCCTGCT GAGGCCCTGA TCTGGCAGAT TGGAAGTGGG GAAGGAGTAC GGCGCGTCCT  
 2461 GGCAATCCGTC AGCCTGGGGAG AGGAAGTCGG CGAGATCCTG TCTGCCTGCT GGGCTTCGA  
 2521 TCTGCAGGAG AGACCCAGCT TCAGCCTGCT GATGGACATG CTGGAGAGGC TGCCCAAGCT  
 2581 GAACCGGGCGG CTCTCCACC CTGGGCACCTT TTGGAAGTCG GCTGACATTA ACAGCAGCAA  
 2641 AGTCATGCC CGCTTTGAAA GGTTGGCCT GGGGACCTCG GAGTCGGTA ATCCAAAGAT

## FIG. 12A-2

2701 GTAGCCAGCC CTGCACGTT ATGCAGAGAG TGTCTTCCTT TCGAAAACAT GATCACGAAA  
2761 CATGCAGACC ACCACCTCAA GGAATCAGAA GCATTGCATC CCAAGCTGCG GACTGGGAGC  
2821 GTGTCTCCTC CCTAAAGGAC GTGCGTGCCT GCGTGCCTGC GTGCGTGCCT GCGTGCCTCA  
2881 CCAAGGTGTG TGGAGCTCAG GATCGCAGCC ATACACGCAA CTCCAGATGA TACCACTACC  
2941 GCCAGTGTGTT ACACAGAGGT TTCTGCCTGG CAAGCTTGGT ATTTTACAGT AGGTGAAGAT  
3001 CATTCTGCAG AAGGGTGTG GCACAGTGGA GCAGCACGGA TGTCCCCAGC CCCCCTTCTG  
3061 GAAGACCCCTA CAGCTGTGAG AGGCCAGGG TTGAGCCAGA TGAAAGAAAA GCTGCGTGGG  
3121 TGTGGGCTGT ACCCGGAAAA GGGCAGGTGG CAGGAGGTTT GCCTTGGCCT GTGCTTGGC  
3181 CGAGAACAC ACTAAGGAGC AGCAGCCTGA GTTAGGAATC TATCTGGATT ACGGGGATCA  
3241 GAGTTCTGG AGAGTGGACT CAGTTCTGC TCTGATCCAG GCCTGTTGTG CTTTTTTTT  
3301 TTCCCCCTTA AAAAAAAAAGTACAGACA GAATCTCAGC GGCTTCTAGA CTGATCTGAT  
3361 GGATCTTAGC CCGGCTTCTA CTGCGGGGGG GAGGGGGGGGA GGGATAGCCA CATATCTGTG  
3421 GAGACACCCA CTTCTTTATC TGAGGCCCTCC AGGTAGGCAC AAAGGCTGTG GAACTCAGCC  
3481 TCTATCATCA GACACCCCCC CCCAATGCCT CATTGACCCC CTTCCCCCAG AGCCAAGGGC  
3541 TAGCCCATCG GGTGTGTGTA CAGTAAGTTC TTGGTGAAGG AGAACAGGGG CGTTGGCAGA  
3601 ACCAGTTTGC AGTGGCCCTA GCATCTTAAA ACCCATTGTC TGTACACCCA GAAGGTTCTA  
3661 GACCTACCAC CACTTCCCTT CCCCCATCTCA TGAAACCTT TTAGGCCATT CTGACCCCTG  
3721 TGTGTGCTCT GAGCTCAGAT CGGGTTATGA GACCGCCCAAG GCACATCAGT CAGGGAGGCT  
3781 CTGATGTGAG CCGCAGACCT CTGTGTTCAT TCTTATGAGC TGGAGGGCT GGACTGGGTG  
3841 GGGTCAGATG TGCTTGGCAG GAACTGTCAG CTGCTGAGCA GGGTGGTCCC TGAGCGGAGG  
3901 ATAAGCAGCA TCAGACTCCA CAACCAGAGG AAGAAAGAAA TGGGGATGGA GCGGAGACCC  
3961 ACGGGCTGAG TCCCGCTGTG GAGTGGCCTT GCAGCTCCCT CTCAGTTAAA ACTCCCAGTA  
4021 AAGCCACAGT TCTCCGAGCA CCCAAGTCTG CTCCAGCCGT CTCTAAAAC AGGCCACTCT  
4081 CTGAGAAGGA ATTC

## FIG. 12B-1

1 GCGAAGCTGG TCCGTTACAT TTGTAAGCAG AGGCAGTGCA AGCTGAGCGT GGCTCCGGT  
 61 GAGAGGACCC CAGAGCTCAA CAGCTACCCCC CGCTTCAGCG ACTGGCTGTA CACTTTCAAC  
 121 GTGAGGCCGG AGGTGGTGCA GGAGATCCCC CGAGACCTCA CGCTGGATGC CCTGCTGGAG  
 181 ATGAATGAGG CCAAGGTGAA GGAGACGCTG CGGCCTGTG GGGCCAGCGG GGATGAGTGT  
 241 GGCGTCTGC AGTATGCCCT CACCTGCCCT CGGAAGGTGA CAGGCCCTGGC TTCATCACCC  
 301 CGCCCACAC ACCCCAGCTG CGACGGCACA CCAAGCTGAA GCCACACCGG ACGCCCCCCC  
 361 CACCCAGCCG CAAGGTCTTC CAGCTGCTGC CCAGCTTCCC CACACTCACC CGGAGCAAGT  
 421 CCCATGAGTC TCAGCTGGGG AACCGCATTG ATGACGTCTC CTCGATGAGG TGAGTTGGGA  
 481 GCACGTTCCCT GCACGTGGCT ATGCTGTGGG GCCTCTCTCA TGAGTCAGAG CGGAGGGAGA  
 541 CAGCTGTGCC TCTGGAGTCT GCTTTTAATT GTCTGGAAAT GCAGAGATGT CTGGTTTTG  
 601 CCTGAGCAAA ATAGGAGTTT ATTTTGATC TATCCCGAGC TGGCTAAGGA GAGTCACGTA  
 661 GCTGTGGGCG GGGTCTTGGG GATGAGGAGG GGTACAGCAG GCAGGGACTA TGCTGAAGTG  
 721 GAGCTGGCTG TAGGAACCCC AGGGAGGCAC AGGGGGAGCA TGAAGAGGAG CTACACTTCC  
 781 CTCCCTTAGT GCCCCGGCAG AAACCTCCAG GGCCCTTCAC AGAACCTTGG AGGAACATTC  
 841 AACACCCCCA TCTCTAGGAC AGCCCCAGCC TTGTCATCCT CCAATTGCTG TGGTAACACG  
 901 GGGACTGGAG CAGTGAGATT ATTAGGCCTT CAGGGCCAGT GTCTCCATGC AGATCAGATG  
 961 GAGGCGGTGC TTGGCACATA CACCACCTCA CTGCCCATGC CCCCAGAAGT TGGTGCAGAT  
 1021 CATAAGGTGG CTTTTGGGC TAATTGATTG AAGTTCCAAC ATAGTCTGTT TCTCCTAGGC  
 1081 TGGTAGCTGG CACCTTGGC CCCATGTGTT TTTAATTAT TTTTCTTTT GAGACGAAAT  
 1141 CTCGCTCTAT CACCCAGGCT GAAGTGCAGT AGTGAATCT CAGCTCACTG CAGCCTCTGC  
 1201 CTCCCGGGTT CAAGCAATT CTCCTGCCATCA GCCTCCCGAG TAGCCAGGAT TAAAGGTGCC  
 1261 TGCCACCA CATTGGCTAAT TTTTGTATTT TTAATAGAGA CGGGGTTCA CCATGTTAGC  
 1321 CAGGCTGGTC TCAAACCTCCT GACCTCAGGT GATCTTCCTG CCTCAGCCTC CCAAAGTGC  
 1381 GGGATTACAG GTGTGAGCCA CTGCGCCAG TCATGCCCAT GTGTTTGGT GGTCTTGCT  
 1441 GCTGATGGGT GGGGTGAGCC CCAGGAGGAA GTTGGGACAA GTCAACCTCA TGGCAGATGT  
 1501 GCCAGGGAGA GCTGCCGGTG AGATAGATTG TTCCTATCCC CCTCTCCCTG ATGTGGGAGG  
 1561 ACTCAGTACC TCCAGCACAC CCTTCTCATG GAGGTTGGTT ATGTGGTACT TGGCCTCAAG  
 1621 TGAACCAGCA CTTCATGAGT CCAGCTTGT GCTAGACCAG CACTTGGAT TGAGGGGGC  
 1681 AGTGGCCACC CTCGGGGAC CTTCTGACTC AGAGGACATG AGATGGCCAC ACTCGAGCAC  
 1741 TGTGTTCTG ACCTTCTGG GTCACAGGTC ACCTTGATGA TTGGATGAAA GTCTTAGATC  
 1801 TTCTTCCAG AGAAAAGTCT ACAACATTCT ACTGAACCAAG TCCAGAGGTT TCCCAGACCC  
 1861 CCGAAGCCA CCCATGGCT GGCTCTGGG GGCAATGGCG CTGAGTATGG GGGCATCTCT  
 1921 CGCATGGATC CCCACAGATG GTACGGAGGG ATATCGGGCT GTGGTGACG CACAGGTCT  
 1981 CCACCAAGTC CTGGCTGTG CAGGTCTGCC ACGTGTGCCA GAAGAGCATG ATATTGGAG  
 2041 TGAAGTGCAGA GCATTGCAAG TTGAAGTGTCA ACAACAAATG TACCAAAGAA GCCCCTGCC  
 2101 GTAGAATATC CTTCCCTGCCA CTAACCTGGC TTGGAGGAC AGAATCTGTC CCCTCGGACA  
 2161 TCAACAAACCC GGTGGACAGA GCAGCCGAAC CCCATTGGT AACCCCTCCCC AAAGCACTGA  
 2221 CAAAGAAGGA GCACCCCTCCG GCCATGAATC ACCTGGACTC CAGCAGCAAC CCTTCCTCCA  
 2281 CCACCTCCTC CACACCCTCC TCACCGGGCG CCTTCCCGAC ATCATCCAAC CCATCCAGCG

## FIG. 12B-2

2341 CCACCACGCC CCCAACCCCC TCACCTGGCC AGCGGGACAG CAGGTTCAAC TTCCCAGCTG  
2401 CCTACTTCAT TCATCATAGA CAGCAGTTA TCTTTCAGA CATTTCAGCC TTTGCACACG  
2461 CAGCCCCGCT CCCTGAAGCT GCCGACGGTA CCCGGCTCGA TGACCAGCCG AAAGCAGATG  
2521 TGTGGAAGC TCACGAAGCG GAGGCTGAGG AGCCAGAGGC TGGCAAGTCA GAGGCAGAAG  
2581 ACGATGAGGA CGAGGTGGAC GACTTGCGA GCTCTCGCCG GCCCTGGCGG GGCCCCATCT  
2641 CTCGCAAGGC CAGCCAGACC AGCGTGTACC TGCAAGGAGTG GGACATCCCC TTTCGAGCAGG  
2701 TAGAGCTGGG CGAGCCCATC GGGCAGGGCC GCTGGGGCCG GGTGCACCAGC GGCGCTGGC  
2761 ATGGCGAGGT GGCCATTGCG CTGCTGGAGA TGGACGGCCA CAACCAGGAC CACCTGAAGC  
2821 TCTTCAAGAA AGAGGTGATG AACTACCGGC AGACGCGGCA TGAGAACGTG GTGCTTTCA  
2881 TGGGGGCTG CATGAACCCG CCCCACCTGG CCATTATCAC CAGCTTCTGC AAGGGGCGGA  
2941 CGTGCACTC GTTGTGAGG GACCCCAAGA CGTCTCTGGA CATCAACAAG ACGAGGCAAA  
3001 TCGCTCAGGA GATCATCAAG GGCATGGGAT ATCTTCATGC CAAGGGCATC GTACACAAAG  
3061 ATCTCAAATC TAAGAACGTC TTCTATGACA ACGGCAAGGT GGTCATCACA GACTTCGGC  
3121 TGTGGGGAT CTCAGCGTG GTCCGAGAGG GACGGCGTGA GAACCAGCTA AAGCTGTCCC  
3181 ACGACTGGCT GTGCTATCTG GCCCCTGAGA TTGTACGCGA GATGACCCCC GGGAAAGGACG  
3241 AGGATCAGCT GCCATTCTCC AAAGCTGCTG ATGTCTATGC ATTTGGGACT GTTTGGTATG  
3301 AGCTGCAAGC AAGAGACTGG CCCTTGAAGA ACCAGGCTGC AGAGGCATCC ATCTGGCAGA  
3361 TTGGAAGCGG GGAAGGAATG AAGCGTGTCC TGACTTCTGT CAGCTTGGGG AAGGAAGTCA  
3421 GTGAGATCCT GTCGGCCTGC TGGGCTTTCG ACCTGCAGGA GAGACCCAGC TTCAGCCTGC  
3481 TGATGGACAT GCTGGAGAAA CTTCCAAGC TGAACCAGCG GCTCTCCAC CCTGGACACT  
3541 TCTGGAAGTC AGCTGAGTTG TAGGCCTGGC TGCCCTGCAT GCACCAAGGGG CTTTCTTCCT  
3601 CCTAATCAAC AACTCAGCAC CGTGACTTCT GCTAAAATGC AAAATGAGAT GCGGGCACTA  
3661 ACCCAGGGGA TGCCACCTCT GCTGCTCCAG TCGTCTCTCT CGAGGCTACT TCTTTGCTT  
3721 TGTGTTAAAA ACTGGCCCTC TGCCCTCTCC ACGTGGCCTG CATATGCCA AG

32/47

FIG. 13A





FIG. 13B



## FIG. 14

1 atggagaga aggagggcgg tggcggggg gatgcggcgg ccgcggaggg tggcgcaggg  
60 gcccggcca gccggggcgt gcagcagtgt gggcagctcc agaagctcat cgacatctcc  
120 atcggcagtc tgcgcggcgt gcgcaccaag tgcgcagtgt ctaacgaccc caccggcag  
180 gagatacgtga ccctagaggg aaagctggtc cgttacattt gtaagcagag gcagtgcag  
240 ctgagcgtgg ctccgggtga gaggacccca gagctcaaca gctacccccc cttcagcgcac  
300 tggctgtaca ctttcaacgt gaggccggag gtggcgcagg agatcccccg agacccctac  
360 ctggatgccc tgctggagat gaatgaggcc aaggtaagg agacgctgcg ggcgtgtgg  
420 gcccggcggg atgagtgtgg ccgtctgcag tatgcctca cctgcctgcg gaagggtgaca  
480 ggcctggag gggagcacaa ggaggactcc agttggagtt cattggatgc gcggcgggaa  
540 agtggctcag ggccttccac ggacaccctc tcagcagcca gcctgcctg gccccccagg  
600 agctccacgc tgggcagagc aggcaacagc gcccaggggc caccgcctcat ctccgtgtca  
660 gctctggcc cctcagactc cccacccccc agttcagtg agggcctctc agacacctgt  
720 attccctgc acggcagggc cggcgtgacc cccctgtccc tgcacagctt catcaccccg  
780 cccaccacac cccagctcgc acggcacacc aagctgaagc caccacggac gcccccccca  
840 cccagccgca aggtcttcca gtcgtgcctt agcttccca cactcaccgg gagcaagtcc  
900 catgagtctc agctggggaa ccgcattgtat gacgtctctt cgatgaggtt tgatctctcg  
960 catggatccc cacagatggt acggaggat atcgggtgt cggtgacgca cagggtctcc  
1020 accaagtctt ggctgtcgca ggtctccac gtgtgccaga agagcatgtat atttggagtg  
1080 aagtgcagc attgcagggtt gaagtgtcac aacaaatgtt ccaaagaagc ccctgcctgt  
1140 agaatatctt tcctgcactt aactcggctt cggaggacag aatctgtccc ctggacatc  
1200 aacaacccgg tggacagagc agccgaaccc cattttggaa ccctcccaa agcactgaca  
1260 aagaaggagc accctccggc catgaatcac ctggactccca gcagcaaccc ttccctccacc  
1320 acctcctcca caccctctcc accggcggcc ttcccgacat catccaaaccc atccagcggc  
1380 accacgcccc ccaacccctc acctggccag cgggacagca ggttcaactt cccagctgcc  
1440 tacttcattt atcatagaca gcagtttac tttccagaca tttcagcctt tgacacacgca  
1500 gccccctcc ctgaagctgc cgacgttacc cggctcgatg accagccgaa agcagatgt  
1560 ttggaagctc acgaagcggg ggctgaggag ccagaggctg gcaagtccaga ggcagaagac  
1620 gatgaggacg aggtggacga cttggccagc ttccggccggc cctggggggg cccatctt  
1680 cgcaaggcga gccagaccag cgttacccgt caggagtggg acatccccctt cgagcaggta  
1740 gagctggcg agcccatcggt gcagggccgc tggggccggg tgcaccggcgg ccgctggcat  
1800 ggcgaggtgg ccatcgcctt gctggagatg gacggccaca accaggacca cctgaagctc  
1860 ttcaagaaag aggtgtatgaa ctacccggcag acggccatg agaacgtggt gctttcatg  
1920 ggggcctgca tgaacccgc ccacccggcc attatccca gcttctgcaa gggggggac  
1980 ttgcactcgt ttgtgaggga ccccaagacg tctctggaca tcaacaagac gaggcaaaatc  
2040 gctcaggaga tcatcaaggg catggatattt cttcatgcctt agggcatctt acacaaagat  
2100 ctc当地atcta agaacgtctt ctatgacaac ggcaagggtgg tcatcacaga ttccggctt  
2160 tttggatct caggcgtggt ccggaggaa cggcgtgaga accagctaaa gctgtccac  
2220 gactggctgt gctatctggc ccctgagatt gtacgcgaga tgaccccccgg gaaggacgag  
2280 gatcagctgc cattctccaa agctgctgtat gtctatgcatttggactgt ttggatgt  
2340 ctgcaagcaa gagactggcc cttgaagaac caggctgcag aggcacccat ctggcagatt  
2400 ggaaggcgggg aaggaatgaa gcgtgtccctg acttctgtca gcttggggaa ggaagtca  
2460 gagatcctgt cggcctgcgtt ggcttcgac ctgcaggaga gacccagctt cggcctgcgt  
2520 atggacatgc tggagaaact tcccaagctt aaccggcggc tctccaccc tggacactt  
2580 tggagtcag ctgagttgtat g

## FIG. 15A

atgggagagaaggaggggcggtggcggggggatgcggccgcggagggtggcgagg 20  
 M G E K E G G G G D A A A A E G G A G 20  
  
 gccgcggccagccggcgctgcagcagtgtggcagctccagaagctcatcgacatctcc 40  
 A A A S R A L Q Q C G Q L Q K L I D I S 40  
CA1 (32-72)  
  
 atcggcagtcgtcgccggctgcgcaccaagtgcgcagtgcttaacgacacctcaccaggcag 60  
I G S L R G L R T K C A V S N D L T Q Q 60  
AS-ODN3 (42-47) AS-ODN2 (52-57)  
  
 gagatacggaccctagaggcaaagctggccgttacattgttaagcagaggcagtgcag 80  
E I R T L E A K L V R Y I C K Q R Q C K 80  
AS-ODN1 (63-68)  
  
 ctgagcgtggctcccggtgagaggaccccagagctcaacagctaccccgcttcagcag 100  
 L S V A P G E R T P E L N S Y P R F S D 100  
  
 tggctgtacacttcaacgtgaggccggaggtggcagggagatccccgagacacctcacg 120  
 W L Y T F N V R P E V V Q E I P R D L T 120  
  
 ctggatgcctgctggagatgaatgaggccaaggtaaggagacgcgtgcggcgtgtgg 140  
 L D A L L E M N E A K V K E T L R R C G 140  
  
 gccagccccatgagtgccgtctgcagtatgcctcacctgcgtcgaaaggta 160  
 A S G D E C G R L Q Y A L T C L R K V T 160  
  
 gccctggggggggggcacaaggaggactccagttggagttcattggatgcgcggggaa 180  
 G L G G E H K E D S S W S S L D A R R E 180  
  
 agtggctcagggccttccacggacaccctctcagcagccagcgtgcctggccccagg 200  
 S G S G P S T D T L S A A S L P W P P G 200  
  
 agctcccagctggcagagcaggcaacagcgcacccaggccacgcgtccatctccgtca 220  
 S S Q L G R A G N S A Q G P R S I S V S 220  
  
 gctctgcccgcctcagactccccacccctcagttcagtgaggcctctcagacacctgt 240  
 A L P A S D S P T P S F S E G L S D T C 240  
  
 attccccctgcacgccagcggccggctgaccccccgtgcctgcacagcttcaccccg 260  
 I P L H A S G R L T P R A L H S F I T P 260  
  
 cccaccacacccctgcacggcacaaggctgaagccaccacggacgcgggggggg 280  
 P T T P Q L R R H T K L K P P R T P P P 280  
  
 cccagcccaaggcttcagctgtccagttccacactcaccggaggcaagtcc 300  
P S R K V F Q L L P S F P T L T R S K S 300  
CA2 (277-289)  
  
 catgagtctcagctggggacccgcattgtatgacgtctctcgatgagggttcatctcg 320  
 H E S Q L G N R I D D V S S M R F D L S 320  
  
 catggatccccacagatggtacggaggatatcggctgtcggtgacgcacaggcttc 340  
 H G S P Q M V R R D I G L S V T H R F S 340  
  
 accaagtccctggctgtcgcaggctgccacgtgtgccagaagagcatgatattggagtg

## FIG. 15B

T K S W L S Q V C H V C Q K S M I F G V 360  
CA3 (335-380)  
 aagtgcagacattgcaggttgaagtgtcacaacaaatgtaccaagaaggccctcgtgt  
K C K H C R L K C H N K C T K E A P A C 380  
  
 agaatatcccttcctgccactaactcggcttcggaggacagaatctgtccctcggacatc  
R I S F L P L T R L R R T E S V P S D I 400  
  
 aacaacccgggtggacagagcaggccaacccattttggaaccctccccaaagcactgaca  
N N P V D R A A E P H F G T L P K A L T 420  
  
 aagaaggaggcaccctccggccatgaatcacctggactccaggcaaccttccacc  
K K E H P P A M N H L D S S S N P S S T 440  
  
 acctccccacaccctcctcaccggcgccctccgacatcatccaacccatccaggcgcc  
T S S T P S S P A P F P T S S N P S S A 460  
CA4 (432-498)  
 accacgcccccaacccctcacttggccagccggacagcaggttcaactttccagctgg  
T T P P N P S P G Q R D S R F N F P A A 480  
  
 tacttcattcatcatagacagcagtttatcttccagacatttcagccttgcacacga  
Y F I H H R Q Q F I F P D I S A F A H A 500  
  
 gccccgctccctgaagctgccgacggtacccggctcgatgaccagccaaagcagatgtg  
A P L P E A A D G T R L D D Q P K A D V 520  
  
 ttggaagctacgaagcgggaggctgaggagccagggctggcaagtcagaggcaagac  
L E A H E A E E P E A G K S E A E D 540  
  
 gatgaggacgagggtggacgtgccagcttcgcccctggggggccatctct  
D E D E V D D L P S S R R P W R G P I S 560  
  
 cgcaaggccagccacccagccgtgtacctgcagggtggacatccccttcgagccgtta  
R K A S Q T S V Y L Q E W D I P F E Q V 580  
  
 gagctggcgagccatcgccagggccctggggccgggtgcacccgcggccctggcat  
E L G E P I G Q G R W G R V H R G R W H 600  
CAS (565-836, consisting of 11 conserved subdomains)  
 ggcgagggtggccattcgcctgtggagatggacggccacaccaggacctgaagctcc  
G E V A I R L L E M D G H N Q D H L K L 620  
  
 ttcaagaaagagggtatgaaactaccggcagaccgggcatgagaacgtggtctcttcatg  
F K K E V M N Y R Q T R H E N V V L F M 640  
  
 gggcctgcatgaacccccccacctggccattatcaccagcttcgcaaggggacg  
G A C M N P P H L A I I T S F C K G R T 660  
  
 ttgcactcgttgtgaggggacccaaagacgtctctggacatcaacaagacgaggcaatc  
L H S F V R D P K T S L D I N K T R Q I 680  
  
 gctcaggagatcaaggcatggatatttcatgccaaggcatgtacacaaaagat  
A Q E I I K G M G Y L H A K G I V H K D 700

## FIG. 15C

ctcaaatctaagaacgtttctatgacaacggcaagggtgtcatcacagacttcgggctg  
L K S K N V F Y D N G K V V I T D F G L 720

tttggatctcaggcgtggccgagagggacggcgtgagaaccagctaaagctgtcccac  
F G I S G V V R E G R R E N Q L K L S H 740

gactggctgtgctatctggccctgagattgtacgcgagatgaccccccggaaaggacgag  
D W L C Y L A P E I V R E M T P G K D E 760

gatcagctgccattctccaaagctgtgttatgcattggactgtttgttatgag  
D Q L P F S K A A D V Y A F G T V W Y E 780

ctgcaagcaagagactggcccttgaagaaccaggctgcagaggcatccatctggcagatt  
L Q A R D W P L K N Q A A E A S I W Q I 800

ggaagcgggaaaggaatgaagcgtgtcctgacttctgtcagcttgggaaaggaagtca  
G S G E G M K R V L T S V S L G K E V S 820

gagatcctgtcggcctgtggcttgcacctgcaggagagacccagcttcagcctgctg  
E I L S A C W A F D L Q E R P S F S L L 840

atggacatgtggagaaacttccaaagctgaaccggcggtctccaccctggacacttc  
M D M L E K L P K L N R R L S H P G H F 860

tggaagtca  
tgatgttag  
W K S A E L -

## FIG. 16A

Atggatagagcggcggtgcgcggcagcgatggcgagaaaaaggagggcgccggcggg  
 M D R A A L R A A A M G E K K E G G G G G 20  
  
 Ggcgccggcgacggggcgccgtcagccggcgctgcagcagtgcggc  
 G A A A D G G A G A A V S R A L Q Q C G 40  
  
 Cagctgcagaagctcatcgatatctccatcgccagtctgcgcggctgcgcaccaagtgc  
 Q L Q K L I D I S I G S L R G L R T K C 60  
CA1 (42-81) AS-ODN3 (51-56)  
 tcagtgtctaaccgacccacacaggcaggatccggacccttagaggcaaagctggtaaaa  
S V S N D L T Q Q E I R T L E A K L V K 80  
AS-ODN2 (61-66) AS-ODN1 (72-77)  
 tacatttgcaggcaggcaggcaagcttagtgtgaccccaagcgcacaggaccgcccagg  
Y I C K Q Q S K L S V T P S D R T A E 100  
  
 ctcaacagctacccacgcttcagtgactggctgtacatcttcaacgtgaggcctgaggta  
 L N S Y P R F S D W L Y I F N V R P E V 120  
  
 gtgcaggagatccccaaagagactcacactggatgctctgctggagatggacgaggccaaa  
 V Q E I P Q E L T L D A L L E M D E A K 140  
  
 gccaaggagatgctggcgctggggccagcacggaggatgcagccgcctacagcaa  
 A K E M L R R W G A S T E E C S R L Q Q 160  
  
 gcccattacctgccttcggaaagggtgactggctggaggggagcacaatggactcagg  
 A L T C L R K V T G L G G E H K M D S G 180  
  
 tggagttcaacagatgctcgagacagtagctggccatggacatgcttcctcg  
 W S S T D A R D S S L G P P M D M L S S 200  
  
 ctgggcagagcgggtgccagcactcagggacccgttccatctccgtgtccgcctgcct  
 L G R A G A S T Q G P R S I S V S A L P 220  
  
 gcctcagactctccggccccggctcagtggggcctctcgactcctgtatccccttg  
 A S D S P V P G L S E G L S D S C I P L 240  
  
 cacaccagcggccggctgaccccccggccctgcacagctcatcacgccccctaccaca  
 H T S G R L T P R A L H S F I T P P T T 260  
  
 ccccaagctacgacggcacgccaagctgaagccaccaaggacacccaccgccaagccgc  
 P Q L R R H A K L K P P R T P P P P S R 280  
CA2 (274-286)  
 aagggtttccagctgctccccagttcccccacactcacacggagcaagtccacgagtc  
K V F Q L L P S F P T L T R S K S H E S 300  
  
 cagctggaaaccgaatcgacgacgtcaccggatgaagttgaactccctcatggatcc  
 Q L G N R I D D V T P M K F E L P H G S 320  
  
 ccacagctggtaacgaaggatatcggtctcggtgacgcacaggttctccacaaagtca  
 P Q L V R R D I G L S V T H R F S T K S 340

## FIG. 16B

tggttgtcacaggtgtcaacgtgtgccagaagagcatgat~~ttttggcgt~~gaagtgc~~aaa~~  
 W L S Q V C N V C Q K S M I F G V K C K 360  
CA3 (331-377)  
 cactgcaggtaaaatgccataacaagtgcacaaggaa~~gctccgc~~ctgcaggatcacc  
 H C R L K C H N K C T K E A P A C R I T 380  
  
 ttcccccactggccagg~~ttcg~~gaggacag~~act~~gtccgc~~t~~ca~~gat~~atcaacaaccc  
 F L P L A R L R R T E S V P S D I N N P 400  
  
 gtggacagagcagcagagccccat~~tt~~ggaacc~~tt~~cccaaggcc~~ct~~gacaaagaaggag  
 V D R A A E P H F G T L P K A L T K K E 420  
  
 caccctccagccatgaac~~ct~~ggactcc~~ag~~caacccat~~cc~~caccacgtc~~ct~~ccaca  
 H P P A M N L D S S S N P S S T T S S T 440  
  
 ccctcatcgccggcac~~ttt~~c~~t~~gac~~ct~~cat~~ta~~at~~cc~~c~~cc~~actg~~cc~~accac~~gg~~c~~ct~~cc  
 P S S P A P F L T S S N P S S A T T P P 460  
CA4 (428-480)  
 aacc~~cg~~tcac~~ct~~ggccagcgggac~~ag~~cagg~~tt~~cag~~tt~~ccagacattcag~~ct~~gttct  
N P S P G Q R D S R F S F P D I S A C S 480  
  
 caggcagcccc~~ct~~gt~~tc~~c~~ag~~cac~~ag~~cc~~ac~~gt~~ac~~c~~gg~~ct~~cg~~ac~~g~~acc~~cc~~aaaaca  
 Q A A P L S S T A D S T R L D D Q P K T 500  
  
 gatgtgctagg~~gtt~~ca~~g~~ca~~g~~agg~~ct~~gagg~~gg~~ctgagg~~ct~~ggca~~gt~~ca~~g~~agg~~ca~~  
 D V L G V H E A E E P E A G K S E A 520  
  
 gaggatgac~~agg~~aggatgagg~~gt~~ggac~~g~~ac~~ct~~cc~~cc~~ag~~ct~~cc~~cc~~gg~~cc~~ct~~gg~~gagg~~gg~~  
 E D D E E D E V D D L P S S R R P W R G 540  
  
 cccatctctcgaaaggccagccagacc~~ag~~cg~~ttt~~ac~~ct~~g~~ca~~ag~~ag~~gt~~gg~~ac~~at~~cc~~cc~~ttt  
 P I S R K A S Q T S V Y L Q E W D I P F 560  
  
 gaacaggtg~~aa~~act~~gg~~gc~~gg~~ccatt~~gg~~ac~~gg~~gt~~gg~~ct~~gg~~gg~~cc~~gg~~tt~~gc~~ac~~cc~~gg~~  
E Q V E L G E P I G Q G R W G R V H R G 580  
CA5 (548-819, consisting of 11 conserved subdomains)  
 cgttggcatggcgagg~~tt~~ggcatt~~gg~~ct~~gg~~gt~~gg~~gagat~~gg~~ac~~gg~~ccacaat~~gg~~accac  
R W H G E V A I R L L E M D G H N Q D H 600  
  
 ctgaagct~~tt~~caaga~~aa~~agagg~~gt~~gat~~g~~aact~~cc~~ggcag~~ac~~gc~~gg~~cat~~g~~aga~~ac~~gt~~gg~~tg  
L K L F K K E V M N Y R Q T R H E N V V 620  
  
 ctcttc~~at~~ggggc~~ct~~g~~cat~~gaacc~~cc~~ac~~ct~~cac~~ct~~ggc~~at~~ttat~~cacc~~ag~~ct~~ct~~g~~caag  
L F M G A C M N P P H L A I I T S F C K 640  
  
 gggcggacatt~~gc~~att~~tc~~gt~~g~~agg~~gg~~ac~~cc~~caag~~ac~~gt~~ct~~ct~~g~~gac~~at~~caataagact  
G R T L H S F V R D P K T S L D I N K T 660  
  
 agg~~c~~ag~~at~~cg~~cc~~agg~~ag~~at~~ca~~agg~~gg~~cat~~gg~~ttat~~ctt~~cat~~g~~caaagg~~at~~cg~~tg~~  
R Q I A Q E I I K G M G Y L H A K G I V 680  
  
 cacaagg~~ac~~ct~~ca~~ag~~t~~caaga~~at~~gt~~tt~~ct~~at~~gaca~~ac~~gg~~ca~~aa~~ag~~gt~~gg~~cat~~ca~~ca~~g~~ac

## FIG. 16C

H K D L K S K N V F Y D N G K V V I T D 700  
ttcgggctttggatctcggtgtggccgagaggaacggcgagaaaccaactgaaa  
F G L F G I S G V V R E E R R E N Q L K 720

ctgtcacatgactggctgtgctacctggccccgagatcgatcgagaaatgatccgggg  
L S H D W L C Y L A P E I V R E M I P G 740

cgggacgaggaccagctcccttccaaagcagccatgtctatgcattcggactgtg  
R D E D Q L P F S K A A D V Y A F G T V 760

tggatgaactacaggcaagagactggcccttaagcaccagcctgctgaggccttgc  
W Y E L Q A R D W P F K H Q P A E A L I 780

tggcagattggaaagtggaaaggactacggccgtcctggcatccgtcagcctggaaag  
W Q I G S G E G V R R V L A S V S L G K 800

gaagtccggcagatcctgtctgcctgctggcttcgatctgcaggagagaccagcttc  
E V G E I L S A C W A F D L Q E R P S F 820

agcctgctgtggacatgctggagaggctgcccagctgaaccggcgctctccaccct  
S L L M D M L E R L P K L N R R L S H P 840

gggcactttggaaagtccgtgacattaacacgcacaaagtcatcccccttggaaagg  
G H F W K S A D I N S S K V M P R F E R 860

Tttggcctggggaccctggagtcggtaatccaaagatgtag  
F G L G T L E S G N P K M - 880

## FIG. 17A

1        atggagaga aggagggcgg tgggggggg gatgcggcgg ccgcggaggg tggcgacagg  
 1        AS-ODN4 (1-18)  
 60      gcccggcca gccggggcgt gcagcagtgt gggcagctcc agaagctcat cgacatctcc  
 120     atcggcagtc tgcgcggct ggcacccaag tgcgcagtgt ctaacgacct cacccagcag  
 120     AS-ODN3 (124-141)        AS-ODN2 (154-171)  
 180     gagatacggg ccctagggc aaagctggc cgttacattt gtaagcagag gcagtgcag  
 180     AS-ODN1 (187-204)        AS-ODN5 (205-222)  
 240     ctgagcgtgg ctcccggtga gaggaccca gagctcaaca gctacccccc cttcagcgcac  
 240     AS-ODN6 (247-264)  
 300     tggctgtaca ctttcaacgt gaggccggag gtgggtcagg agatcccccc agacctcacg  
 300     AS-ODN7 (298-315)        AS-ODN8 (321-338)        AS-ODN9 (351-368)  
 360     ctggatgccc tgctggagat gaatgaggcc aaggtaagg agacgctgcg ggcgtgtggg  
 360     AS-ODN10 (379-396)  
 420     gccagcgggg atgagtgtgg ccgtctgcag tatgcctca cctgcctgcg gaaggtgaca  
 480     ggcctgggag gggagcacaa ggaggactcc agttggagtt catggatgc ggcgggggaa  
 480     AS-ODN11 (511-528)        AS-ODN12  
 540     agtggctcag ggccttcac ggacaccctc tcagcagcca gcctccctg gcccccaggg  
 540     (531-548)  
 600     agctcccagc tgggcagagc aggcaacagc gcccaggcc cacgctccat ctccgtgtca  
 660     gctctccccg cctcagactc cccacccccc agttcaagt agggcctctc agacacctgt  
 720     attccccgc acgccaggg ccggctgacc cccctgtccc tgcacagtt catcaccctcg  
 780     cccaccacac cccagctgcg acggcacacc aagctgaagc caccacggac gccccccca  
 840     cccaagccca aggttttca gctgctgccc agttccccca cactcacccg gagcaagtcc  
 900     catgagtctc agctggggaa ccgcattgt gacgtctctc cgatgaggtt tgcacatctcg  
 960     catggatccc cacagatgtt acggagggat atcgggtgtt cggtgacgca caggttctcc  
 1020    accaagtctt ggctgtcgc ggtctgccac gtgtgccaga agagcatgtt atttggagtg  
 1080    aagtgcagc attgcagggtt gaagtgtcac aacaatgtt ccaaaaagc ccctgcctgt  
 1140    agaatatcct tcctgccact aactcggtt cggaggacag aatctgtccc ctcggacatc  
 1200    aacaacccgg tggacagagc agccgaaccc cattttggaa ccctcccaa agcaactgaca  
 1260    aagaaggagc accctccggc catgaatcac ctggactcca gcagcaaccc ttccctccacc  
 1320    acccctccca caccctccct accggcgccc ttcccgacat catccaaccc atccagcgcc  
 1380    accacgcccc ccaacccctc acctggccag cgggacagca ggttcaactt cccagctgcc  
 1440    tacttcattc atcatagaca gcagtttatac tttccagaca tttcagcctt tgcacacgca  
 1500    gccccgtcc ctgaagctgc cgacgggtacc cggctcgatg accagccgaa agcagatgt  
 1560    ttgaaagctc acgaagcgga ggctgaggag ccagaggctg gcaagtcaaa ggcagaagac  
 1620    gatgaggacg aggtggacga cttggccagc tctggccggc cctggggggg ccccatctct  
 1680    cgcaaggcca gccagaccag cgtgtacctg caggagttgg acatccccctt cgagcaggtt  
 1740    gagctggcg agcccatcg gcaggccgc tggggccggg tgcacccggg cccgtggcat  
 1800    ggcgagggtgg ccattcgct gctggagatg gacggccaca accaggacca cctgaagctc  
 1860    ttcaagaaag aggtgtatgaa ctaccggcag acgcggcatg agaacgtgtt gctttcatg  
 1920    ggggcctgca tgaacccggc ccacctggcc attatcacca gcttctgcaa ggggcccggc  
 1980    ttgcactcgat ttgtgaggga ccccaagacg tctctggaca tcaacaagac gaggcaaatc  
 2040    gctcaggaga tcatcaaggg catggatat cttcatgcca agggcatcgat acacaaagat

## FIG. 17B

2100 ctc当地tca agaacgtctt ctatgacaac ggcaagggtgg tcatcacaga cttcgggctg  
2160 tttggatct caggcgtggt ccgagaggga cggcgtgaga accagctaaa gctgtccac  
2220 gactggctgt gctatctggc ccctgagatt gtacgcgaga tgaaccccgga aaggacgag  
2280 gatcagctgc cattctccaa agctgctgat gtctatgcat ttggactgt ttggatgag  
2340 ctgcaagcaa gagactggcc cttgaagaac caggctgcag agccatccat ctggcagatt  
2400 ggaagcgggg aaggaatgaa gcgtgtcctg acttctgtca gcttggggaa ggaagtca  
2460 gagatcctgt cggcctgctg ggcttcgac ctgcaggaga gacccagctt cagcctgctg  
2520 atggacatgc tggagaaact tcccaagctg aaccggcggc tctcccaccc tggacacttc  
2580 tggaaagtca ctgagttgt a

FIG. 18




FIG. 19






FIG. 20



45/47  
FIG. 21

A



B

Cell lines	D <sub>0</sub> (Gy)	D <sub>q</sub> (Gy)	D <sub>0.1</sub> (Gy)	Dose Ratios (Surv.=0.1)
pTRE	1.77 ± 0.14	2.26 ± 0.44	6.27 ± 0.50	
KSR-S	1.65 ± 0.18	4.57 ± 0.24	8.29 ± 0.45	0.76 ± 0.07
KSR-AS	1.21 ± 0.18	0.62 ± 0.38	2.56 ± 0.49	2.44 ± 0.28

## FIG. 22B





FIG. 22A



## SEQUENCE LISTING

<110> Memorial Sloan-Kettering Cancer Center  
Kolesnick, Richard N.  
King, Hong-Mei R.

<120> KINASE SUPPRESSOR OF RAS INACTIVATION FOR THERAPY OF RAS MEDIATED TUMORIGENESIS

<130> 1216-1-006CIPPCT

<140> UNASSIGNED  
<141> 2004-12-03

<150> 60/384,228  
<151> 2002-05-30

<150> 60/460,023  
<151> 2003-04-03

<150> PCT/US03/16961  
<151> 2003-05-29

<150> 10/727,358  
<151> 2003-12-03

<160> 39

<170> PatentIn version 3.1

<210> 1  
<211> 120  
<212> DNA  
<213> Homo sapiens

<400> 1  
ctgcagaagc tcatcgatat ctccatcggc agtctgcgcg ggctgcgcac caagtgccta 60  
gtgttaacg acctcacaca gcaggagatc cggaccctag aggcaaagct ggtgaaatac 120

<210> 2  
<211> 41  
<212> PRT  
<213> Homo sapiens

<400> 2

Leu Gln Lys Leu Ile Asp Ile Ser Ile Gly Ser Leu Arg Gly Leu Arg  
1 5 10 15

Thr Lys Cys Ser Val Ser Asn Asp Leu Thr Gln Gln Glu Ile Arg Thr  
20 25 30

Leu Glu Ala Lys Leu Val Lys Tyr Ile

35 40

<210> 3  
<211> 19  
<212> DNA  
<213> Homo sapiens

<400> 3  
ggcagtctgc gcgggctgc

19

<210> 4  
<211> 18  
<212> DNA  
<213> Homo sapiens

<400> 4  
tcagtgtcta acgacctc

18

<210> 5  
<211> 18  
<212> DNA  
<213> Homo sapiens

<400> 5  
cggaccctag aggcaaag

18

<210> 6  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 6  
cagcccgcbc agactgccg

19

<210> 7  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 7  
gagggtcgta gacactga

18

<210> 8  
<211> 16  
<212> DNA

<213> Artificial Sequence

<220>

<223> antisense oligonucleotide

<400> 8

ctttgcctctt agggtc

16

<210> 9

<211> 873

<212> PRT

<213> Mus musculus

<400> 9

Met Asp Arg Ala Ala Leu Arg Ala Ala Ala Met Gly Glu Lys Lys Glu  
1 5 10 15

Gly Gly Gly Gly Gly Ala Ala Ala Asp Gly Gly Ala Gly Ala Ala Val  
20 25 30

Ser Arg Ala Leu Gln Gln Cys Gly Gln Leu Gln Lys Leu Ile Asp Ile  
35 40 45

Ser Ile Gly Ser Leu Arg Gly Leu Arg Thr Lys Cys Ser Val Ser Asn  
50 55 60

Asp Leu Thr Gln Gln Glu Ile Arg Thr Leu Glu Ala Lys Leu Val Lys  
65 70 75 80

Tyr Ile Cys Lys Gln Gln Ser Lys Leu Ser Val Thr Pro Ser Asp  
85 90 95

Arg Thr Ala Glu Leu Asn Ser Tyr Pro Arg Phe Ser Asp Trp Leu Tyr  
100 105 110

Ile Phe Asn Val Arg Pro Glu Val Val Gln Glu Ile Pro Gln Glu Leu  
115 120 125

Thr Leu Asp Ala Leu Leu Glu Met Asp Glu Ala Lys Ala Lys Glu Met  
130 135 140

Leu Arg Arg Trp Gly Ala Ser Thr Glu Glu Cys Ser Arg Leu Gln Gln  
145 150 155 160

Ala Leu Thr Cys Leu Arg Lys Val Thr Gly Leu Gly Gly Glu His Lys

165 170 175

Met Asp Ser Gly Trp Ser Ser Thr Asp Ala Arg Asp Ser Ser Leu Gly  
180 185 190

Pro Pro Met Asp Met Leu Ser Ser Leu Gly Arg Ala Gly Ala Ser Thr  
195 200 205

Gln Gly Pro Arg Ser Ile Ser Val Ser Ala Leu Pro Ala Ser Asp Ser  
210 215 220

Pro Val Pro Gly Leu Ser Glu Gly Leu Ser Asp Ser Cys Ile Pro Leu  
225 230 240

His Thr Ser Gly Arg Leu Thr Pro Arg Ala Leu His Ser Phe Ile Thr  
245 250 255

Pro Pro Thr Thr Pro Gln Leu Arg Arg His Ala Lys Leu Lys Pro Pro  
260 265 270

Arg Thr Pro Pro Pro Ser Arg Lys Val Phe Gln Leu Leu Pro Ser  
275 280 285

Phe Pro Thr Leu Thr Arg Ser Lys Ser His Glu Ser Gln Leu Gly Asn  
290 295 300

Arg Ile Asp Asp Val Thr Pro Met Lys Phe Glu Leu Pro His Gly Ser  
305 310 320

...  
Pro Gln Leu Val Arg Arg Asp Ile Gly Leu Ser Val Thr His Arg Phe  
325 330 335

Ser Thr Lys Ser Trp Leu Ser Gln Val Cys Asn Val Cys Gln Lys Ser  
340 345 350

Met Ile Phe Gly Val Lys Cys Lys His Cys Arg Leu Lys Cys His Asn  
355 360 365

Lys Cys Thr Lys Glu Ala Pro Ala Cys Arg Ile Thr Phe Leu Pro Leu  
370 375 380

Ala Arg Leu Arg Arg Thr Glu Ser Val Pro Ser Asp Ile Asn Asn Pro  
385 390 395 400

Val Asp Arg Ala Ala Glu Pro His Phe Gly Thr Leu Pro Lys Ala Leu  
405 410 415

Thr Lys Lys Glu His Pro Pro Ala Met Asn Leu Asp Ser Ser Ser Asn  
420 425 430

Pro Ser Ser Thr Thr Ser Ser Thr Pro Ser Ser Pro Ala Pro Phe Leu  
435 440 445

Thr Ser Ser Asn Pro Ser Ser Ala Thr Thr Pro Pro Asn Pro Ser Pro  
450 455 460

Gly Gln Arg Asp Ser Arg Phe Ser Phe Pro Asp Ile Ser Ala Cys Ser  
465 470 475 480

Gln Ala Ala Pro Leu Ser Ser Thr Ala Asp Ser Thr Arg Leu Asp Asp  
485 490 495

Gln Pro Lys Thr Asp Val Leu Gly Val His Glu Ala Glu Ala Glu Glu  
500 505 510

Pro Glu Ala Gly Lys Ser Glu Ala Glu Asp Asp Glu Glu Asp Glu Val  
515 520 525

Asp Asp Leu Pro Ser Ser Arg Arg Pro Trp Arg Gly Pro Ile Ser Arg  
530 535 540

Lys Ala Ser Gln Thr Ser Val Tyr Leu Gln Glu Trp Asp Ile Pro Phe  
545 550 555 560

Glu Gln Val Glu Leu Gly Glu Pro Ile Gly Gln Gly Arg Trp Gly Arg  
565 570 575

Val His Arg Gly Arg Trp His Gly Glu Val Ala Ile Arg Leu Leu Glu  
580 585 590

Met Asp Gly His Asn Gln Asp His Leu Lys Leu Phe Lys Lys Glu Val  
595 600 605

Met Asn Tyr Arg Gln Thr Arg His Glu Asn Val Val Leu Phe Met Gly  
610 615 620

Ala Cys Met Asn Pro Pro His Leu Ala Ile Ile Thr Ser Phe Cys Lys  
625 630 635 640

Gly Arg Thr Leu His Ser Phe Val Arg Asp Pro Lys Thr Ser Leu Asp  
645 650 655

Ile Asn Lys Thr Arg Gln Ile Ala Gln Glu Ile Ile Lys Gly Met Gly  
660 665 670

Tyr Leu His Ala Lys Gly Ile Val His Lys Asp Leu Lys Ser Lys Asn  
675 680 685

Val Phe Tyr Asp Asn Gly Lys Val Val Ile Thr Asp Phe Gly Leu Phe  
690 695 700

Gly Ile Ser Gly Val Val Arg Glu Glu Arg Arg Glu Asn Gln Leu Lys  
705 710 715 720

Leu Ser His Asp Trp Leu Cys Tyr Leu Ala Pro Glu Ile Val Arg Glu  
725 730 735

Met Ile Pro Gly Arg Asp Glu Asp Gln Leu Pro Phe Ser Lys Ala Ala  
740 745 750

Asp Val Tyr Ala Phe Gly Thr Val Trp Tyr Glu Leu Gln Ala Arg Asp  
755 760 765

Trp Pro Phe Lys His Gln Pro Ala Glu Ala Leu Ile Trp Gln Ile Gly  
.770 775 780

Ser Gly Glu Gly Val Arg Arg Val Leu Ala Ser Val Ser Leu Gly Lys  
785 790 795 800

Glu Val Gly Glu Ile Leu Ser Ala Cys Trp Ala Phe Asp Leu Gln Glu  
805 810 815

Arg Pro Ser Phe Ser Leu Leu Met Asp Met Leu Glu Arg Leu Pro Lys  
820 825 830

Leu Asn Arg Arg Leu Ser His Pro Gly His Phe Trp Lys Ser Ala Asp  
835 840 845

Ile Asn Ser Ser Lys Val Met Pro Arg Phe Glu Arg Phe Gly Leu Gly  
850 855 860

Thr Leu Glu Ser Gly Asn Pro Lys Met  
865 870

<210> 10  
<211> 866  
<212> PRT  
<213> Homo sapiens

<400> 10

Met Gly Glu Lys Glu Gly Gly Gly Gly Asp Ala Ala Ala Ala Glu  
1 5 10 15

Gly Gly Ala Gly Ala Ala Ala Ser Arg Ala Leu Gln Gln Cys Gly Gln  
20 25 30

Leu Gln Lys Leu Ile Asp Ile Ser Ile Gly Ser Leu Arg Gly Leu Arg  
35 40 45

Thr Lys Cys Ala Val Ser Asn Asp Leu Thr Gln Gln Glu Ile Arg Thr  
50 55 60

Leu Glu Ala Lys Leu Val Arg Tyr Ile Cys Lys Gln Arg Gln Cys Lys  
65 70 75 80

Leu Ser Val Ala Pro Gly Glu Arg Thr Pro Glu Leu Asn Ser Tyr Pro  
85 90 95

...

Arg Phe Ser Asp Trp Leu Tyr Thr Phe Asn Val Arg Pro Glu Val Val  
100 105 110

Gln Glu Ile Pro Arg Asp Leu Thr Leu Asp Ala Leu Leu Glu Met Asn  
115 120 125

Glu Ala Lys Val Lys Glu Thr Leu Arg Arg Cys Gly Ala Ser Gly Asp  
130 135 140

Glu Cys Gly Arg Leu Gln Tyr Ala Leu Thr Cys Leu Arg Lys Val Thr  
145 150 155 160

Gly Leu Gly Gly Glu His Lys Glu Asp Ser Ser Trp Ser Ser Leu Asp  
165 170 175

Ala Arg Arg Glu Ser Gly Ser Gly Pro Ser Thr Asp Thr Leu Ser Ala  
180 185 190

Ala Ser Leu Pro Trp Pro Pro Gly Ser Ser Gln Leu Gly Arg Ala Gly  
195 200 205

Asn Ser Ala Gln Gly Pro Arg Ser Ile Ser Val Ser Ala Leu Pro Ala  
210 215 220

Ser Asp Ser Pro Thr Pro Ser Phe Ser Glu Gly Leu Ser Asp Thr Cys  
225 230 235 240

Ile Pro Leu His Ala Ser Gly Arg Leu Thr Pro Arg Ala Leu His Ser  
245 250 255

Phe Ile Thr Pro Pro Thr Thr Pro Gln Leu Arg Arg His Thr Lys Leu  
260 265 270

Lys Pro Pro Arg Thr Pro Pro Pro Ser Arg Lys Val Phe Gln Leu  
275 280 285

Leu Pro Ser Phe Pro Thr Leu Thr Arg Arg Lys Ser His Glu Ser Gln  
290 295 300

Leu Gly Asn Arg Ile Asp Asp Val Ser Ser Met Arg Phe Asp Leu Ser  
305 310 315 320

His Gly Ser Pro Gln Met Val Arg Arg Asp Ile Gly Leu Ser Val Thr  
325 330 335

His Arg Phe Ser Thr Lys Ser Trp Leu Ser Gln Val Cys His Val Cys  
340 345 350

Gln Lys Ser Met Ile Phe Gly Val Lys Cys Lys His Cys Arg Leu Lys  
355 360 365

Cys His Asn Lys Cys Thr Lys Glu Ala Pro Ala Cys Arg Ile Ser Phe  
370 375 380

Leu Pro Leu Thr Arg Leu Arg Arg Thr Glu Ser Val Pro Ser Asp Ile  
385 390 395 400

Asn Asn Pro Val Asp Arg Ala Ala Glu Pro His Phe Gly Thr Leu Pro  
405 410 415

Lys Ala Leu Thr Lys Lys Glu His Pro Pro Ala Met Asn His Leu Asp  
420 425 430

Ser Ser Ser Asn Pro Ser Ser Thr Thr Ser Ser Thr Pro Ser Ser Pro  
435 440 445

Ala Pro Phe Pro Thr Ser Ser Asn Pro Ser Ser Ala Thr Thr Pro Pro  
450 455 460

Asn Pro Ser Pro Gly Gln Arg Asp Ser Arg Phe Asn Phe Pro Ala Ala  
465 470 475 480

Tyr Phe Ile His His Arg Gln Gln Phe Ile Phe Pro Asp Ile Ser Ala  
485 490 495

Phe Ala His Ala Ala Pro Leu Pro Glu Ala Ala Asp Gly Thr Arg Leu  
500 505 510

Asp Asp Gln Pro Lys Ala Asp Val Leu Glu Ala His Glu Ala Glu Ala  
515 520 525

Glu Glu Pro Glu Ala Gly Lys Ser Glu Ala Glu Asp Asp Glu Asp Glu  
530 535 540

Val Asp Asp Leu Pro Ser Ser Arg Arg Pro Trp Arg Gly Pro Ile Ser  
545\*\*\* 550 555 560

Arg Lys Ala Ser Gln Thr Ser Val Tyr Leu Gln Glu Trp Asp Ile Pro  
565 570 575

Phe Glu Gln Val Glu Leu Gly Glu Pro Ile Gly Gln Gly Arg Trp Gly  
580 585 590

Arg Val His Arg Gly Arg Trp His Gly Glu Val Ala Ile Arg Leu Leu  
595 600 605

Glu Met Asp Gly His Asn Gln Asp His Leu Lys Leu Phe Lys Lys Glu  
610 615 620

Val Met Asn Tyr Arg Gln Thr Arg His Glu Asn Val Val Leu Phe Met  
625 630 635 640

Gly Ala Cys Met Asn Pro Pro His Leu Ala Ile Ile Thr Ser Phe Cys  
645 650 655

Lys Gly Arg Thr Leu His Ser Phe Val Arg Asp Pro Lys Thr Ser Leu  
660 665 670

Asp Ile Asn Lys Thr Arg Gln Ile Ala Gln Glu Ile Ile Lys Gly Met  
675 680 685

Gly Tyr Leu His Ala Lys Gly Ile Val His Lys Asp Leu Lys Ser Lys  
690 695 700

Asn Val Phe Tyr Asp Asn Gly Lys Val Val Ile Thr Asp Phe Gly Leu  
705 710 715 720

Phe Gly Ile Ser Gly Val Val Arg Glu Gly Arg Arg Glu Asn Gln Leu  
725 730 735

Lys Leu Ser His Asp Trp Leu Cys Tyr Leu Ala Pro Glu Ile Val Arg  
740 745 750

Glu Met Thr Pro Gly Lys Asp Glu Asp Gln Leu Pro Phe Ser Lys Ala  
755 760 765

Ala Asp Val Tyr Ala Phe Gly Thr Val Trp Tyr Glu Leu Gln Ala Arg  
770 775 780

...

Asp Trp Pro Leu Lys Asn Gln Ala Ala Glu Ala Ser Ile Trp Gln Ile  
785 790 795 800

Gly Ser Gly Glu Gly Met Lys Arg Val Leu Thr Ser Val Ser Leu Gly  
805 810 815

Lys Glu Val Ser Glu Ile Leu Ser Ala Cys Trp Ala Phe Asp Leu Gln  
820 825 830

Glu Arg Pro Ser Phe Ser Leu Leu Met Asp Met Leu Glu Lys Leu Pro  
835 840 845

Lys Leu Asn Arg Arg Leu Ser His Pro Gly His Phe Trp Lys Ser Ala

850 855 860

Glu Leu  
865<210> 11  
<211> 4094  
<212> DNA  
<213> Mus musculus

<400> 11						
gaattccctc	ggggctttcc	tgccgaggcg	cccggtgtccc	cgggctcctc	gcctcgcccc	60
ccagcggccc	cgtatgccgag	gcatggatag	agcggcggttg	cgcgcggcag	cgatgggcga	120
gaaaaaggag	ggcggcggcg	ggggcgccgc	ggcggacggg	ggcgcagggg	ccgccgtcag	180
ccgggcgctg	cagcagtgcg	gccagctgca	gaagctcatc	gatatctcca	tcggcagtct	240
gcgcgggctg	cgcaccaagt	gctcagtgtc	taacgaccc	acacagcagg	agatccggac	300
cctagaggca	aagctggtga	aatacatttgc	caagcagcag	cagagcaagc	ttagtgtgac	360
cccaagcgcac	aggaccgccc	agctcaacag	ctacccacgc	tgcagtgtact	ggctgtacat	420
cttcaacgtg	aggcctgagg	tggtgccagga	gatccccaa	gagctcacac	tggatgctct	480
gctggagatg	gacgaggcca	aagccaagga	gatgctgcgg	cgctgggggg	ccagcacgga	540
ggagtgcagc	cgcctacagc	aagcccttac	ctgccttcgg	aaggtgactg	gcctgggagg	600
ggagcacaaa	atggactcag	gttggagttc	aacagatgct	cgagacagta	gcttggggcc	660
tcccatggac	atgcttcct	cgctgggcag	agcgggtgcc	agcaactcagg	gaccgggttc	720
catctccgtg	tccgcctgc	ctgcctcaga	ctctccggc	cccgccctca	gtgagggcct	780
ctcggactcc	tgtatcccc	tgcacaccag	cgccggctg	accccccggg	ccctgcacag	840
cttcatcacg	ccccctacca	cacccagct	acgacggcac	gccaaagctga	agccaccaag	900
gacaccccca	ccgccaagcc	gcaaggtctt	ccagctgctc	cccagcttcc	ccacactcac	960
acggagcaag	tcccacgagt	cccagctggg	aaaccgaatc	gacgacgtca	ccccgatgaa	1020
gtttgaactc	cctcatggat	ccccacagct	ggtacgaagg	gatatcgccc	tctcggtgac	1080
gcacaggttc	tccacaaaagt	catggttgtc	acaggtgtgc	aacgtgtgcc	agaagagcat	1140
gatttttggc	gtgaagtgca	aacactgcag	gttaaaatgc	cataacaagt	gcacaaagga	1200
agctcccgcc	tgcaggatca	ccttcctccc	actggccagg	cttcggagga	cagagtctgt	1260
cccgtagat	atcaacaacc	cagtggacag	agcagcagag	ccccatttg	gaacccttcc	1320

caaggccctg acaaagaagg agcaccctcc agccatgaac ctggactcca gcagcaaccc 1380  
atcctccacc acgtcctcca caccctcatc gccggcacct ttcctgaccc catctaattcc 1440  
ctccagtgcc accacgcctc ccaacccgtc acctggccag cgggacagca ggttcagctt 1500  
cccagacatt tcagcctgtt ctcaggcagc cccgctgtcc agcacagccg acagtagacg 1560  
gctcgacgac cagcccaaaa cagatgtgct aggtgttacac gaagcagagg ctgaggagcc 1620  
tgaggctggc aagttagagg cagaggatga cgaggaggat gaggtggacg acctccccag 1680  
ctccccccgg ccctggaggg gccccatctc tcgaaaggcc agccagacca gcgttaccc 1740  
gcaagagtgg gacatccccct ttgaacaggt ggaactgggc gagccattt gacagggtcg 1800  
ctggggccgg gtgcacccgag gccgttggca tggcgaggtg gccattcggc tgctggagat 1860  
ggacggccac aatcaggacc acctgaagct gttcaagaaa gaggtgatga actaccggca 1920  
gacgccccat gagaacgtgg tgctttcat gggggcctgc atgaacccac ctcacctggc 1980  
cattatcacc agttctgca agggcgccac attgcattca ttctgtggg accccaagac 2040  
gtctctggac atcaataaga ctaggcagat cgccccaggag atcatcaagg gcatgggta 2100  
tcttcattgca aaaggcatcg tgcacaagga cctcaagtcc aagaatgtct tctatgacaa 2160  
cgccaaagtg gtcacacag acttcgggct gtttggatc tcgggtgtgg tccgagagga 2220  
acggcgccgag aaccaactga aactgtcaca tgactggctg tgctacctgg ccccccggat 2280  
cgtacggagaa atgatccccgg ggcgggacga ggaccagctg cccttctcca aagcagccga 2340  
tgtctatgca ttctggactg tgtggatga actacaggca agagactggc cctttaagca 2400  
ccagcctgct gaggccttga tctggcagat tggaaagtggg gaaggaggtac ggcgcgtcct 2460  
ggcattccgtc agcctggggaa aggaagtcgg cgagatcctg tctgcctgct gggctttcga 2520  
tctgcaggag agacccagct tcagcctgct gatggacatg ctggagaggc tgcccaagct 2580  
gaaccggccgg ctctcccacc ctgggcactt ttggaaagtgg gctgacatta acagcagcaa 2640  
agtcatgccc cgctttgaaa gtttggcct ggggaccctg gagtccggta atccaaagat 2700  
gtagccagcc ctgcacgttc atgcagagag tgtcttcctt tcgaaaacat gatcagccaa 2760  
catgcagacc accacctcaa ggaatcagaa gcattgcattt ccaagctgcg gactgggagc 2820  
gtgtctccctc cctaaaggac gtgcgtgcgt gcgtgcgtgc gtgcgtgcgt gcgtgcgtca 2880  
ccaagggtgtg tggagctcag gatgcagcc atacacgcaa ctccagatga taccactacc 2940  
gccagtggtt acacagaggt ttctgcctgg caagcttggt attttacagt aggtgaagat 3000  
cattctgcag aagggtgctg gcacagtggaa gcagcacggaa tgcgtcccccagc ccccggttctg 3060

tgtgggctgt	acccggaaaa	gggcaggtgg	caggaggttt	gccttggcct	gtgcttggc	3180
cgagaaccac	actaaggagc	agcagcctga	gttaggaatc	tatctggatt	acggggatca	3240
gagttcctgg	agagtggact	cagttctgc	tctgatccag	gcctgttgc	ctttttttt	3300
ttccccctta	aaaaaaaaaa	agtacagaca	gaatctcagc	ggcttctaga	ctgatctgat	3360
ggatcttagc	ccggcttcta	ctgcgggggg	gagggggggg	gggatagcca	catactgtg	3420
gagacaccca	cttcttatac	tgaggcctcc	aggtaggcac	aaaggctgtg	gaactcagcc	3480
tctatcatca	gacacccccc	cccaatgcct	cattgacccc	cttccccag	agccaagggc	3540
tagcccatcg	ggtgtgtgta	cagtaagttc	ttggtaagg	agaacaggga	cgttggcaga	3600
agcagttgc	agtggcccta	gcatctaaa	acccattgtc	tgtcacacca	gaaggttcta	3660
gacctaccac	cacttccctt	ccccatctca	tggaaacctt	ttagccatt	ctgacccctg	3720
tgtgtgctct	gagctcagat	cgggttatga	gaccgcccag	gcacatcagt	cagggaggct	3780
ctgatgtgag	ccgcagacct	ctgtgttcat	tcctatgagc	tggaggggct	ggactgggtg	3840
gggtcagatg	tgcttggcag	gaactgtcag	ctgctgagca	gggtggtccc	tgagcggagg	3900
ataagcagca	tcaagactcca	caaccagagg	aagaaagaaa	tggggatgga	gcggagaccc	3960
acgggctgag	tcccgctgtg	gagtggcctt	gcagctccct	ctcagttaaa	actcccagta	4020
aagccacagt	tctccgagca	cccaagtctg	ctccagccgt	ctctaaaac	aggccactct	4080
ctgagaagga	attc					4094

<210> 12  
 <211> 3772  
 <212> DNA  
 <213> Homo sapiens

<400> 12	gcgaagctgg	tccgttacat	ttgtaagcag	aggcagtgc	agctgagcgt	ggctcccggt	60
	gagaggaccc	cagagctcaa	cagctacccc	cgcttcagcg	actggctgta	cactttcaac	120
	gtgaggccgg	aggtggtgca	ggagatcccc	cgagaccta	cgctggatgc	cctgctggag	180
	atgaatgagg	ccaaggtgaa	ggagacgctg	cggcgctgt	ggccagcgg	ggatgagtgt	240
	ggccgtctgc	agtatgccct	cacctgcctg	cggaagggtga	caggcctggc	ttcatcaccc	300
	cggccaccac	accccagctg	cgacggcaca	ccaagctgaa	gccaccacgg	acgccccccc	360
	cacccagccg	caaggtcttc	cagctgctgc	ccagcttccc	cacactcacc	cggagcaagt	420

cccatgagtc tcagctgggg aaccgcattg atgacgtctc ctgcgtgagg tgagttggga 480  
gcacgttcct gcacgtggct atgctgtggg gcctctctca tgagtcagag cggagggaga 540  
cagctgtgcc tctggagtct gctttaatt gtctggaaat gcagagatgt ctggttttg 600  
cctgagcaaa ataggagttt attttgtac tatcccagc tggctaagga gagtcacgta 660  
gctgtggcg gggcttggg gatgaggagg ggtacagcag gcagggacta tgctgaagt 720  
gagctggctg taggaacccc agggaggcac agggggagca tgaagaggag ctacacttcc 780  
ctcccttagt gccccggcag aaactccccag gccccctcac agaaccttgg aggaacattc 840  
aacacccca tctctaggac agccccagcc ttgtcatcct ccaattgctg tggtaacacg 900  
gggactggag cagttagatt attaggcctt cagggccagt gtctccatgc agatcagatg 960  
gaggcggtgc ttggcacata caccaccta ctgcccattgc cccagaagt tggcagat 1020  
cataaggtgg cttttgggc taattgattt aagttccaac atagtctgtt tctccttaggc 1080  
tggtagctgg caccttggc cccatgtgtt ttttaattat tttttttt gagacgaaat 1140  
ctcgctctat cacccaggct gaagtgcagt agtcaatct cagctcaactg cagcctctgc 1200  
ctcccggtt caagcaattc tcctgcctca gcctcccag tagccaggat taaaggtgcc 1260  
tgccaccaca catggctaattttt ttaatagaga cggggtttca ccatgttagc 1320  
caggctggtc tcaaactcct gacctcaggt gatcttcctg cctcagcctc ccaaagtgc 1380  
gggattacag gtgtgagcca ctgcgcccag tcatgcccattt gttttttttt ggtcttgct 1440  
gctgatgggt ggggtgagcc ccaggaggaa gttgggacaa gtcaaccta tggcagatgt 1500  
gccagggaga gctgcgggtg agatagattt ttcctatccc cctctccttgc atgtgggagg 1560  
actcagtacc tccagcacac ctttcattgc gaggttgggtt atgtggtaact tggcctcaag 1620  
tgaaccagca cttcatgagt ccagcttgc gctagaccag cacttggat tgagggggc 1680  
agtggccacc ctcggggac cttctgactc agaggacatg agatggccac actcgagcac 1740  
tgtgttcctg acctttctgg gtcacaggc accttgcattt ttggatgaaa gtcttagatc 1800  
ttctttccag agaaaagtct acaacattct actgaaccag tccagagggt tcccgaccc 1860  
ccgaagccca cccatgggtt ggctctggga ggcaatggcg ctgagttatgg gggcatctct 1920  
cgcattggatc cccacagatg gtacggaggat atatcggtt gtcgggtacg cacaggttct 1980  
ccaccaagtc ctggctgtcg caggctgtgcc acgtgtgccaa gaagagcatg atatttggag 2040  
tgaagtgcaa gcattgcagg ttgaagtgtc acaacaaatg taccaaagaa gcccctgcct 2100

gtagaatatac cttcctgcc a ctaactcgac ttcggaggac agaatctgtc ccctcgac 2160  
tcaacaaccc ggtggacaga gcagccgaac cccatTTgg aaccctcccc aaagcactga 2220  
caaagaagga gcaccctccg gccatgaatc acctggactc cagcagcaac cttcctcca 2280  
ccacccctcc cacaccctcc tcaccggcgc cttcccgac atcatccaac ccatccagcg 2340  
ccaccacgac ccccaacccc tcacctggcc agcgggacag caggttcaac ttcccagctg 2400  
cctacttcat tcatcataga cagcagttt tctttccaga catttcagcc tttgcacacg 2460  
cagccccgct ccctgaagct gccgacggta cccggctcga tgaccagccg aaagcagatg 2520  
tgttggaaagc tcacgaagcg gaggctgagg agccagaggc tggcaagtca gaggcagaag 2580  
acgatgagga cgaggtggac gacttgcga gctctgcgc gcccggcgg ggccccatct 2640  
ctcgcaaggc cagccagacc agcgtgtacc tgcaggagtg ggacatcccc ttcgagcagg 2700  
tagagctggg cgagccccatc gggcagggcc gctggggccg ggtgcaccgc ggccgctggc 2760  
atggcgaggt ggccattcgc ctgctggaga tggacggcca caaccaggac cacctgaagc 2820  
tcttcaagaa agaggtgatg aactaccggc agacgcccga tgagaacgtg gtgctttca 2880  
tgggggcctg catgaaccccg ccccacctgg ccattatcac cagttctgc aaggggcgga 2940  
cgttgcactc gtttgcagg gacccaaga cgtctctgga catcaacaag acgaggcaaa 3000  
tcgctcagga gatcatcaag ggcattggat atcttcatgc caagggcatc gtacacaaag 3060  
atctcaaatc taagaacgtc ttctatgaca acggcaaggt ggtcatcaca gacttcggc 3120  
tgttgggat ctcaggcgtg gtccgagagg gacggcgtga gaaccagcta aagctgtccc 3180  
acgactggct gtgctatctg gcccctgaga ttgtacgcga gatgacccccc gggaggacg 3240  
aggatcagct gccattctcc aaagctgctg atgtctatgc atttggact gtttggatg 3300  
agctgcaagc aagagactgg cccttgaaga accaggctgc agaggcatcc atctggcaga 3360  
ttggaagcgg ggaaggaatg aagcgtgtcc tgacttctgt cagcttgggg aaggaagtca 3420  
gtgagatcct gtcggcctgc tggccttcg acctgcagga gagacccagc ttcagcctgc 3480  
tgatggacat gctggagaaa cttcccaagc tgaaccggcg gctctccac cctggacact 3540  
tctggaaagtc agctgagttg taggcctggc tgccttgcac gcaccagggg ctttcttcct 3600  
cctaattcaac aactcagcac cgtgacttct gctaaaatgc aaaatgagat gggggacta 3660  
acccagggga tgccacccctc gctgctccag tgcgtctctc cgaggctact tctttgctt 3720  
tgttttaaaa actggccctc tgccctctcc acgtggcctg catatgcccc ag 3772

<210> 13  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 13  
ggaaccttac ttctgtggtg tgac

24

<210> 14  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 14  
tagcagacac tctatgcctg tgtg

24

<210> 15  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> sense oligonucleotide

<400> 15  
cggaccctag aggcaaag

18

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> control oligonucleotide

<400> 16  
cacgtcacgc gcgcactatt

20

<210> 17  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 17

Gly Ser Leu Arg Gly Leu  
1 5

<210> 18  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 18

Ala Val Ser Asn Asp Leu  
1 5

<210> 19  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 19

Arg Thr Leu Glu Ala Lys  
1 5

<210> 20  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 20  
tatctccatc ggcagtct

18

<210> 21  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 21  
tcgacgctca cacttcaa

18

<210> 22  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 22

ctgaccgctt cctcgta

17

<210> 23  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 23  
atagagccca ccgcattcc

18

<210> 24  
<211> 2601  
<212> DNA  
<213> Homo sapiens

&lt;400&gt; 24

atgggagaga aggagggcgg tggcggggg gatgcggcgg ccgcggaggg tggcgcaggg 60  
gccgcggcca gccgggcgt gcagcagtgt gggcagctcc agaagctcat cgacatctcc 120  
atcggcagtc tgcgccggct ggcaccaag tgccagttgt ctaacgacct cacccagcag 180  
gagatacggc ccctagaggc aaagctggc cgttacatgg ttaaggcagag gcagtgcgg 240  
ctgagcgtgg ctcccggtga gaggacccca gagctcaaca gctacccccc cttcagcgcac 300  
tggctgtaca ctttcaacgt gaggccggag gtggcggagg agatcccccg agacctcact 360  
ctggatgccc tgctggagat gaatgaggcc aaggtgaagg agacgctgcg ggcgtgtggg 420  
gccagcgggg atgagtgtgg ccgtctgcag tatgcctca cctgcctgcg gaaggtgaca 480  
ggcctgggag gggagcacaa ggaggactcc agttggagtt cattggatgc gggcgggaa 540  
...  
agtggctcag ggccttccac ggacaccctc tcagcagcca gcctgcctg gcccccagg 600  
agctcccagc tggcagagc aggcaacagc gcccaggccc cacgctccat ctccgtgtca 660  
gctctgcccc cctcagactc cccacccccc agttcagtg agggcctctc agacacctgt 720  
attccctgc acggcagcgg ccggctgacc cccctgcggc tgcacagctt catcaccctc 780  
cccaccacac cccagctgcg acggcacacc aagctgaagc caccacggac gccccccca 840  
cccagccgca aggtttcca gctgctgccc agttccca cactcacccg gagcaagtcc 900  
catgagtctc agctggggaa ccgcattgtat gacgtctcct cgatgagggt tgatctctcg 960  
catggatccc cacagatggt acggagggat atcggctgtat cggtgacgca caggttctcc 1020  
accaagtccct ggctgtcgca ggtctgccac gtgtgccaga agagcatgtat atttggagtg 1080

aagtgcaga attgcaggtt gaagtgtcac aacaaatgta ccaaagaagc ccctgcctgt 1140  
agaatatcct tcctgccact aactcggtt cggaggacag aatctgtccc ctcggacatc 1200  
aacaacccgg tggacagagc agccgaaccc cattttggaa ccctcccaa agcaactgaca 1260  
aagaaggagc accctccggc catgaatcac ctggactcca gcagcaaccc ttcctccacc 1320  
acctcctcca caccctcctc accggcgccc ttcccacat catccaaccc atccagcgcc 1380  
accacgcccc ccaacccctc acctggccag cgggacagca gttcaactt cccagctgcc 1440  
tacttcattc atcatagaca gcagtttac ttccagaca ttccagcctt tgcacacgca 1500  
cccccgctcc ctgaagctgc cgacggtacc cggctcgatg accagccgaa agcagatgtg 1560  
ttggaagctc acgaagcggg ggctgaggag ccagaggctg gcaagtcaga ggcagaagac 1620  
gatgaggacg aggtggacga cttgcccggc tctcgccggc cctggcgggg cccatctct 1680  
cgcaaggcca gccagaccag cgtgtacctg caggagtgg acatccctt cgagcaggta 1740  
gagctggcg agcccatcgg gcagggccgc tggggccggg tgcaccgcgg ccgctggcat 1800  
ggcgaggtgg ccattcgct gctggagatg gacggccaca accaggacca cctgaagctc 1860  
ttcaagaaaag aggtgatgaa ctaccggcag acgcggcatg agaacgtggt gctttcatg 1920  
ggggcctgca tgaacccgccc ccacctggcc attatcacca gttctgcaa ggggcggacg 1980  
ttgcactcgt ttgtgaggga ccccaagacg tctctggaca tcaacaagac gaggcaaatc 2040  
gctcaggaga tcatcaaggg catggatat cttcatgcca agggcatcgt acacaaagat 2100  
ctcaaatcta agaacgtctt ctatgacaac ggcaagggtgg tcatcacaga cttcgggctg 2160  
tttggatct caggcgtggt ccgagagggc cggcgtgaga accagctaaa gctgtcccac 2220  
gactggctgt gctatctggc ccctgagatt gtacgcgaga tgaccccccgg gaaggacgag 2280  
gatcagctgc cattctccaa agctgctgat gtctatgcat ttggactgt ttgttatgag 2340  
ctgcaagcaa gagactggcc cttgaagaac caggctgcag aggcattccat ctggcagatt 2400  
ggaagcgggg aaggaatgaa gcgtgtcctg acttctgtca gcttggggaa ggaagtcagt 2460  
gagatcctgt cggcctgctg ggcttcgac ctgcaggaga gaccagctt cagcctgctg 2520  
atggacatgc tggagaaact tcccaagctg aaccggcgcc tctcccaccc tggacacttc 2580  
tggaaagtca gctgagttgtat g 2601

<210> 25  
<211> 121  
<212> DNA  
<213> Homo sapiens

<400> 25  
ctccagaagc tcatcgacat ctccatcgcc agtctgcgcg ggctgcgcac caagtgcgca 60  
gtgtctaacg acctcaccca gcaggagata cggaccctag aggcaaagct ggtccgttac 120  
a 121

<210> 26  
<211> 40  
<212> PRT  
<213> Homo sapiens

<400> 26

Leu Gln Lys Leu Ile Asp Ile Ser Ile Gly Ser Leu Arg Gly Leu Arg  
1 5 10 15

Thr Lys Cys Ala Val Ser Asn Asp Leu Thr Gln Gln Glu Ile Arg Thr  
20 25 30

Leu Glu Ala Lys Leu Val Arg Tyr  
35 40

<210> 27  
<211> 18  
<212> DNA  
<213> Homo sapiens

<400> 27  
gcagtgtcta acgacctc 18

<210> 28  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 28  
ctttgcctct agggtccg 18

<210> 29  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 29  
cagcccgccg agactgcc

18

<210> 30  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 30  
gaggtcgat gacactgc

18

<210> 31  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 31  
gccctccat tctccat

18

<210> 32  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 32  
acaaatgtaa cggaccag

18

<210> 33  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 33  
cctctcaccg ggagccac

18

<210> 34  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 34  
gaaaagtgtac agccagtc

18

<210> 35  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide  
  
<400> 35  
tgccaccacct ccgggcctc

18

<210> 36  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide  
  
<400> 36  
tgaggctctcg ggggatct

18

<210> 37  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide  
...  
<400> 37  
caccttggcc tcattcat

18

<210> 38  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide  
  
<400> 38  
atccaaatgaa ctccaaact

18

<210> 39  
<211> 18

<212> DNA  
<213> Artificial Sequence

<220>  
<223> antisense oligonucleotide

<400> 39  
gagccactt cccgcccgc

18